10067845	In conclusion, our results demonstrate that growth inhibition of LNCaP cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of AR gene expression.	CGE-increased	subj_mechanism subj_preceded subj_induction subj_AR gene subj_expression obj_demonstrate obj_growth obj_inhibition obj_LNCaP obj_cells obj_1,25-(OH)2D3 obj_9-cis
10067845	In conclusion, our results demonstrate that growth inhibition of LNCaP cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of AR gene expression.	IGE-unidentifiable	subj_mechanism subj_preceded subj_induction subj_AR gene subj_expression obj_demonstrate obj_growth obj_inhibition obj_LNCaP obj_cells obj_1,25-(OH)2D3 obj_9-cis
10067845	In conclusion, our results demonstrate that growth inhibition of LNCaP cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of AR gene expression.	CCS-cancerTOnormal	subj_mechanism subj_preceded subj_induction subj_AR gene subj_expression obj_demonstrate obj_growth obj_inhibition obj_LNCaP obj_cells obj_1,25-(OH)2D3 obj_9-cis
10067845	In conclusion, our results demonstrate that growth inhibition of LNCaP cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of AR gene expression.	PT-observation	subj_mechanism subj_preceded subj_induction subj_AR gene subj_expression obj_demonstrate obj_growth obj_inhibition obj_LNCaP obj_cells obj_1,25-(OH)2D3 obj_9-cis
10216950	A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed prostate carcinoma, all scored positive for expression of PTI-1, while corresponding normal tissues or blood samples were negative.	CGE-increased	subj_scored subj_positive subj_expression subj_PTI-1 subj_normal subj_tissues subj_blood obj_samples obj_patients obj_confirmed obj_prostate carcinoma obj_scored obj_positive obj_expression
10216950	A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed prostate carcinoma, all scored positive for expression of PTI-1, while corresponding normal tissues or blood samples were negative.	IGE-unchanged	subj_scored subj_positive subj_expression subj_PTI-1 subj_normal subj_tissues subj_blood obj_samples obj_patients obj_confirmed obj_prostate carcinoma obj_scored obj_positive obj_expression
10216950	A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed prostate carcinoma, all scored positive for expression of PTI-1, while corresponding normal tissues or blood samples were negative.	CCS-normalTOcancer	subj_scored subj_positive subj_expression subj_PTI-1 subj_normal subj_tissues subj_blood obj_samples obj_patients obj_confirmed obj_prostate carcinoma obj_scored obj_positive obj_expression
10216950	A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed prostate carcinoma, all scored positive for expression of PTI-1, while corresponding normal tissues or blood samples were negative.	PT-observation	subj_scored subj_positive subj_expression subj_PTI-1 subj_normal subj_tissues subj_blood obj_samples obj_patients obj_confirmed obj_prostate carcinoma obj_scored obj_positive obj_expression
10323669	It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.	CGE-increased	subj_E2 subj_) subj_stimulate subj_Src/p21ras/mitogen-activated protein kinase subj_pathway subj_breast subj_cancer obj_mediate obj_E2-induced obj_stimulation obj_breast cancer obj_cell obj_proliferation obj_activation
10323669	It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.	IGE-unidentifiable	subj_E2 subj_) subj_stimulate subj_Src/p21ras/mitogen-activated protein kinase subj_pathway subj_breast subj_cancer obj_mediate obj_E2-induced obj_stimulation obj_breast cancer obj_cell obj_proliferation obj_activation
10323669	It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.	CCS-normalTOcancer	subj_E2 subj_) subj_stimulate subj_Src/p21ras/mitogen-activated protein kinase subj_pathway subj_breast subj_cancer obj_mediate obj_E2-induced obj_stimulation obj_breast cancer obj_cell obj_proliferation obj_activation
10323669	It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.	PT-causality	subj_E2 subj_) subj_stimulate subj_Src/p21ras/mitogen-activated protein kinase subj_pathway subj_breast subj_cancer obj_mediate obj_E2-induced obj_stimulation obj_breast cancer obj_cell obj_proliferation obj_activation
10342830	In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.	CGE-increased	subj_exogenous subj_activin subj_suggests subj_activin subj_overexpression subj_PA1 subj_cells obj_suggests obj_activin obj_overexpression obj_PA1 obj_cells obj_regulate obj_activin
10342830	In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.	IGE-	subj_exogenous subj_activin subj_suggests subj_activin subj_overexpression subj_PA1 subj_cells obj_suggests obj_activin obj_overexpression obj_PA1 obj_cells obj_regulate obj_activin
10342830	In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.	CCS-unidentifiable	subj_exogenous subj_activin subj_suggests subj_activin subj_overexpression subj_PA1 subj_cells obj_suggests obj_activin obj_overexpression obj_PA1 obj_cells obj_regulate obj_activin
10342830	In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.	PT-	subj_exogenous subj_activin subj_suggests subj_activin subj_overexpression subj_PA1 subj_cells obj_suggests obj_activin obj_overexpression obj_PA1 obj_cells obj_regulate obj_activin
10397458	Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers.	CGE-increased	subj_Overexpression subj_c-erbB-2 oncoprotein subj_( subj_21.9 subj_% obj_% obj_) obj_32 obj_epithelial ovarian cancers
10397458	Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers.	IGE-unchanged	subj_Overexpression subj_c-erbB-2 oncoprotein subj_( subj_21.9 subj_% obj_% obj_) obj_32 obj_epithelial ovarian cancers
10397458	Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers.	CCS-normalTOcancer	subj_Overexpression subj_c-erbB-2 oncoprotein subj_( subj_21.9 subj_% obj_% obj_) obj_32 obj_epithelial ovarian cancers
10397458	Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers.	PT-observation	subj_Overexpression subj_c-erbB-2 oncoprotein subj_( subj_21.9 subj_% obj_% obj_) obj_32 obj_epithelial ovarian cancers
10408832	Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2.	CGE-increased	subj_induces subj_fibroblasts subj_activate subj_proMMP-2 subj_presence subj_TIMP-2 obj_I obj_ovarian tumours obj_induces obj_fibroblasts obj_activate
10408832	Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2.	IGE-	subj_induces subj_fibroblasts subj_activate subj_proMMP-2 subj_presence subj_TIMP-2 obj_I obj_ovarian tumours obj_induces obj_fibroblasts obj_activate
10408832	Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2.	CCS-unidentifiable	subj_induces subj_fibroblasts subj_activate subj_proMMP-2 subj_presence subj_TIMP-2 obj_I obj_ovarian tumours obj_induces obj_fibroblasts obj_activate
10408832	Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2.	PT-	subj_induces subj_fibroblasts subj_activate subj_proMMP-2 subj_presence subj_TIMP-2 obj_I obj_ovarian tumours obj_induces obj_fibroblasts obj_activate
10419053	Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.	CGE-increased	subj_receptor subj_alpha subj_( subj_FRalpha subj_) subj_folate subj_binding obj_protein obj_selectively obj_overexpressed obj_ovarian carcinoma obj_regarded obj_suitable obj_target
10419053	Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.	IGE-unchanged	subj_receptor subj_alpha subj_( subj_FRalpha subj_) subj_folate subj_binding obj_protein obj_selectively obj_overexpressed obj_ovarian carcinoma obj_regarded obj_suitable obj_target
10419053	Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.	CCS-normalTOcancer	subj_receptor subj_alpha subj_( subj_FRalpha subj_) subj_folate subj_binding obj_protein obj_selectively obj_overexpressed obj_ovarian carcinoma obj_regarded obj_suitable obj_target
10419053	Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.	PT-observation	subj_receptor subj_alpha subj_( subj_FRalpha subj_) subj_folate subj_binding obj_protein obj_selectively obj_overexpressed obj_ovarian carcinoma obj_regarded obj_suitable obj_target
10428464	The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.	CGE-increased	subj_differentiation subj_gene subj_1 subj_Drg1 subj_markedly subj_upregulated subj_androgens obj_upregulated obj_androgens obj_LNCaP obj_prostatic adenocarcinoma obj_cells obj_
10428464	The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.	IGE-unidentifiable	subj_differentiation subj_gene subj_1 subj_Drg1 subj_markedly subj_upregulated subj_androgens obj_upregulated obj_androgens obj_LNCaP obj_prostatic adenocarcinoma obj_cells obj_
10428464	The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.	CCS-normalTOcancer	subj_differentiation subj_gene subj_1 subj_Drg1 subj_markedly subj_upregulated subj_androgens obj_upregulated obj_androgens obj_LNCaP obj_prostatic adenocarcinoma obj_cells obj_
10428464	The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.	PT-observation	subj_differentiation subj_gene subj_1 subj_Drg1 subj_markedly subj_upregulated subj_androgens obj_upregulated obj_androgens obj_LNCaP obj_prostatic adenocarcinoma obj_cells obj_
10449619	The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755.	CGE-increased	subj_preferential subj_regulation subj_PyNPase subj_activity subj_tumor subj_CPA obj_bearing obj_syngeneic obj_murine obj_mammary adenocarcinoma obj_A755
10449619	The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755.	IGE-	subj_preferential subj_regulation subj_PyNPase subj_activity subj_tumor subj_CPA obj_bearing obj_syngeneic obj_murine obj_mammary adenocarcinoma obj_A755
10449619	The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755.	CCS-unidentifiable	subj_preferential subj_regulation subj_PyNPase subj_activity subj_tumor subj_CPA obj_bearing obj_syngeneic obj_murine obj_mammary adenocarcinoma obj_A755
10449619	The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755.	PT-	subj_preferential subj_regulation subj_PyNPase subj_activity subj_tumor subj_CPA obj_bearing obj_syngeneic obj_murine obj_mammary adenocarcinoma obj_A755
10498868	Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	CGE-decreased	subj_ovarian subj_cancers subj_repression subj_ING1 subj_expression subj_frequently subj_accompanies obj_mutation obj_rare obj_breast obj_ovarian cancers obj_repression obj_ING1 obj_expression
10498868	Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	IGE-	subj_ovarian subj_cancers subj_repression subj_ING1 subj_expression subj_frequently subj_accompanies obj_mutation obj_rare obj_breast obj_ovarian cancers obj_repression obj_ING1 obj_expression
10498868	Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	CCS-unidentifiable	subj_ovarian subj_cancers subj_repression subj_ING1 subj_expression subj_frequently subj_accompanies obj_mutation obj_rare obj_breast obj_ovarian cancers obj_repression obj_ING1 obj_expression
10498868	Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	PT-	subj_ovarian subj_cancers subj_repression subj_ING1 subj_expression subj_frequently subj_accompanies obj_mutation obj_rare obj_breast obj_ovarian cancers obj_repression obj_ING1 obj_expression
10590366	Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid.	CGE-increased	subj_expression subj_Met subj_advanced subj_carcinoma subj_prostate obj_expression obj_Met obj_advanced obj_carcinoma of the prostate obj_stomach obj_pancreas obj_thyroid
10590366	Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid.	IGE-unidentifiable	subj_expression subj_Met subj_advanced subj_carcinoma subj_prostate obj_expression obj_Met obj_advanced obj_carcinoma of the prostate obj_stomach obj_pancreas obj_thyroid
10590366	Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid.	CCS-normalTOcancer	subj_expression subj_Met subj_advanced subj_carcinoma subj_prostate obj_expression obj_Met obj_advanced obj_carcinoma of the prostate obj_stomach obj_pancreas obj_thyroid
10590366	Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid.	PT-observation	subj_expression subj_Met subj_advanced subj_carcinoma subj_prostate obj_expression obj_Met obj_advanced obj_carcinoma of the prostate obj_stomach obj_pancreas obj_thyroid
10602481	Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	CGE-decreased	subj_findings subj_loss subj_E-cadherin subj_expression subj_breast subj_cancers obj_E obj_cadherin obj_expression obj_breast cancers obj_dominant obj_repression obj_trans
10602481	Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	IGE-unchanged	subj_findings subj_loss subj_E-cadherin subj_expression subj_breast subj_cancers obj_E obj_cadherin obj_expression obj_breast cancers obj_dominant obj_repression obj_trans
10602481	Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	CCS-normalTOcancer	subj_findings subj_loss subj_E-cadherin subj_expression subj_breast subj_cancers obj_E obj_cadherin obj_expression obj_breast cancers obj_dominant obj_repression obj_trans
10602481	Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	PT-observation	subj_findings subj_loss subj_E-cadherin subj_expression subj_breast subj_cancers obj_E obj_cadherin obj_expression obj_breast cancers obj_dominant obj_repression obj_trans
10728592	Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells.	CGE-increased	subj_regulation subj_AR subj_1,25(OH)2D3 subj_VDR subj_DHT subj_evidence subj_cross obj_2 obj_signaling obj_pathways obj_OVCAR-3 obj_cells
10728592	Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells.	IGE-	subj_regulation subj_AR subj_1,25(OH)2D3 subj_VDR subj_DHT subj_evidence subj_cross obj_2 obj_signaling obj_pathways obj_OVCAR-3 obj_cells
10728592	Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells.	CCS-unidentifiable	subj_regulation subj_AR subj_1,25(OH)2D3 subj_VDR subj_DHT subj_evidence subj_cross obj_2 obj_signaling obj_pathways obj_OVCAR-3 obj_cells
10728592	Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells.	PT-	subj_regulation subj_AR subj_1,25(OH)2D3 subj_VDR subj_DHT subj_evidence subj_cross obj_2 obj_signaling obj_pathways obj_OVCAR-3 obj_cells
10885804	We found that the functional disruption of IGF-1R markedly influences breast cancer metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.	CGE-decreased	subj_We subj_functional subj_disruption subj_IGF-1R subj_markedly subj_influences subj_breast obj_adhesion obj_invasion obj_metastasis obj_breast cancer obj_cells obj_lung obj_lymph
10885804	We found that the functional disruption of IGF-1R markedly influences breast cancer metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.	IGE-unidentifiable	subj_We subj_functional subj_disruption subj_IGF-1R subj_markedly subj_influences subj_breast obj_adhesion obj_invasion obj_metastasis obj_breast cancer obj_cells obj_lung obj_lymph
10885804	We found that the functional disruption of IGF-1R markedly influences breast cancer metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.	CCS-cancerTOnormal	subj_We subj_functional subj_disruption subj_IGF-1R subj_markedly subj_influences subj_breast obj_adhesion obj_invasion obj_metastasis obj_breast cancer obj_cells obj_lung obj_lymph
10885804	We found that the functional disruption of IGF-1R markedly influences breast cancer metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.	PT-causality	subj_We subj_functional subj_disruption subj_IGF-1R subj_markedly subj_influences subj_breast obj_adhesion obj_invasion obj_metastasis obj_breast cancer obj_cells obj_lung obj_lymph
10931458	These findings suggest that inhibition of COX-2 development may lead not only to inhibition of the proliferation and metastasis of prostate carcinoma but also to the inhibition of prostate carcinogenesis.	CGE-decreased	subj_findings subj_inhibition subj_COX-2 subj_development subj_lead subj_inhibition obj_inhibition obj_proliferation obj_metastasis obj_prostate carcinoma obj_inhibition obj_prostate obj_carcinogenesis
10931458	These findings suggest that inhibition of COX-2 development may lead not only to inhibition of the proliferation and metastasis of prostate carcinoma but also to the inhibition of prostate carcinogenesis.	IGE-unidentifiable	subj_findings subj_inhibition subj_COX-2 subj_development subj_lead subj_inhibition obj_inhibition obj_proliferation obj_metastasis obj_prostate carcinoma obj_inhibition obj_prostate obj_carcinogenesis
10931458	These findings suggest that inhibition of COX-2 development may lead not only to inhibition of the proliferation and metastasis of prostate carcinoma but also to the inhibition of prostate carcinogenesis.	CCS-cancerTOnormal	subj_findings subj_inhibition subj_COX-2 subj_development subj_lead subj_inhibition obj_inhibition obj_proliferation obj_metastasis obj_prostate carcinoma obj_inhibition obj_prostate obj_carcinogenesis
10931458	These findings suggest that inhibition of COX-2 development may lead not only to inhibition of the proliferation and metastasis of prostate carcinoma but also to the inhibition of prostate carcinogenesis.	PT-causality	subj_findings subj_inhibition subj_COX-2 subj_development subj_lead subj_inhibition obj_inhibition obj_proliferation obj_metastasis obj_prostate carcinoma obj_inhibition obj_prostate obj_carcinogenesis
10945637	Thus, FGF6 is increased in PIN and prostate cancer and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.	CGE-increased	subj_Thus subj_FGF6 subj_increased subj_PIN subj_prostate obj_FGF6 obj_increased obj_PIN obj_prostate cancer obj_promote obj_proliferation obj_transformed
10945637	Thus, FGF6 is increased in PIN and prostate cancer and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.	IGE-unchanged	subj_Thus subj_FGF6 subj_increased subj_PIN subj_prostate obj_FGF6 obj_increased obj_PIN obj_prostate cancer obj_promote obj_proliferation obj_transformed
10945637	Thus, FGF6 is increased in PIN and prostate cancer and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.	CCS-normalTOcancer	subj_Thus subj_FGF6 subj_increased subj_PIN subj_prostate obj_FGF6 obj_increased obj_PIN obj_prostate cancer obj_promote obj_proliferation obj_transformed
10945637	Thus, FGF6 is increased in PIN and prostate cancer and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.	PT-causality	subj_Thus subj_FGF6 subj_increased subj_PIN subj_prostate obj_FGF6 obj_increased obj_PIN obj_prostate cancer obj_promote obj_proliferation obj_transformed
10998426	Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.	CGE-increased	subj_Transfection subj_IGFBP-3 subj_increased subj_radiosensitivity subj_T47D obj_IGFBP-3 obj_increased obj_radiosensitivity obj_T47D obj_increased obj_IR obj_induced
10998426	Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.	IGE-unidentifiable	subj_Transfection subj_IGFBP-3 subj_increased subj_radiosensitivity subj_T47D obj_IGFBP-3 obj_increased obj_radiosensitivity obj_T47D obj_increased obj_IR obj_induced
10998426	Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.	CCS-cancerTOnormal	subj_Transfection subj_IGFBP-3 subj_increased subj_radiosensitivity subj_T47D obj_IGFBP-3 obj_increased obj_radiosensitivity obj_T47D obj_increased obj_IR obj_induced
10998426	Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.	PT-causality	subj_Transfection subj_IGFBP-3 subj_increased subj_radiosensitivity subj_T47D obj_IGFBP-3 obj_increased obj_radiosensitivity obj_T47D obj_increased obj_IR obj_induced
11014575	Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.	CGE-increased	subj_cells subj_effusions subj_regulation subj_Tn subj_Sialyl subj_Tn subj_representing obj_Ovarian carcinoma obj_cells obj_effusions obj_regulation
11014575	Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.	IGE-unidentifiable	subj_cells subj_effusions subj_regulation subj_Tn subj_Sialyl subj_Tn subj_representing obj_Ovarian carcinoma obj_cells obj_effusions obj_regulation
11014575	Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.	CCS-normalTOcancer	subj_cells subj_effusions subj_regulation subj_Tn subj_Sialyl subj_Tn subj_representing obj_Ovarian carcinoma obj_cells obj_effusions obj_regulation
11014575	Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.	PT-observation	subj_cells subj_effusions subj_regulation subj_Tn subj_Sialyl subj_Tn subj_representing obj_Ovarian carcinoma obj_cells obj_effusions obj_regulation
11026599	These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.	CGE-increased	subj_continuous subj_stimulation subj_gonadotropins subj_LH subj_negative subj_feedback subj_phenomenon obj_NF obj_treatment obj_induces obj_ovarian tumors obj_mice obj_continuous obj_stimulation
11026599	These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.	IGE-unidentifiable	subj_continuous subj_stimulation subj_gonadotropins subj_LH subj_negative subj_feedback subj_phenomenon obj_NF obj_treatment obj_induces obj_ovarian tumors obj_mice obj_continuous obj_stimulation
11026599	These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.	CCS-normalTOcancer	subj_continuous subj_stimulation subj_gonadotropins subj_LH subj_negative subj_feedback subj_phenomenon obj_NF obj_treatment obj_induces obj_ovarian tumors obj_mice obj_continuous obj_stimulation
11026599	These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.	PT-causality	subj_continuous subj_stimulation subj_gonadotropins subj_LH subj_negative subj_feedback subj_phenomenon obj_NF obj_treatment obj_induces obj_ovarian tumors obj_mice obj_continuous obj_stimulation
11032026	Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.	CGE-increased	subj_Moreover subj_cav-1 subj_expression subj_induced subj_IGROV1 obj_cav-1 obj_expression obj_induced obj_IGROV1 obj_cells obj_transfection obj_intracellular
11032026	Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.	IGE-	subj_Moreover subj_cav-1 subj_expression subj_induced subj_IGROV1 obj_cav-1 obj_expression obj_induced obj_IGROV1 obj_cells obj_transfection obj_intracellular
11032026	Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.	CCS-unidentifiable	subj_Moreover subj_cav-1 subj_expression subj_induced subj_IGROV1 obj_cav-1 obj_expression obj_induced obj_IGROV1 obj_cells obj_transfection obj_intracellular
11032026	Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.	PT-	subj_Moreover subj_cav-1 subj_expression subj_induced subj_IGROV1 obj_cav-1 obj_expression obj_induced obj_IGROV1 obj_cells obj_transfection obj_intracellular
11069386	The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.	CGE-decreased	subj_partly subj_ability subj_suppress subj_IGF-II subj_expression obj_regulating obj_AR obj_expression obj_prostate cancer obj_cells obj_action obj_anti
11069386	The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.	IGE-	subj_partly subj_ability subj_suppress subj_IGF-II subj_expression obj_regulating obj_AR obj_expression obj_prostate cancer obj_cells obj_action obj_anti
11069386	The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.	CCS-unidentifiable	subj_partly subj_ability subj_suppress subj_IGF-II subj_expression obj_regulating obj_AR obj_expression obj_prostate cancer obj_cells obj_action obj_anti
11069386	The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.	PT-	subj_partly subj_ability subj_suppress subj_IGF-II subj_expression obj_regulating obj_AR obj_expression obj_prostate cancer obj_cells obj_action obj_anti
11104617	Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis.	CGE-increased	subj_cancer subj_patients subj_elevated subj_CA 125 subj_levels subj_chemotherapy subj_courses obj_Ovarian cancer obj_patients obj_elevated obj_CA
11104617	Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis.	IGE-unidentifiable	subj_cancer subj_patients subj_elevated subj_CA 125 subj_levels subj_chemotherapy subj_courses obj_Ovarian cancer obj_patients obj_elevated obj_CA
11104617	Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis.	CCS-normalTOcancer	subj_cancer subj_patients subj_elevated subj_CA 125 subj_levels subj_chemotherapy subj_courses obj_Ovarian cancer obj_patients obj_elevated obj_CA
11104617	Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis.	PT-observation	subj_cancer subj_patients subj_elevated subj_CA 125 subj_levels subj_chemotherapy subj_courses obj_Ovarian cancer obj_patients obj_elevated obj_CA
11118434	Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.	CGE-increased	subj_1-dominated subj_structures subj_expression subj_ST3Gal-I subj_increased subj_breast subj_cancer obj_ST3Gal obj_I obj_increased obj_breast cancer
11118434	Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.	IGE-unchanged	subj_1-dominated subj_structures subj_expression subj_ST3Gal-I subj_increased subj_breast subj_cancer obj_ST3Gal obj_I obj_increased obj_breast cancer
11118434	Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.	CCS-normalTOcancer	subj_1-dominated subj_structures subj_expression subj_ST3Gal-I subj_increased subj_breast subj_cancer obj_ST3Gal obj_I obj_increased obj_breast cancer
11118434	Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.	PT-observation	subj_1-dominated subj_structures subj_expression subj_ST3Gal-I subj_increased subj_breast subj_cancer obj_ST3Gal obj_I obj_increased obj_breast cancer
11150789	From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).Results: In 13 pts referred for suspicion of OR, FDG-CDET was true positive (TP) in 11 cases all confirmed by histology after surgery and was true negative (TN) in the remaining 2 cases as confirmed by spontaneous normalization of CA-125 levels and no events during a 20-month follow-up.	CGE-increased	subj_defined subj_increase subj_serum subj_CA-125 subj_levels subj_negative subj_conventional obj_referred obj_suspected obj_recurrence obj_ovarian carcinoma obj_: obj_occult obj_recurrence
11150789	From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).Results: In 13 pts referred for suspicion of OR, FDG-CDET was true positive (TP) in 11 cases all confirmed by histology after surgery and was true negative (TN) in the remaining 2 cases as confirmed by spontaneous normalization of CA-125 levels and no events during a 20-month follow-up.	IGE-unidentifiable	subj_defined subj_increase subj_serum subj_CA-125 subj_levels subj_negative subj_conventional obj_referred obj_suspected obj_recurrence obj_ovarian carcinoma obj_: obj_occult obj_recurrence
11150789	From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).Results: In 13 pts referred for suspicion of OR, FDG-CDET was true positive (TP) in 11 cases all confirmed by histology after surgery and was true negative (TN) in the remaining 2 cases as confirmed by spontaneous normalization of CA-125 levels and no events during a 20-month follow-up.	CCS-normalTOcancer	subj_defined subj_increase subj_serum subj_CA-125 subj_levels subj_negative subj_conventional obj_referred obj_suspected obj_recurrence obj_ovarian carcinoma obj_: obj_occult obj_recurrence
11150789	From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).Results: In 13 pts referred for suspicion of OR, FDG-CDET was true positive (TP) in 11 cases all confirmed by histology after surgery and was true negative (TN) in the remaining 2 cases as confirmed by spontaneous normalization of CA-125 levels and no events during a 20-month follow-up.	PT-observation	subj_defined subj_increase subj_serum subj_CA-125 subj_levels subj_negative subj_conventional obj_referred obj_suspected obj_recurrence obj_ovarian carcinoma obj_: obj_occult obj_recurrence
11156389	We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance.	CGE-decreased	subj_tumor subj_progression subj_loss subj_ERalpha subj_expression subj_observed subj_human obj_expression obj_observed obj_human obj_breast cancers obj_clinical obj_significance
11156389	We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance.	IGE-unidentifiable	subj_tumor subj_progression subj_loss subj_ERalpha subj_expression subj_observed subj_human obj_expression obj_observed obj_human obj_breast cancers obj_clinical obj_significance
11156389	We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance.	CCS-normalTOcancer	subj_tumor subj_progression subj_loss subj_ERalpha subj_expression subj_observed subj_human obj_expression obj_observed obj_human obj_breast cancers obj_clinical obj_significance
11156389	We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance.	PT-observation	subj_tumor subj_progression subj_loss subj_ERalpha subj_expression subj_observed subj_human obj_expression obj_observed obj_human obj_breast cancers obj_clinical obj_significance
11280739	In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein.	CGE-increased	subj_phosphorylated subj_Akt subj_levels subj_XIAP subj_overexpression subj_failed subj_increase obj_In obj_cell obj_( obj_OVCAR-3 obj_) obj_basal obj_phosphorylated
11280739	In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein.	IGE-	subj_phosphorylated subj_Akt subj_levels subj_XIAP subj_overexpression subj_failed subj_increase obj_In obj_cell obj_( obj_OVCAR-3 obj_) obj_basal obj_phosphorylated
11280739	In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein.	CCS-unidentifiable	subj_phosphorylated subj_Akt subj_levels subj_XIAP subj_overexpression subj_failed subj_increase obj_In obj_cell obj_( obj_OVCAR-3 obj_) obj_basal obj_phosphorylated
11280739	In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein.	PT-	subj_phosphorylated subj_Akt subj_levels subj_XIAP subj_overexpression subj_failed subj_increase obj_In obj_cell obj_( obj_OVCAR-3 obj_) obj_basal obj_phosphorylated
11410510	In vivid contrast, antisense oligodeoxynucleotides to L-FABP (overexpressed in prostate cancer) decreased proliferation and caused apoptosis.	CGE-increased	subj_contrast subj_antisense subj_oligodeoxynucleotides subj_L-FABP subj_( subj_overexpressed subj_prostate obj_FABP obj_( obj_overexpressed obj_prostate cancer obj_) obj_decreased obj_proliferation
11410510	In vivid contrast, antisense oligodeoxynucleotides to L-FABP (overexpressed in prostate cancer) decreased proliferation and caused apoptosis.	IGE-unchanged	subj_contrast subj_antisense subj_oligodeoxynucleotides subj_L-FABP subj_( subj_overexpressed subj_prostate obj_FABP obj_( obj_overexpressed obj_prostate cancer obj_) obj_decreased obj_proliferation
11410510	In vivid contrast, antisense oligodeoxynucleotides to L-FABP (overexpressed in prostate cancer) decreased proliferation and caused apoptosis.	CCS-normalTOcancer	subj_contrast subj_antisense subj_oligodeoxynucleotides subj_L-FABP subj_( subj_overexpressed subj_prostate obj_FABP obj_( obj_overexpressed obj_prostate cancer obj_) obj_decreased obj_proliferation
11410510	In vivid contrast, antisense oligodeoxynucleotides to L-FABP (overexpressed in prostate cancer) decreased proliferation and caused apoptosis.	PT-causality	subj_contrast subj_antisense subj_oligodeoxynucleotides subj_L-FABP subj_( subj_overexpressed subj_prostate obj_FABP obj_( obj_overexpressed obj_prostate cancer obj_) obj_decreased obj_proliferation
11459464	An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer)	CGE-increased	subj_vitro subj_internalization subj_study subj_Av-G6Gd subj_accumulated subj_internalized subj_SHIN3 obj_cells obj_( obj_human obj_ovarian cancer
11459464	An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer)	IGE-unidentifiable	subj_vitro subj_internalization subj_study subj_Av-G6Gd subj_accumulated subj_internalized subj_SHIN3 obj_cells obj_( obj_human obj_ovarian cancer
11459464	An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer)	CCS-normalTOcancer	subj_vitro subj_internalization subj_study subj_Av-G6Gd subj_accumulated subj_internalized subj_SHIN3 obj_cells obj_( obj_human obj_ovarian cancer
11459464	An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer)	PT-observation	subj_vitro subj_internalization subj_study subj_Av-G6Gd subj_accumulated subj_internalized subj_SHIN3 obj_cells obj_( obj_human obj_ovarian cancer
11518717	We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.	CGE-increased	subj_We subj_IGF-IR subj_overexpression subj_markedly subj_stimulated obj_cad obj_positive obj_MCF-7 obj_breast cancer obj_cells obj_E obj_cad
11518717	We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.	IGE-	subj_We subj_IGF-IR subj_overexpression subj_markedly subj_stimulated obj_cad obj_positive obj_MCF-7 obj_breast cancer obj_cells obj_E obj_cad
11518717	We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.	CCS-unidentifiable	subj_We subj_IGF-IR subj_overexpression subj_markedly subj_stimulated obj_cad obj_positive obj_MCF-7 obj_breast cancer obj_cells obj_E obj_cad
11518717	We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.	PT-	subj_We subj_IGF-IR subj_overexpression subj_markedly subj_stimulated obj_cad obj_positive obj_MCF-7 obj_breast cancer obj_cells obj_E obj_cad
11544097	P1, a high mobility group-like protein is depressed in human breast adenocarcinoma.	CGE-decreased	subj_differences subj_observed subj_P1 subj_high mobility group-like protein subj_depressed subj_human subj_breast obj_protein obj_depressed obj_human obj_breast adenocarcinoma obj_
11544097	P1, a high mobility group-like protein is depressed in human breast adenocarcinoma.	IGE-unchanged	subj_differences subj_observed subj_P1 subj_high mobility group-like protein subj_depressed subj_human subj_breast obj_protein obj_depressed obj_human obj_breast adenocarcinoma obj_
11544097	P1, a high mobility group-like protein is depressed in human breast adenocarcinoma.	CCS-normalTOcancer	subj_differences subj_observed subj_P1 subj_high mobility group-like protein subj_depressed subj_human subj_breast obj_protein obj_depressed obj_human obj_breast adenocarcinoma obj_
11544097	P1, a high mobility group-like protein is depressed in human breast adenocarcinoma.	PT-observation	subj_differences subj_observed subj_P1 subj_high mobility group-like protein subj_depressed subj_human subj_breast obj_protein obj_depressed obj_human obj_breast adenocarcinoma obj_
11550075	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in hormone-dependent breast cancer.	CGE-decreased	subj_Inhibition subj_aromatase subj_approach subj_reducing subj_growth obj_estrogens obj_hormone obj_dependent obj_breast cancer
11550075	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in hormone-dependent breast cancer.	IGE-unidentifiable	subj_Inhibition subj_aromatase subj_approach subj_reducing subj_growth obj_estrogens obj_hormone obj_dependent obj_breast cancer
11550075	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in hormone-dependent breast cancer.	CCS-cancerTOnormal	subj_Inhibition subj_aromatase subj_approach subj_reducing subj_growth obj_estrogens obj_hormone obj_dependent obj_breast cancer
11550075	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in hormone-dependent breast cancer.	PT-causality	subj_Inhibition subj_aromatase subj_approach subj_reducing subj_growth obj_estrogens obj_hormone obj_dependent obj_breast cancer
11564899	In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the FGFR2 in a breast cancer cell line, but only a low frequency of involvement in primary breast tumors.	CGE-increased	subj_level subj_amplification subj_overexpression subj_FGFR2 subj_breast subj_cancer subj_cell obj_frequency obj_involvement obj_primary obj_breast tumors
11564899	In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the FGFR2 in a breast cancer cell line, but only a low frequency of involvement in primary breast tumors.	IGE-unidentifiable	subj_level subj_amplification subj_overexpression subj_FGFR2 subj_breast subj_cancer subj_cell obj_frequency obj_involvement obj_primary obj_breast tumors
11564899	In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the FGFR2 in a breast cancer cell line, but only a low frequency of involvement in primary breast tumors.	CCS-normalTOcancer	subj_level subj_amplification subj_overexpression subj_FGFR2 subj_breast subj_cancer subj_cell obj_frequency obj_involvement obj_primary obj_breast tumors
11564899	In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the FGFR2 in a breast cancer cell line, but only a low frequency of involvement in primary breast tumors.	PT-observation	subj_level subj_amplification subj_overexpression subj_FGFR2 subj_breast subj_cancer subj_cell obj_frequency obj_involvement obj_primary obj_breast tumors
11571633	Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.	CGE-decreased	subj_DNA subj_PK subj_caveolin-1 subj_VEGF subj_prostate subj_cancer subj_cells obj_PK obj_caveolin-1 obj_VEGF obj_prostate cancer obj_cells obj_
11571633	Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.	IGE-	subj_DNA subj_PK subj_caveolin-1 subj_VEGF subj_prostate subj_cancer subj_cells obj_PK obj_caveolin-1 obj_VEGF obj_prostate cancer obj_cells obj_
11571633	Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.	CCS-unidentifiable	subj_DNA subj_PK subj_caveolin-1 subj_VEGF subj_prostate subj_cancer subj_cells obj_PK obj_caveolin-1 obj_VEGF obj_prostate cancer obj_cells obj_
11571633	Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.	PT-	subj_DNA subj_PK subj_caveolin-1 subj_VEGF subj_prostate subj_cancer subj_cells obj_PK obj_caveolin-1 obj_VEGF obj_prostate cancer obj_cells obj_
11601039	In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.	CGE-increased	subj_recurrence subj_ovary subj_tumor subj_IAP subj_levels subj_increased subj_compare obj_patients obj_recurrence obj_ovary tumor obj_IAP obj_levels obj_increased
11601039	In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.	IGE-unchanged	subj_recurrence subj_ovary subj_tumor subj_IAP subj_levels subj_increased subj_compare obj_patients obj_recurrence obj_ovary tumor obj_IAP obj_levels obj_increased
11601039	In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.	CCS-normalTOcancer	subj_recurrence subj_ovary subj_tumor subj_IAP subj_levels subj_increased subj_compare obj_patients obj_recurrence obj_ovary tumor obj_IAP obj_levels obj_increased
11601039	In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.	PT-observation	subj_recurrence subj_ovary subj_tumor subj_IAP subj_levels subj_increased subj_compare obj_patients obj_recurrence obj_ovary tumor obj_IAP obj_levels obj_increased
11689445	In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the dominant-negative p85alpha and in MCF-7 cells by the PI3-kinase inhibitor, LY294002.	CGE-increased	subj_3T3 subj_fibroblasts subj_transfection subj_dominant-negative p85alpha subj_MCF-7 subj_cells subj_PI3-kinase obj_dominant obj_negative obj_p85alpha obj_MCF-7 obj_cells obj_PI3-kinase obj_inhibitor
11689445	In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the dominant-negative p85alpha and in MCF-7 cells by the PI3-kinase inhibitor, LY294002.	IGE-	subj_3T3 subj_fibroblasts subj_transfection subj_dominant-negative p85alpha subj_MCF-7 subj_cells subj_PI3-kinase obj_dominant obj_negative obj_p85alpha obj_MCF-7 obj_cells obj_PI3-kinase obj_inhibitor
11689445	In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the dominant-negative p85alpha and in MCF-7 cells by the PI3-kinase inhibitor, LY294002.	CCS-unidentifiable	subj_3T3 subj_fibroblasts subj_transfection subj_dominant-negative p85alpha subj_MCF-7 subj_cells subj_PI3-kinase obj_dominant obj_negative obj_p85alpha obj_MCF-7 obj_cells obj_PI3-kinase obj_inhibitor
11689445	In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the dominant-negative p85alpha and in MCF-7 cells by the PI3-kinase inhibitor, LY294002.	PT-	subj_3T3 subj_fibroblasts subj_transfection subj_dominant-negative p85alpha subj_MCF-7 subj_cells subj_PI3-kinase obj_dominant obj_negative obj_p85alpha obj_MCF-7 obj_cells obj_PI3-kinase obj_inhibitor
11704864	Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line	CGE-increased	subj_increase subj_level subj_expression subj_Bcl-2 subj_human subj_prostate subj_carcinoma obj_expression obj_Bcl-2 obj_human obj_prostate carcinoma obj_cell
11704864	Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line	IGE-	subj_increase subj_level subj_expression subj_Bcl-2 subj_human subj_prostate subj_carcinoma obj_expression obj_Bcl-2 obj_human obj_prostate carcinoma obj_cell
11704864	Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line	CCS-unidentifiable	subj_increase subj_level subj_expression subj_Bcl-2 subj_human subj_prostate subj_carcinoma obj_expression obj_Bcl-2 obj_human obj_prostate carcinoma obj_cell
11704864	Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line	PT-	subj_increase subj_level subj_expression subj_Bcl-2 subj_human subj_prostate subj_carcinoma obj_expression obj_Bcl-2 obj_human obj_prostate carcinoma obj_cell
11722842	We therefore conclude that MUC18 expression is increased during prostate cancer initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.	CGE-increased	subj_We subj_conclude subj_MUC18 subj_expression subj_increased subj_prostate obj_MUC18 obj_expression obj_increased obj_prostate cancer obj_initiation obj_( obj_grade
11722842	We therefore conclude that MUC18 expression is increased during prostate cancer initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.	IGE-unchanged	subj_We subj_conclude subj_MUC18 subj_expression subj_increased subj_prostate obj_MUC18 obj_expression obj_increased obj_prostate cancer obj_initiation obj_( obj_grade
11722842	We therefore conclude that MUC18 expression is increased during prostate cancer initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.	CCS-normalTOcancer	subj_We subj_conclude subj_MUC18 subj_expression subj_increased subj_prostate obj_MUC18 obj_expression obj_increased obj_prostate cancer obj_initiation obj_( obj_grade
11722842	We therefore conclude that MUC18 expression is increased during prostate cancer initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.	PT-observation	subj_We subj_conclude subj_MUC18 subj_expression subj_increased subj_prostate obj_MUC18 obj_expression obj_increased obj_prostate cancer obj_initiation obj_( obj_grade
11753647	Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)).	CGE-increased	subj_42-bp subj_sequence subj_increased subj_ERCC1 mRNA subj_expression subj_assessment subj_121 obj_expression obj_assessment obj_121 obj_ovarian cancer obj_specimens obj_( obj_p2<10(-6
11753647	Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)).	IGE-unidentifiable	subj_42-bp subj_sequence subj_increased subj_ERCC1 mRNA subj_expression subj_assessment subj_121 obj_expression obj_assessment obj_121 obj_ovarian cancer obj_specimens obj_( obj_p2<10(-6
11753647	Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)).	CCS-normalTOcancer	subj_42-bp subj_sequence subj_increased subj_ERCC1 mRNA subj_expression subj_assessment subj_121 obj_expression obj_assessment obj_121 obj_ovarian cancer obj_specimens obj_( obj_p2<10(-6
11753647	Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)).	PT-observation	subj_42-bp subj_sequence subj_increased subj_ERCC1 mRNA subj_expression subj_assessment subj_121 obj_expression obj_assessment obj_121 obj_ovarian cancer obj_specimens obj_( obj_p2<10(-6
11774200	Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.	CGE-increased	subj_Overexpression subj_HER2 subj_independent subj_prognostic subj_significance obj_independent obj_prognostic obj_significance obj_breast cancer obj_predict obj_response obj_hormonal
11774200	Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.	IGE-unchanged	subj_Overexpression subj_HER2 subj_independent subj_prognostic subj_significance obj_independent obj_prognostic obj_significance obj_breast cancer obj_predict obj_response obj_hormonal
11774200	Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.	CCS-normalTOcancer	subj_Overexpression subj_HER2 subj_independent subj_prognostic subj_significance obj_independent obj_prognostic obj_significance obj_breast cancer obj_predict obj_response obj_hormonal
11774200	Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.	PT-observation	subj_Overexpression subj_HER2 subj_independent subj_prognostic subj_significance obj_independent obj_prognostic obj_significance obj_breast cancer obj_predict obj_response obj_hormonal
11776599	Increase in nitric oxide synthase activity might be related to the growth and malignant behavior of ovarian cancer.	CGE-increased	subj_Increase subj_nitric oxide synthase subj_activity subj_growth subj_malignant obj_growth obj_malignant obj_behavior obj_ovarian cancer
11776599	Increase in nitric oxide synthase activity might be related to the growth and malignant behavior of ovarian cancer.	IGE-unidentifiable	subj_Increase subj_nitric oxide synthase subj_activity subj_growth subj_malignant obj_growth obj_malignant obj_behavior obj_ovarian cancer
11776599	Increase in nitric oxide synthase activity might be related to the growth and malignant behavior of ovarian cancer.	CCS-normalTOcancer	subj_Increase subj_nitric oxide synthase subj_activity subj_growth subj_malignant obj_growth obj_malignant obj_behavior obj_ovarian cancer
11776599	Increase in nitric oxide synthase activity might be related to the growth and malignant behavior of ovarian cancer.	PT-causality	subj_Increase subj_nitric oxide synthase subj_activity subj_growth subj_malignant obj_growth obj_malignant obj_behavior obj_ovarian cancer
11839580	Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).	CGE-increased	subj_cancer subj_( subj_) subj_ER-alpha subj_[ subj_median subj_57.00 obj_patients obj_progressed obj_breast cancer obj_( obj_) obj_ER
11839580	Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).	IGE-unidentifiable	subj_cancer subj_( subj_) subj_ER-alpha subj_[ subj_median subj_57.00 obj_patients obj_progressed obj_breast cancer obj_( obj_) obj_ER
11839580	Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).	CCS-normalTOcancer	subj_cancer subj_( subj_) subj_ER-alpha subj_[ subj_median subj_57.00 obj_patients obj_progressed obj_breast cancer obj_( obj_) obj_ER
11839580	Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).	PT-observation	subj_cancer subj_( subj_) subj_ER-alpha subj_[ subj_median subj_57.00 obj_patients obj_progressed obj_breast cancer obj_( obj_) obj_ER
11839683	These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the growth stimulatory molecule RIalpha, induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive prostate cancer cell growth.	CGE-decreased	subj_antisense subj_efficient subj_depletion subj_growth stimulatory molecule RIalpha subj_induces subj_growth subj_inhibition obj_combat obj_hormone obj_insensitive obj_prostate cancer obj_cell obj_growth
11839683	These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the growth stimulatory molecule RIalpha, induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive prostate cancer cell growth.	IGE-unidentifiable	subj_antisense subj_efficient subj_depletion subj_growth stimulatory molecule RIalpha subj_induces subj_growth subj_inhibition obj_combat obj_hormone obj_insensitive obj_prostate cancer obj_cell obj_growth
11839683	These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the growth stimulatory molecule RIalpha, induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive prostate cancer cell growth.	CCS-cancerTOnormal	subj_antisense subj_efficient subj_depletion subj_growth stimulatory molecule RIalpha subj_induces subj_growth subj_inhibition obj_combat obj_hormone obj_insensitive obj_prostate cancer obj_cell obj_growth
11839683	These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the growth stimulatory molecule RIalpha, induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive prostate cancer cell growth.	PT-causality	subj_antisense subj_efficient subj_depletion subj_growth stimulatory molecule RIalpha subj_induces subj_growth subj_inhibition obj_combat obj_hormone obj_insensitive obj_prostate cancer obj_cell obj_growth
11877386	According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	CGE-decreased	subj_5'-UTRb subj_contributes subj_decrease subj_BRCA1 protein subj_observed subj_sporadic subj_breast obj_observed obj_sporadic obj_breast obj_ovarian cancers
11877386	According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	IGE-unchanged	subj_5'-UTRb subj_contributes subj_decrease subj_BRCA1 protein subj_observed subj_sporadic subj_breast obj_observed obj_sporadic obj_breast obj_ovarian cancers
11877386	According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	CCS-normalTOcancer	subj_5'-UTRb subj_contributes subj_decrease subj_BRCA1 protein subj_observed subj_sporadic subj_breast obj_observed obj_sporadic obj_breast obj_ovarian cancers
11877386	According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	PT-observation	subj_5'-UTRb subj_contributes subj_decrease subj_BRCA1 protein subj_observed subj_sporadic subj_breast obj_observed obj_sporadic obj_breast obj_ovarian cancers
11891846	We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).	CGE-decreased	subj_RU-486 subj_) subj_block subj_c-fms RNA subj_protein subj_expression subj_breast obj_RNA obj_protein obj_expression obj_breast cancer obj_cell obj_lines obj_increase
11891846	We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).	IGE-	subj_RU-486 subj_) subj_block subj_c-fms RNA subj_protein subj_expression subj_breast obj_RNA obj_protein obj_expression obj_breast cancer obj_cell obj_lines obj_increase
11891846	We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).	CCS-unidentifiable	subj_RU-486 subj_) subj_block subj_c-fms RNA subj_protein subj_expression subj_breast obj_RNA obj_protein obj_expression obj_breast cancer obj_cell obj_lines obj_increase
11891846	We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).	PT-	subj_RU-486 subj_) subj_block subj_c-fms RNA subj_protein subj_expression subj_breast obj_RNA obj_protein obj_expression obj_breast cancer obj_cell obj_lines obj_increase
11926891	Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).	CGE-increased	subj_Osteopontin subj_levels subj_plasma subj_( obj_) obj_51 obj_patients obj_epithelial ovarian cancer obj_( obj_486.5 obj_/
11926891	Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).	IGE-unchanged	subj_Osteopontin subj_levels subj_plasma subj_( obj_) obj_51 obj_patients obj_epithelial ovarian cancer obj_( obj_486.5 obj_/
11926891	Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).	CCS-normalTOcancer	subj_Osteopontin subj_levels subj_plasma subj_( obj_) obj_51 obj_patients obj_epithelial ovarian cancer obj_( obj_486.5 obj_/
11926891	Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).	PT-observation	subj_Osteopontin subj_levels subj_plasma subj_( obj_) obj_51 obj_patients obj_epithelial ovarian cancer obj_( obj_486.5 obj_/
11964084	Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.	CGE-increased	subj_ornithine subj_decarboxylase subj_( subj_ODC subj_) subj_rate subj_limiting obj_factor obj_survival obj_human obj_breast cancer obj_suggesting obj_role obj_PA
11964084	Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.	IGE-unidentifiable	subj_ornithine subj_decarboxylase subj_( subj_ODC subj_) subj_rate subj_limiting obj_factor obj_survival obj_human obj_breast cancer obj_suggesting obj_role obj_PA
11964084	Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.	CCS-normalTOcancer	subj_ornithine subj_decarboxylase subj_( subj_ODC subj_) subj_rate subj_limiting obj_factor obj_survival obj_human obj_breast cancer obj_suggesting obj_role obj_PA
11964084	Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.	PT-observation	subj_ornithine subj_decarboxylase subj_( subj_ODC subj_) subj_rate subj_limiting obj_factor obj_survival obj_human obj_breast cancer obj_suggesting obj_role obj_PA
12006545	These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression.	CGE-decreased	subj_induction subj_apoptosis subj_suppression subj_topoisomerase I subj_activity subj_cancer subj_cells obj_expression obj_enhances obj_sensitivity obj_ovarian cancer obj_cells obj_irinotecan obj_induction
12006545	These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression.	IGE-unidentifiable	subj_induction subj_apoptosis subj_suppression subj_topoisomerase I subj_activity subj_cancer subj_cells obj_expression obj_enhances obj_sensitivity obj_ovarian cancer obj_cells obj_irinotecan obj_induction
12006545	These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression.	CCS-cancerTOnormal	subj_induction subj_apoptosis subj_suppression subj_topoisomerase I subj_activity subj_cancer subj_cells obj_expression obj_enhances obj_sensitivity obj_ovarian cancer obj_cells obj_irinotecan obj_induction
12006545	These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression.	PT-causality	subj_induction subj_apoptosis subj_suppression subj_topoisomerase I subj_activity subj_cancer subj_cells obj_expression obj_enhances obj_sensitivity obj_ovarian cancer obj_cells obj_irinotecan obj_induction
12006585	Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells.	CGE-decreased	subj_reduction subj_transcription subj_efficiency subj_Cdc6 promoter-luciferase construct subj_metastatic subj_PC3 subj_cells obj_luciferase obj_construct obj_metastatic obj_PC3 obj_cells obj_compared obj_BPH-1
12006585	Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells.	IGE-unidentifiable	subj_reduction subj_transcription subj_efficiency subj_Cdc6 promoter-luciferase construct subj_metastatic subj_PC3 subj_cells obj_luciferase obj_construct obj_metastatic obj_PC3 obj_cells obj_compared obj_BPH-1
12006585	Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells.	CCS-normalTOcancer	subj_reduction subj_transcription subj_efficiency subj_Cdc6 promoter-luciferase construct subj_metastatic subj_PC3 subj_cells obj_luciferase obj_construct obj_metastatic obj_PC3 obj_cells obj_compared obj_BPH-1
12006585	Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells.	PT-observation	subj_reduction subj_transcription subj_efficiency subj_Cdc6 promoter-luciferase construct subj_metastatic subj_PC3 subj_cells obj_luciferase obj_construct obj_metastatic obj_PC3 obj_cells obj_compared obj_BPH-1
12036928	We had reported previously that although both BT474 and MKN7 cells overexpress ErbB2, only BT474 cells show an antiproliferative response to mAb 4D5 treatment.	CGE-increased	subj_MKN7 subj_cells subj_overexpress subj_ErbB2 subj_BT474 subj_cells subj_antiproliferative obj_cells obj_overexpress obj_ErbB2 obj_BT474 obj_cells obj_antiproliferative obj_response
12036928	We had reported previously that although both BT474 and MKN7 cells overexpress ErbB2, only BT474 cells show an antiproliferative response to mAb 4D5 treatment.	IGE-unchanged	subj_MKN7 subj_cells subj_overexpress subj_ErbB2 subj_BT474 subj_cells subj_antiproliferative obj_cells obj_overexpress obj_ErbB2 obj_BT474 obj_cells obj_antiproliferative obj_response
12036928	We had reported previously that although both BT474 and MKN7 cells overexpress ErbB2, only BT474 cells show an antiproliferative response to mAb 4D5 treatment.	CCS-normalTOcancer	subj_MKN7 subj_cells subj_overexpress subj_ErbB2 subj_BT474 subj_cells subj_antiproliferative obj_cells obj_overexpress obj_ErbB2 obj_BT474 obj_cells obj_antiproliferative obj_response
12036928	We had reported previously that although both BT474 and MKN7 cells overexpress ErbB2, only BT474 cells show an antiproliferative response to mAb 4D5 treatment.	PT-observation	subj_MKN7 subj_cells subj_overexpress subj_ErbB2 subj_BT474 subj_cells subj_antiproliferative obj_cells obj_overexpress obj_ErbB2 obj_BT474 obj_cells obj_antiproliferative obj_response
12066248	Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases.	CGE-increased	subj_ovarian subj_carcinoma subj_elevated subj_CA-125 subj_level subj_: subj_report obj_tuberculosis obj_simulating obj_disseminated obj_ovarian carcinoma obj_elevated obj_CA-125 obj_level
12066248	Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases.	IGE-unidentifiable	subj_ovarian subj_carcinoma subj_elevated subj_CA-125 subj_level subj_: subj_report obj_tuberculosis obj_simulating obj_disseminated obj_ovarian carcinoma obj_elevated obj_CA-125 obj_level
12066248	Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases.	CCS-normalTOcancer	subj_ovarian subj_carcinoma subj_elevated subj_CA-125 subj_level subj_: subj_report obj_tuberculosis obj_simulating obj_disseminated obj_ovarian carcinoma obj_elevated obj_CA-125 obj_level
12066248	Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases.	PT-observation	subj_ovarian subj_carcinoma subj_elevated subj_CA-125 subj_level subj_: subj_report obj_tuberculosis obj_simulating obj_disseminated obj_ovarian carcinoma obj_elevated obj_CA-125 obj_level
12095941	Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.	CGE-increased	subj_induced subj_twofold subj_increase subj_connexin 43 subj_( subj_Cx43 subj_) obj_reduction obj_Cx32 obj_expression obj_RWPE-1 obj_cells
12095941	Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.	IGE-	subj_induced subj_twofold subj_increase subj_connexin 43 subj_( subj_Cx43 subj_) obj_reduction obj_Cx32 obj_expression obj_RWPE-1 obj_cells
12095941	Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.	CCS-unidentifiable	subj_induced subj_twofold subj_increase subj_connexin 43 subj_( subj_Cx43 subj_) obj_reduction obj_Cx32 obj_expression obj_RWPE-1 obj_cells
12095941	Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.	PT-	subj_induced subj_twofold subj_increase subj_connexin 43 subj_( subj_Cx43 subj_) obj_reduction obj_Cx32 obj_expression obj_RWPE-1 obj_cells
12149147	These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.	CGE-decreased	subj_These subj_regulation subj_PRA subj_development subj_ovarian subj_epithelial obj_regulation obj_PRA obj_development obj_ovarian epithelial carcinoma
12149147	These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.	IGE-unidentifiable	subj_These subj_regulation subj_PRA subj_development subj_ovarian subj_epithelial obj_regulation obj_PRA obj_development obj_ovarian epithelial carcinoma
12149147	These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.	CCS-normalTOcancer	subj_These subj_regulation subj_PRA subj_development subj_ovarian subj_epithelial obj_regulation obj_PRA obj_development obj_ovarian epithelial carcinoma
12149147	These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.	PT-observation	subj_These subj_regulation subj_PRA subj_development subj_ovarian subj_epithelial obj_regulation obj_PRA obj_development obj_ovarian epithelial carcinoma
12174904	Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.	CGE-increased	subj_vary subj_individual subj_Induction subj_MDR1-gene subj_expression subj_antineoplastic subj_agents obj_expression obj_antineoplastic obj_agents obj_ovarian cancer obj_cell obj_lines obj_
12174904	Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.	IGE-	subj_vary subj_individual subj_Induction subj_MDR1-gene subj_expression subj_antineoplastic subj_agents obj_expression obj_antineoplastic obj_agents obj_ovarian cancer obj_cell obj_lines obj_
12174904	Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.	CCS-unidentifiable	subj_vary subj_individual subj_Induction subj_MDR1-gene subj_expression subj_antineoplastic subj_agents obj_expression obj_antineoplastic obj_agents obj_ovarian cancer obj_cell obj_lines obj_
12174904	Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.	PT-	subj_vary subj_individual subj_Induction subj_MDR1-gene subj_expression subj_antineoplastic subj_agents obj_expression obj_antineoplastic obj_agents obj_ovarian cancer obj_cell obj_lines obj_
12174912	Up-regulation of VDR in ovarian carcinomas is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.	CGE-increased	subj_Up subj_regulation subj_VDR subj_ovarian subj_carcinomas subj_exclusively obj_Up obj_regulation obj_VDR obj_ovarian carcinomas obj_exclusively obj_induced obj_increase
12174912	Up-regulation of VDR in ovarian carcinomas is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.	IGE-unidentifiable	subj_Up subj_regulation subj_VDR subj_ovarian subj_carcinomas subj_exclusively obj_Up obj_regulation obj_VDR obj_ovarian carcinomas obj_exclusively obj_induced obj_increase
12174912	Up-regulation of VDR in ovarian carcinomas is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.	CCS-normalTOcancer	subj_Up subj_regulation subj_VDR subj_ovarian subj_carcinomas subj_exclusively obj_Up obj_regulation obj_VDR obj_ovarian carcinomas obj_exclusively obj_induced obj_increase
12174912	Up-regulation of VDR in ovarian carcinomas is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.	PT-observation	subj_Up subj_regulation subj_VDR subj_ovarian subj_carcinomas subj_exclusively obj_Up obj_regulation obj_VDR obj_ovarian carcinomas obj_exclusively obj_induced obj_increase
12231537	Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.	CGE-decreased	subj_Maspin subj_noninhibitory subj_serpin subj_family obj_serpin obj_family obj_regulated obj_breast carcinoma obj_overexpressed obj_pancreatic obj_carcinoma
12231537	Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.	IGE-unchanged	subj_Maspin subj_noninhibitory subj_serpin subj_family obj_serpin obj_family obj_regulated obj_breast carcinoma obj_overexpressed obj_pancreatic obj_carcinoma
12231537	Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.	CCS-normalTOcancer	subj_Maspin subj_noninhibitory subj_serpin subj_family obj_serpin obj_family obj_regulated obj_breast carcinoma obj_overexpressed obj_pancreatic obj_carcinoma
12231537	Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.	PT-observation	subj_Maspin subj_noninhibitory subj_serpin subj_family obj_serpin obj_family obj_regulated obj_breast carcinoma obj_overexpressed obj_pancreatic obj_carcinoma
12359757	Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.	CGE-increased	subj_Inhibition subj_ligand subj_mediated subj_HER2 subj_activation subj_androgen subj_independent obj_mediated obj_HER2 obj_activation obj_androgen-independent prostate cancer obj_
12359757	Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.	IGE-	subj_Inhibition subj_ligand subj_mediated subj_HER2 subj_activation subj_androgen subj_independent obj_mediated obj_HER2 obj_activation obj_androgen-independent prostate cancer obj_
12359757	Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.	CCS-unidentifiable	subj_Inhibition subj_ligand subj_mediated subj_HER2 subj_activation subj_androgen subj_independent obj_mediated obj_HER2 obj_activation obj_androgen-independent prostate cancer obj_
12359757	Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.	PT-	subj_Inhibition subj_ligand subj_mediated subj_HER2 subj_activation subj_androgen subj_independent obj_mediated obj_HER2 obj_activation obj_androgen-independent prostate cancer obj_
12409226	Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines.	CGE-increased	subj_BN subj_dependent subj_activation subj_transcription factor Elk-1 subj_increase subj_cell subj_proliferation obj_increase obj_cell obj_proliferation obj_prostate cancer obj_cell obj_lines
12409226	Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines.	IGE-unidentifiable	subj_BN subj_dependent subj_activation subj_transcription factor Elk-1 subj_increase subj_cell subj_proliferation obj_increase obj_cell obj_proliferation obj_prostate cancer obj_cell obj_lines
12409226	Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines.	CCS-normalTOcancer	subj_BN subj_dependent subj_activation subj_transcription factor Elk-1 subj_increase subj_cell subj_proliferation obj_increase obj_cell obj_proliferation obj_prostate cancer obj_cell obj_lines
12409226	Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines.	PT-observation	subj_BN subj_dependent subj_activation subj_transcription factor Elk-1 subj_increase subj_cell subj_proliferation obj_increase obj_cell obj_proliferation obj_prostate cancer obj_cell obj_lines
12414626	We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.	CGE-increased	subj_We subj_increase subj_activated subj_mitogen-activated protein (MAP) kinase subj_prostate subj_tumors subj_patients obj_MAP obj_) obj_kinase obj_prostate tumors obj_patients obj_receiving obj_HF
12414626	We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.	IGE-	subj_We subj_increase subj_activated subj_mitogen-activated protein (MAP) kinase subj_prostate subj_tumors subj_patients obj_MAP obj_) obj_kinase obj_prostate tumors obj_patients obj_receiving obj_HF
12414626	We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.	CCS-unidentifiable	subj_We subj_increase subj_activated subj_mitogen-activated protein (MAP) kinase subj_prostate subj_tumors subj_patients obj_MAP obj_) obj_kinase obj_prostate tumors obj_patients obj_receiving obj_HF
12414626	We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.	PT-	subj_We subj_increase subj_activated subj_mitogen-activated protein (MAP) kinase subj_prostate subj_tumors subj_patients obj_MAP obj_) obj_kinase obj_prostate tumors obj_patients obj_receiving obj_HF
12422056	Moving forward: Herceptin in the adjuvant setting.
HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy.	CGE-increased	subj_adjuvant subj_setting subj_ subj_HER2 subj_overexpression subj_/ subj_amplification obj_/ obj_amplification obj_event obj_breast cancer obj_development obj_poor obj_prognosis
12422056	Moving forward: Herceptin in the adjuvant setting.
HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy.	IGE-unchanged	subj_adjuvant subj_setting subj_ subj_HER2 subj_overexpression subj_/ subj_amplification obj_/ obj_amplification obj_event obj_breast cancer obj_development obj_poor obj_prognosis
12422056	Moving forward: Herceptin in the adjuvant setting.
HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy.	CCS-normalTOcancer	subj_adjuvant subj_setting subj_ subj_HER2 subj_overexpression subj_/ subj_amplification obj_/ obj_amplification obj_event obj_breast cancer obj_development obj_poor obj_prognosis
12422056	Moving forward: Herceptin in the adjuvant setting.
HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy.	PT-observation	subj_adjuvant subj_setting subj_ subj_HER2 subj_overexpression subj_/ subj_amplification obj_/ obj_amplification obj_event obj_breast cancer obj_development obj_poor obj_prognosis
12433721	Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 (CRISP-3), that is up-regulated in prostate cancer, and of which the expression is relatively prostate-specific.	CGE-increased	subj_rich subj_secretoryprotein-3 subj_( subj_CRISP-3 subj_) subj_regulated subj_prostate obj_CRISP-3 obj_) obj_regulated obj_prostate cancer obj_expression obj_prostate obj_specific
12433721	Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 (CRISP-3), that is up-regulated in prostate cancer, and of which the expression is relatively prostate-specific.	IGE-unchanged	subj_rich subj_secretoryprotein-3 subj_( subj_CRISP-3 subj_) subj_regulated subj_prostate obj_CRISP-3 obj_) obj_regulated obj_prostate cancer obj_expression obj_prostate obj_specific
12433721	Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 (CRISP-3), that is up-regulated in prostate cancer, and of which the expression is relatively prostate-specific.	CCS-normalTOcancer	subj_rich subj_secretoryprotein-3 subj_( subj_CRISP-3 subj_) subj_regulated subj_prostate obj_CRISP-3 obj_) obj_regulated obj_prostate cancer obj_expression obj_prostate obj_specific
12433721	Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 (CRISP-3), that is up-regulated in prostate cancer, and of which the expression is relatively prostate-specific.	PT-observation	subj_rich subj_secretoryprotein-3 subj_( subj_CRISP-3 subj_) subj_regulated subj_prostate obj_CRISP-3 obj_) obj_regulated obj_prostate cancer obj_expression obj_prostate obj_specific
12442345	Similarly, neoadjuvant studies demonstrate that letrozole substantially inhibits aromatase activity in both malignant and nonmalignant breast tissues, and markedly suppresses endogenous estrogens within the breast cancers.	CGE-decreased	subj_demonstrate subj_letrozole subj_inhibits subj_aromatase subj_activity subj_malignant subj_nonmalignant obj_suppresses obj_endogenous obj_estrogens obj_breast cancers
12442345	Similarly, neoadjuvant studies demonstrate that letrozole substantially inhibits aromatase activity in both malignant and nonmalignant breast tissues, and markedly suppresses endogenous estrogens within the breast cancers.	IGE-	subj_demonstrate subj_letrozole subj_inhibits subj_aromatase subj_activity subj_malignant subj_nonmalignant obj_suppresses obj_endogenous obj_estrogens obj_breast cancers
12442345	Similarly, neoadjuvant studies demonstrate that letrozole substantially inhibits aromatase activity in both malignant and nonmalignant breast tissues, and markedly suppresses endogenous estrogens within the breast cancers.	CCS-unidentifiable	subj_demonstrate subj_letrozole subj_inhibits subj_aromatase subj_activity subj_malignant subj_nonmalignant obj_suppresses obj_endogenous obj_estrogens obj_breast cancers
12442345	Similarly, neoadjuvant studies demonstrate that letrozole substantially inhibits aromatase activity in both malignant and nonmalignant breast tissues, and markedly suppresses endogenous estrogens within the breast cancers.	PT-	subj_demonstrate subj_letrozole subj_inhibits subj_aromatase subj_activity subj_malignant subj_nonmalignant obj_suppresses obj_endogenous obj_estrogens obj_breast cancers
12459033	In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of Tf gene expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in MCF-7 cells transfected with a construct containing a -3600 to +39	CGE-increased	subj_) subj_increased subj_rate subj_Tf gene subj_expression subj_3-fold subj_1 obj_gene obj_activity obj_induced obj_MCF-7 obj_cells obj_transfected obj_construct
12459033	In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of Tf gene expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in MCF-7 cells transfected with a construct containing a -3600 to +39	IGE-	subj_) subj_increased subj_rate subj_Tf gene subj_expression subj_3-fold subj_1 obj_gene obj_activity obj_induced obj_MCF-7 obj_cells obj_transfected obj_construct
12459033	In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of Tf gene expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in MCF-7 cells transfected with a construct containing a -3600 to +39	CCS-unidentifiable	subj_) subj_increased subj_rate subj_Tf gene subj_expression subj_3-fold subj_1 obj_gene obj_activity obj_induced obj_MCF-7 obj_cells obj_transfected obj_construct
12459033	In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of Tf gene expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in MCF-7 cells transfected with a construct containing a -3600 to +39	PT-	subj_) subj_increased subj_rate subj_Tf gene subj_expression subj_3-fold subj_1 obj_gene obj_activity obj_induced obj_MCF-7 obj_cells obj_transfected obj_construct
12481432	Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer.	CGE-decreased	subj_Overall subj_implicate subj_inhibition subj_DNA-PK subj_component subj_TLK286 subj_cytotoxicity obj_management obj_cisplatin obj_resistant obj_ovarian cancer
12481432	Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer.	IGE-	subj_Overall subj_implicate subj_inhibition subj_DNA-PK subj_component subj_TLK286 subj_cytotoxicity obj_management obj_cisplatin obj_resistant obj_ovarian cancer
12481432	Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer.	CCS-unidentifiable	subj_Overall subj_implicate subj_inhibition subj_DNA-PK subj_component subj_TLK286 subj_cytotoxicity obj_management obj_cisplatin obj_resistant obj_ovarian cancer
12481432	Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer.	PT-	subj_Overall subj_implicate subj_inhibition subj_DNA-PK subj_component subj_TLK286 subj_cytotoxicity obj_management obj_cisplatin obj_resistant obj_ovarian cancer
12507906	In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.	CGE-increased	subj_cDNA subj_hydroxyflutamide subj_enhanced subj_AR subj_activity subj_extent subj_bicalutamide obj_prostate cancer obj_DU-145 obj_cells obj_transiently
12507906	In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.	IGE-	subj_cDNA subj_hydroxyflutamide subj_enhanced subj_AR subj_activity subj_extent subj_bicalutamide obj_prostate cancer obj_DU-145 obj_cells obj_transiently
12507906	In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.	CCS-unidentifiable	subj_cDNA subj_hydroxyflutamide subj_enhanced subj_AR subj_activity subj_extent subj_bicalutamide obj_prostate cancer obj_DU-145 obj_cells obj_transiently
12507906	In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.	PT-	subj_cDNA subj_hydroxyflutamide subj_enhanced subj_AR subj_activity subj_extent subj_bicalutamide obj_prostate cancer obj_DU-145 obj_cells obj_transiently
12507965	The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase.	CGE-increased	subj_proportion subj_PSA-ACT subj_increased subj_prostate subj_cancer obj_PSA obj_ACT obj_increased obj_prostate cancer obj_( obj_PCa obj_)
12507965	The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase.	IGE-unchanged	subj_proportion subj_PSA-ACT subj_increased subj_prostate subj_cancer obj_PSA obj_ACT obj_increased obj_prostate cancer obj_( obj_PCa obj_)
12507965	The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase.	CCS-normalTOcancer	subj_proportion subj_PSA-ACT subj_increased subj_prostate subj_cancer obj_PSA obj_ACT obj_increased obj_prostate cancer obj_( obj_PCa obj_)
12507965	The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase.	PT-observation	subj_proportion subj_PSA-ACT subj_increased subj_prostate subj_cancer obj_PSA obj_ACT obj_increased obj_prostate cancer obj_( obj_PCa obj_)
12539225	Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.	CGE-increased	subj_expression subj_bone morphogenetic protein-7 subj_bone subj_metastatic subj_prostate obj_morphogenetic obj_protein-7 obj_bone obj_metastatic prostate cancer obj_
12539225	Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.	IGE-unchanged	subj_expression subj_bone morphogenetic protein-7 subj_bone subj_metastatic subj_prostate obj_morphogenetic obj_protein-7 obj_bone obj_metastatic prostate cancer obj_
12539225	Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.	CCS-normalTOcancer	subj_expression subj_bone morphogenetic protein-7 subj_bone subj_metastatic subj_prostate obj_morphogenetic obj_protein-7 obj_bone obj_metastatic prostate cancer obj_
12539225	Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.	PT-observation	subj_expression subj_bone morphogenetic protein-7 subj_bone subj_metastatic subj_prostate obj_morphogenetic obj_protein-7 obj_bone obj_metastatic prostate cancer obj_
12544353	Antisense bcl-2 oligodeoxynucleotides decreased Bcl-2 protein levels and significantly inhibited PC-3 cell growth in a dose dependent manner.	CGE-decreased	subj_bcl-2 subj_oligodeoxynucleotides subj_decreased subj_Bcl-2 protein subj_levels subj_inhibited subj_PC-3 obj_protein obj_levels obj_inhibited obj_PC-3 obj_cell obj_growth obj_dose
12544353	Antisense bcl-2 oligodeoxynucleotides decreased Bcl-2 protein levels and significantly inhibited PC-3 cell growth in a dose dependent manner.	IGE-unidentifiable	subj_bcl-2 subj_oligodeoxynucleotides subj_decreased subj_Bcl-2 protein subj_levels subj_inhibited subj_PC-3 obj_protein obj_levels obj_inhibited obj_PC-3 obj_cell obj_growth obj_dose
12544353	Antisense bcl-2 oligodeoxynucleotides decreased Bcl-2 protein levels and significantly inhibited PC-3 cell growth in a dose dependent manner.	CCS-cancerTOnormal	subj_bcl-2 subj_oligodeoxynucleotides subj_decreased subj_Bcl-2 protein subj_levels subj_inhibited subj_PC-3 obj_protein obj_levels obj_inhibited obj_PC-3 obj_cell obj_growth obj_dose
12544353	Antisense bcl-2 oligodeoxynucleotides decreased Bcl-2 protein levels and significantly inhibited PC-3 cell growth in a dose dependent manner.	PT-observation	subj_bcl-2 subj_oligodeoxynucleotides subj_decreased subj_Bcl-2 protein subj_levels subj_inhibited subj_PC-3 obj_protein obj_levels obj_inhibited obj_PC-3 obj_cell obj_growth obj_dose
12569365	Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%).	CGE-increased	subj_Cdc25B subj_frequently subj_overexpressed subj_human obj_frequently obj_overexpressed obj_human obj_prostate cancer obj_tissues obj_( obj_29
12569365	Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%).	IGE-unchanged	subj_Cdc25B subj_frequently subj_overexpressed subj_human obj_frequently obj_overexpressed obj_human obj_prostate cancer obj_tissues obj_( obj_29
12569365	Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%).	CCS-normalTOcancer	subj_Cdc25B subj_frequently subj_overexpressed subj_human obj_frequently obj_overexpressed obj_human obj_prostate cancer obj_tissues obj_( obj_29
12569365	Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%).	PT-observation	subj_Cdc25B subj_frequently subj_overexpressed subj_human obj_frequently obj_overexpressed obj_human obj_prostate cancer obj_tissues obj_( obj_29
12576450	Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.	CGE-decreased	subj_Consequently subj_Id-1 subj_inhibition subj_future subj_benefit obj_future obj_benefit obj_patients obj_ovarian cancer
12576450	Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.	IGE-	subj_Consequently subj_Id-1 subj_inhibition subj_future subj_benefit obj_future obj_benefit obj_patients obj_ovarian cancer
12576450	Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.	CCS-unidentifiable	subj_Consequently subj_Id-1 subj_inhibition subj_future subj_benefit obj_future obj_benefit obj_patients obj_ovarian cancer
12576450	Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.	PT-	subj_Consequently subj_Id-1 subj_inhibition subj_future subj_benefit obj_future obj_benefit obj_patients obj_ovarian cancer
12598323	By immunohistochemical analysis, we have found that PTOV1 is overexpressed in 71% of 38 prostate carcinomas and in 80% of samples with prostate intraepithelial neoplasia.	CGE-increased	subj_immunohistochemical subj_analysis subj_PTOV1 subj_overexpressed subj_71 subj_% obj_71 obj_% obj_38 obj_prostate carcinomas obj_80 obj_% obj_samples
12598323	By immunohistochemical analysis, we have found that PTOV1 is overexpressed in 71% of 38 prostate carcinomas and in 80% of samples with prostate intraepithelial neoplasia.	IGE-unchanged	subj_immunohistochemical subj_analysis subj_PTOV1 subj_overexpressed subj_71 subj_% obj_71 obj_% obj_38 obj_prostate carcinomas obj_80 obj_% obj_samples
12598323	By immunohistochemical analysis, we have found that PTOV1 is overexpressed in 71% of 38 prostate carcinomas and in 80% of samples with prostate intraepithelial neoplasia.	CCS-normalTOcancer	subj_immunohistochemical subj_analysis subj_PTOV1 subj_overexpressed subj_71 subj_% obj_71 obj_% obj_38 obj_prostate carcinomas obj_80 obj_% obj_samples
12598323	By immunohistochemical analysis, we have found that PTOV1 is overexpressed in 71% of 38 prostate carcinomas and in 80% of samples with prostate intraepithelial neoplasia.	PT-observation	subj_immunohistochemical subj_analysis subj_PTOV1 subj_overexpressed subj_71 subj_% obj_71 obj_% obj_38 obj_prostate carcinomas obj_80 obj_% obj_samples
12603425	The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy.	CGE-decreased	subj_absence subj_CD38 subj_presence subj_HLA subj_DR obj_prostatic obj_epithelium obj_consistent obj_BPH obj_tissue obj_surrounding obj_tumour
12603425	The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy.	IGE-	subj_absence subj_CD38 subj_presence subj_HLA subj_DR obj_prostatic obj_epithelium obj_consistent obj_BPH obj_tissue obj_surrounding obj_tumour
12603425	The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy.	CCS-unidentifiable	subj_absence subj_CD38 subj_presence subj_HLA subj_DR obj_prostatic obj_epithelium obj_consistent obj_BPH obj_tissue obj_surrounding obj_tumour
12603425	The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy.	PT-	subj_absence subj_CD38 subj_presence subj_HLA subj_DR obj_prostatic obj_epithelium obj_consistent obj_BPH obj_tissue obj_surrounding obj_tumour
12618764	MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.	CGE-increased	subj_MEK5 subj_overexpression subj_metastatic subj_prostate obj_overexpression obj_metastatic obj_prostate cancer obj_stimulates obj_proliferation obj_MMP-9
12618764	MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.	IGE-unchanged	subj_MEK5 subj_overexpression subj_metastatic subj_prostate obj_overexpression obj_metastatic obj_prostate cancer obj_stimulates obj_proliferation obj_MMP-9
12618764	MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.	CCS-normalTOcancer	subj_MEK5 subj_overexpression subj_metastatic subj_prostate obj_overexpression obj_metastatic obj_prostate cancer obj_stimulates obj_proliferation obj_MMP-9
12618764	MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.	PT-causality	subj_MEK5 subj_overexpression subj_metastatic subj_prostate obj_overexpression obj_metastatic obj_prostate cancer obj_stimulates obj_proliferation obj_MMP-9
12759391	In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation.	CGE-increased	subj_LPA subj_increase subj_level subj_cyclin D1 subj_ovarian subj_cancer subj_cells obj_level obj_cyclin obj_D1 obj_ovarian cancer obj_cells obj_increasing obj_proliferation
12759391	In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation.	IGE-unidentifiable	subj_LPA subj_increase subj_level subj_cyclin D1 subj_ovarian subj_cancer subj_cells obj_level obj_cyclin obj_D1 obj_ovarian cancer obj_cells obj_increasing obj_proliferation
12759391	In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation.	CCS-normalTOcancer	subj_LPA subj_increase subj_level subj_cyclin D1 subj_ovarian subj_cancer subj_cells obj_level obj_cyclin obj_D1 obj_ovarian cancer obj_cells obj_increasing obj_proliferation
12759391	In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation.	PT-observation	subj_LPA subj_increase subj_level subj_cyclin D1 subj_ovarian subj_cancer subj_cells obj_level obj_cyclin obj_D1 obj_ovarian cancer obj_cells obj_increasing obj_proliferation
12761490	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	CGE-increased	subj_( subj_PI-3K)-dependent subj_activation subj_Akt subj_increased subj_resistance subj_cells obj_Transfection obj_HER2 obj_MCF7 obj_breast cancer obj_cells obj_express obj_HER3
12761490	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	IGE-unidentifiable	subj_( subj_PI-3K)-dependent subj_activation subj_Akt subj_increased subj_resistance subj_cells obj_Transfection obj_HER2 obj_MCF7 obj_breast cancer obj_cells obj_express obj_HER3
12761490	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	CCS-normalTOcancer	subj_( subj_PI-3K)-dependent subj_activation subj_Akt subj_increased subj_resistance subj_cells obj_Transfection obj_HER2 obj_MCF7 obj_breast cancer obj_cells obj_express obj_HER3
12761490	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	PT-observation	subj_( subj_PI-3K)-dependent subj_activation subj_Akt subj_increased subj_resistance subj_cells obj_Transfection obj_HER2 obj_MCF7 obj_breast cancer obj_cells obj_express obj_HER3
12771931	These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-beta1 signalling effectors and subsequently I kappa B alpha.	CGE-increased	subj_initially subj_inducing subj_expression subj_TGF-beta1 subj_signalling subj_effectors subj_subsequently obj_based obj_doxazosin obj_mediates obj_prostate cancer obj_apoptosis obj_initially obj_inducing
12771931	These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-beta1 signalling effectors and subsequently I kappa B alpha.	IGE-unidentifiable	subj_initially subj_inducing subj_expression subj_TGF-beta1 subj_signalling subj_effectors subj_subsequently obj_based obj_doxazosin obj_mediates obj_prostate cancer obj_apoptosis obj_initially obj_inducing
12771931	These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-beta1 signalling effectors and subsequently I kappa B alpha.	CCS-cancerTOnormal	subj_initially subj_inducing subj_expression subj_TGF-beta1 subj_signalling subj_effectors subj_subsequently obj_based obj_doxazosin obj_mediates obj_prostate cancer obj_apoptosis obj_initially obj_inducing
12771931	These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-beta1 signalling effectors and subsequently I kappa B alpha.	PT-causality	subj_initially subj_inducing subj_expression subj_TGF-beta1 subj_signalling subj_effectors subj_subsequently obj_based obj_doxazosin obj_mediates obj_prostate cancer obj_apoptosis obj_initially obj_inducing
12792888	Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas.	CGE-decreased	subj_p21Cip1 subj_expression subj_indicators subj_aggressiveness obj_expression obj_indicators obj_aggressiveness obj_ovarian adenocarcinomas obj_differentially obj_regulated obj_LMP
12792888	Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas.	IGE-unidentifiable	subj_p21Cip1 subj_expression subj_indicators subj_aggressiveness obj_expression obj_indicators obj_aggressiveness obj_ovarian adenocarcinomas obj_differentially obj_regulated obj_LMP
12792888	Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas.	CCS-normalTOcancer	subj_p21Cip1 subj_expression subj_indicators subj_aggressiveness obj_expression obj_indicators obj_aggressiveness obj_ovarian adenocarcinomas obj_differentially obj_regulated obj_LMP
12792888	Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas.	PT-observation	subj_p21Cip1 subj_expression subj_indicators subj_aggressiveness obj_expression obj_indicators obj_aggressiveness obj_ovarian adenocarcinomas obj_differentially obj_regulated obj_LMP
12808114	The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups.	CGE-decreased	subj_deleted subj_prostate subj_cancer subj_6q subj_8p subj_13q subj_A obj_loss obj_frequently obj_deleted obj_prostate cancer obj_6q obj_8p obj_13q
12808114	The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups.	IGE-	subj_deleted subj_prostate subj_cancer subj_6q subj_8p subj_13q subj_A obj_loss obj_frequently obj_deleted obj_prostate cancer obj_6q obj_8p obj_13q
12808114	The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups.	CCS-unidentifiable	subj_deleted subj_prostate subj_cancer subj_6q subj_8p subj_13q subj_A obj_loss obj_frequently obj_deleted obj_prostate cancer obj_6q obj_8p obj_13q
12808114	The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups.	PT-	subj_deleted subj_prostate subj_cancer subj_6q subj_8p subj_13q subj_A obj_loss obj_frequently obj_deleted obj_prostate cancer obj_6q obj_8p obj_13q
12824874	Our results strongly suggest that the induction of Cx26 protein observed in human breast cancers, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.	CGE-increased	subj_Our subj_induction subj_Cx26 protein subj_observed subj_human subj_breast obj_reported obj_relevant obj_development obj_breast cancers obj_Cx26 obj_function obj_tumor
12824874	Our results strongly suggest that the induction of Cx26 protein observed in human breast cancers, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.	IGE-	subj_Our subj_induction subj_Cx26 protein subj_observed subj_human subj_breast obj_reported obj_relevant obj_development obj_breast cancers obj_Cx26 obj_function obj_tumor
12824874	Our results strongly suggest that the induction of Cx26 protein observed in human breast cancers, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.	CCS-unidentifiable	subj_Our subj_induction subj_Cx26 protein subj_observed subj_human subj_breast obj_reported obj_relevant obj_development obj_breast cancers obj_Cx26 obj_function obj_tumor
12824874	Our results strongly suggest that the induction of Cx26 protein observed in human breast cancers, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.	PT-	subj_Our subj_induction subj_Cx26 protein subj_observed subj_human subj_breast obj_reported obj_relevant obj_development obj_breast cancers obj_Cx26 obj_function obj_tumor
12855632	These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.	CGE-increased	subj_These subj_CLDN3 subj_CLDN4 subj_frequently subj_regulated subj_ovarian obj_CLDN4 obj_frequently obj_regulated obj_ovarian tumors obj_cell obj_lines obj_represent
12855632	These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.	IGE-unchanged	subj_These subj_CLDN3 subj_CLDN4 subj_frequently subj_regulated subj_ovarian obj_CLDN4 obj_frequently obj_regulated obj_ovarian tumors obj_cell obj_lines obj_represent
12855632	These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.	CCS-normalTOcancer	subj_These subj_CLDN3 subj_CLDN4 subj_frequently subj_regulated subj_ovarian obj_CLDN4 obj_frequently obj_regulated obj_ovarian tumors obj_cell obj_lines obj_represent
12855632	These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.	PT-observation	subj_These subj_CLDN3 subj_CLDN4 subj_frequently subj_regulated subj_ovarian obj_CLDN4 obj_frequently obj_regulated obj_ovarian tumors obj_cell obj_lines obj_represent
12861063	The analysis of E-cadherin glycoprotein expression is a powerful tool for distinguishing lobular from ductal carcinomas, because complete loss of E-cadherin expression occurs in most infiltrating lobular tumors and lobular carcinomas in situ, but not in ductal tumors.	CGE-decreased	subj_carcinomas subj_complete subj_loss subj_E-cadherin subj_expression subj_occurs subj_infiltrating obj_infiltrating obj_lobular obj_tumors obj_lobular carcinomas obj_situ obj_ductal obj_tumors
12861063	The analysis of E-cadherin glycoprotein expression is a powerful tool for distinguishing lobular from ductal carcinomas, because complete loss of E-cadherin expression occurs in most infiltrating lobular tumors and lobular carcinomas in situ, but not in ductal tumors.	IGE-unidentifiable	subj_carcinomas subj_complete subj_loss subj_E-cadherin subj_expression subj_occurs subj_infiltrating obj_infiltrating obj_lobular obj_tumors obj_lobular carcinomas obj_situ obj_ductal obj_tumors
12861063	The analysis of E-cadherin glycoprotein expression is a powerful tool for distinguishing lobular from ductal carcinomas, because complete loss of E-cadherin expression occurs in most infiltrating lobular tumors and lobular carcinomas in situ, but not in ductal tumors.	CCS-normalTOcancer	subj_carcinomas subj_complete subj_loss subj_E-cadherin subj_expression subj_occurs subj_infiltrating obj_infiltrating obj_lobular obj_tumors obj_lobular carcinomas obj_situ obj_ductal obj_tumors
12861063	The analysis of E-cadherin glycoprotein expression is a powerful tool for distinguishing lobular from ductal carcinomas, because complete loss of E-cadherin expression occurs in most infiltrating lobular tumors and lobular carcinomas in situ, but not in ductal tumors.	PT-observation	subj_carcinomas subj_complete subj_loss subj_E-cadherin subj_expression subj_occurs subj_infiltrating obj_infiltrating obj_lobular obj_tumors obj_lobular carcinomas obj_situ obj_ductal obj_tumors
12875974	The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.	CGE-increased	subj_Bax subj_inhibitor-1 subj_( subj_BI-1 subj_) subj_prostate subj_carcinoma obj_) obj_prostate obj_carcinoma obj_prostate cancer obj_cell obj_lines obj_confirmed
12875974	The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.	IGE-unchanged	subj_Bax subj_inhibitor-1 subj_( subj_BI-1 subj_) subj_prostate subj_carcinoma obj_) obj_prostate obj_carcinoma obj_prostate cancer obj_cell obj_lines obj_confirmed
12875974	The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.	CCS-normalTOcancer	subj_Bax subj_inhibitor-1 subj_( subj_BI-1 subj_) subj_prostate subj_carcinoma obj_) obj_prostate obj_carcinoma obj_prostate cancer obj_cell obj_lines obj_confirmed
12875974	The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.	PT-observation	subj_Bax subj_inhibitor-1 subj_( subj_BI-1 subj_) subj_prostate subj_carcinoma obj_) obj_prostate obj_carcinoma obj_prostate cancer obj_cell obj_lines obj_confirmed
12907652	These observations suggest that U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression.	CGE-decreased	subj_dependent subj_growth subj_inhibition subj_U19 subj_regulation subj_commonly subj_prostate obj_U19 obj_regulation obj_commonly obj_prostate cancer obj_progression
12907652	These observations suggest that U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression.	IGE-unidentifiable	subj_dependent subj_growth subj_inhibition subj_U19 subj_regulation subj_commonly subj_prostate obj_U19 obj_regulation obj_commonly obj_prostate cancer obj_progression
12907652	These observations suggest that U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression.	CCS-normalTOcancer	subj_dependent subj_growth subj_inhibition subj_U19 subj_regulation subj_commonly subj_prostate obj_U19 obj_regulation obj_commonly obj_prostate cancer obj_progression
12907652	These observations suggest that U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression.	PT-causality	subj_dependent subj_growth subj_inhibition subj_U19 subj_regulation subj_commonly subj_prostate obj_U19 obj_regulation obj_commonly obj_prostate cancer obj_progression
12942541	Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos.	CGE-increased	subj_appears subj_responsible subj_induction subj_c-fos obj_Our obj_MCF-7 obj_cells obj_Ang obj_II
12942541	Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos.	IGE-	subj_appears subj_responsible subj_induction subj_c-fos obj_Our obj_MCF-7 obj_cells obj_Ang obj_II
12942541	Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos.	CCS-unidentifiable	subj_appears subj_responsible subj_induction subj_c-fos obj_Our obj_MCF-7 obj_cells obj_Ang obj_II
12942541	Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos.	PT-	subj_appears subj_responsible subj_induction subj_c-fos obj_Our obj_MCF-7 obj_cells obj_Ang obj_II
1317462	Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation.	CGE-increased	subj_detectable subj_immunohistochemical subj_assay subj_p53 protein subj_accumulation subj_ obj_cancer obj_cell obj_lines obj_breast carcinomas obj_detectable obj_immunohistochemical obj_assay
1317462	Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation.	IGE-unchanged	subj_detectable subj_immunohistochemical subj_assay subj_p53 protein subj_accumulation subj_ obj_cancer obj_cell obj_lines obj_breast carcinomas obj_detectable obj_immunohistochemical obj_assay
1317462	Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation.	CCS-normalTOcancer	subj_detectable subj_immunohistochemical subj_assay subj_p53 protein subj_accumulation subj_ obj_cancer obj_cell obj_lines obj_breast carcinomas obj_detectable obj_immunohistochemical obj_assay
1317462	Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation.	PT-observation	subj_detectable subj_immunohistochemical subj_assay subj_p53 protein subj_accumulation subj_ obj_cancer obj_cell obj_lines obj_breast carcinomas obj_detectable obj_immunohistochemical obj_assay
1349318	No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.	CGE-increased	subj_increased subj_PTPase subj_activity subj_c-erbB-2 subj_overexpression subj_grade subj_stage obj_disease obj_primary obj_human obj_mammary tumors
1349318	No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.	IGE-	subj_increased subj_PTPase subj_activity subj_c-erbB-2 subj_overexpression subj_grade subj_stage obj_disease obj_primary obj_human obj_mammary tumors
1349318	No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.	CCS-unidentifiable	subj_increased subj_PTPase subj_activity subj_c-erbB-2 subj_overexpression subj_grade subj_stage obj_disease obj_primary obj_human obj_mammary tumors
1349318	No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.	PT-	subj_increased subj_PTPase subj_activity subj_c-erbB-2 subj_overexpression subj_grade subj_stage obj_disease obj_primary obj_human obj_mammary tumors
1358427	Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer.	CGE-increased	subj_Amplification subj_overexpression subj_c-erbB-2 gene subj_reported subj_correlate subj_poor obj_human obj_breast obj_gastric obj_ovarian cancer
1358427	Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer.	IGE-unchanged	subj_Amplification subj_overexpression subj_c-erbB-2 gene subj_reported subj_correlate subj_poor obj_human obj_breast obj_gastric obj_ovarian cancer
1358427	Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer.	CCS-normalTOcancer	subj_Amplification subj_overexpression subj_c-erbB-2 gene subj_reported subj_correlate subj_poor obj_human obj_breast obj_gastric obj_ovarian cancer
1358427	Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer.	PT-observation	subj_Amplification subj_overexpression subj_c-erbB-2 gene subj_reported subj_correlate subj_poor obj_human obj_breast obj_gastric obj_ovarian cancer
1436241	IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells.	CGE-increased	subj_MDA subj_MB-468 subj_cells subj_HLA class II (DR) subj_expression subj_ZR-75 subj_1 obj_ZR-75 obj_1 obj_BT-20 obj_MDA-MB-468 obj_cells obj_HLA obj_class
1436241	IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells.	IGE-	subj_MDA subj_MB-468 subj_cells subj_HLA class II (DR) subj_expression subj_ZR-75 subj_1 obj_ZR-75 obj_1 obj_BT-20 obj_MDA-MB-468 obj_cells obj_HLA obj_class
1436241	IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells.	CCS-unidentifiable	subj_MDA subj_MB-468 subj_cells subj_HLA class II (DR) subj_expression subj_ZR-75 subj_1 obj_ZR-75 obj_1 obj_BT-20 obj_MDA-MB-468 obj_cells obj_HLA obj_class
1436241	IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells.	PT-	subj_MDA subj_MB-468 subj_cells subj_HLA class II (DR) subj_expression subj_ZR-75 subj_1 obj_ZR-75 obj_1 obj_BT-20 obj_MDA-MB-468 obj_cells obj_HLA obj_class
14516936	BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.	CGE-decreased	subj_BRCA1 subj_expression subj_decreased subj_absent obj_proportion obj_sporadic obj_breast obj_ovarian cancers obj_suggesting obj_wider obj_role
14516936	BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.	IGE-unchanged	subj_BRCA1 subj_expression subj_decreased subj_absent obj_proportion obj_sporadic obj_breast obj_ovarian cancers obj_suggesting obj_wider obj_role
14516936	BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.	CCS-normalTOcancer	subj_BRCA1 subj_expression subj_decreased subj_absent obj_proportion obj_sporadic obj_breast obj_ovarian cancers obj_suggesting obj_wider obj_role
14516936	BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.	PT-observation	subj_BRCA1 subj_expression subj_decreased subj_absent obj_proportion obj_sporadic obj_breast obj_ovarian cancers obj_suggesting obj_wider obj_role
14563607	The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma.	CGE-increased	subj_mass subj_elevated subj_serum subj_CA 125 subj_level subj_mimicking subj_disseminated obj_level obj_mimicking obj_disseminated obj_ovarian carcinoma
14563607	The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma.	IGE-unchanged	subj_mass subj_elevated subj_serum subj_CA 125 subj_level subj_mimicking subj_disseminated obj_level obj_mimicking obj_disseminated obj_ovarian carcinoma
14563607	The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma.	CCS-normalTOcancer	subj_mass subj_elevated subj_serum subj_CA 125 subj_level subj_mimicking subj_disseminated obj_level obj_mimicking obj_disseminated obj_ovarian carcinoma
14563607	The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma.	PT-observation	subj_mass subj_elevated subj_serum subj_CA 125 subj_level subj_mimicking subj_disseminated obj_level obj_mimicking obj_disseminated obj_ovarian carcinoma
1458483	Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.	CGE-increased	subj_findings subj_bcl-2 subj_expression subj_augmented subj_androgen obj_ablation obj_correlated obj_progression obj_prostate cancer obj_androgen obj_dependence obj_androgen
1458483	Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.	IGE-unidentifiable	subj_findings subj_bcl-2 subj_expression subj_augmented subj_androgen obj_ablation obj_correlated obj_progression obj_prostate cancer obj_androgen obj_dependence obj_androgen
1458483	Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.	CCS-normalTOcancer	subj_findings subj_bcl-2 subj_expression subj_augmented subj_androgen obj_ablation obj_correlated obj_progression obj_prostate cancer obj_androgen obj_dependence obj_androgen
1458483	Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.	PT-observation	subj_findings subj_bcl-2 subj_expression subj_augmented subj_androgen obj_ablation obj_correlated obj_progression obj_prostate cancer obj_androgen obj_dependence obj_androgen
14607217	OC expression is elevated in prostate tumor cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.	CGE-increased	subj_OC subj_expression subj_elevated subj_prostate obj_expression obj_elevated obj_prostate tumor obj_cells obj_prostate obj_bone
14607217	OC expression is elevated in prostate tumor cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.	IGE-unchanged	subj_OC subj_expression subj_elevated subj_prostate obj_expression obj_elevated obj_prostate tumor obj_cells obj_prostate obj_bone
14607217	OC expression is elevated in prostate tumor cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.	CCS-normalTOcancer	subj_OC subj_expression subj_elevated subj_prostate obj_expression obj_elevated obj_prostate tumor obj_cells obj_prostate obj_bone
14607217	OC expression is elevated in prostate tumor cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.	PT-observation	subj_OC subj_expression subj_elevated subj_prostate obj_expression obj_elevated obj_prostate tumor obj_cells obj_prostate obj_bone
14624913	To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).	CGE-increased	subj_specific subj_antigen subj_( subj_PSA subj_) subj_and/or subj_abnormal obj_TURP obj_) obj_diagnosing obj_prostate cancer obj_patients obj_obstructive obj_voiding
14624913	To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).	IGE-	subj_specific subj_antigen subj_( subj_PSA subj_) subj_and/or subj_abnormal obj_TURP obj_) obj_diagnosing obj_prostate cancer obj_patients obj_obstructive obj_voiding
14624913	To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).	CCS-unidentifiable	subj_specific subj_antigen subj_( subj_PSA subj_) subj_and/or subj_abnormal obj_TURP obj_) obj_diagnosing obj_prostate cancer obj_patients obj_obstructive obj_voiding
14624913	To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).	PT-	subj_specific subj_antigen subj_( subj_PSA subj_) subj_and/or subj_abnormal obj_TURP obj_) obj_diagnosing obj_prostate cancer obj_patients obj_obstructive obj_voiding
14629195	We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.	CGE-increased	subj_We subj_expression subj_activated subj_Src subj_breast subj_cancer subj_cells obj_expression obj_activated obj_Src obj_breast cancer obj_cells obj_increased obj_expression
14629195	We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.	IGE-	subj_We subj_expression subj_activated subj_Src subj_breast subj_cancer subj_cells obj_expression obj_activated obj_Src obj_breast cancer obj_cells obj_increased obj_expression
14629195	We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.	CCS-unidentifiable	subj_We subj_expression subj_activated subj_Src subj_breast subj_cancer subj_cells obj_expression obj_activated obj_Src obj_breast cancer obj_cells obj_increased obj_expression
14629195	We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.	PT-	subj_We subj_expression subj_activated subj_Src subj_breast subj_cancer subj_cells obj_expression obj_activated obj_Src obj_breast cancer obj_cells obj_increased obj_expression
1464654	Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.	CGE-increased	subj_cell subj_growth subj_secretion subj_procathepsin D subj_120-kilodalton subj_protein subj_human obj_120-kilodalton obj_protein obj_human obj_ovarian cancer obj_cell obj_BG-1 obj_
1464654	Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.	IGE-unidentifiable	subj_cell subj_growth subj_secretion subj_procathepsin D subj_120-kilodalton subj_protein subj_human obj_120-kilodalton obj_protein obj_human obj_ovarian cancer obj_cell obj_BG-1 obj_
1464654	Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.	CCS-normalTOcancer	subj_cell subj_growth subj_secretion subj_procathepsin D subj_120-kilodalton subj_protein subj_human obj_120-kilodalton obj_protein obj_human obj_ovarian cancer obj_cell obj_BG-1 obj_
1464654	Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.	PT-observation	subj_cell subj_growth subj_secretion subj_procathepsin D subj_120-kilodalton subj_protein subj_human obj_120-kilodalton obj_protein obj_human obj_ovarian cancer obj_cell obj_BG-1 obj_
14665875	The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.	CGE-increased	subj_specific subj_antigen subj_( subj_PSA subj_) subj_increases subj_extended obj_prostate cancer obj_detection obj_rate obj_patients
14665875	The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.	IGE-	subj_specific subj_antigen subj_( subj_PSA subj_) subj_increases subj_extended obj_prostate cancer obj_detection obj_rate obj_patients
14665875	The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.	CCS-unidentifiable	subj_specific subj_antigen subj_( subj_PSA subj_) subj_increases subj_extended obj_prostate cancer obj_detection obj_rate obj_patients
14665875	The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.	PT-	subj_specific subj_antigen subj_( subj_PSA subj_) subj_increases subj_extended obj_prostate cancer obj_detection obj_rate obj_patients
14676836	Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1.	CGE-increased	subj_CDKIs subj_) subj_p15INK4B subj_p27KIP1 obj_Finally obj_androgen obj_treatment obj_LNCaP obj_cells obj_upregulated obj_levels
14676836	Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1.	IGE-	subj_CDKIs subj_) subj_p15INK4B subj_p27KIP1 obj_Finally obj_androgen obj_treatment obj_LNCaP obj_cells obj_upregulated obj_levels
14676836	Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1.	CCS-unidentifiable	subj_CDKIs subj_) subj_p15INK4B subj_p27KIP1 obj_Finally obj_androgen obj_treatment obj_LNCaP obj_cells obj_upregulated obj_levels
14676836	Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1.	PT-	subj_CDKIs subj_) subj_p15INK4B subj_p27KIP1 obj_Finally obj_androgen obj_treatment obj_LNCaP obj_cells obj_upregulated obj_levels
14687488	Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.	CGE-increased	subj_findings subj_increased subj_HIF-1alpha protein subj_expression subj_BPH subj_Pca obj_potential obj_role obj_protein obj_BPH obj_Pca
14687488	Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.	IGE-unidentifiable	subj_findings subj_increased subj_HIF-1alpha protein subj_expression subj_BPH subj_Pca obj_potential obj_role obj_protein obj_BPH obj_Pca
14687488	Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.	CCS-normalTOcancer	subj_findings subj_increased subj_HIF-1alpha protein subj_expression subj_BPH subj_Pca obj_potential obj_role obj_protein obj_BPH obj_Pca
14687488	Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.	PT-observation	subj_findings subj_increased subj_HIF-1alpha protein subj_expression subj_BPH subj_Pca obj_potential obj_role obj_protein obj_BPH obj_Pca
14694444	Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.	CGE-decreased	subj_studies subj_reduction subj_BRCA1 mRNA subj_protein subj_result subj_increased obj_increased obj_proliferation obj_BG-1 obj_ovarian cancer obj_cells obj_vitro obj_vivo
14694444	Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.	IGE-unidentifiable	subj_studies subj_reduction subj_BRCA1 mRNA subj_protein subj_result subj_increased obj_increased obj_proliferation obj_BG-1 obj_ovarian cancer obj_cells obj_vitro obj_vivo
14694444	Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.	CCS-normalTOcancer	subj_studies subj_reduction subj_BRCA1 mRNA subj_protein subj_result subj_increased obj_increased obj_proliferation obj_BG-1 obj_ovarian cancer obj_cells obj_vitro obj_vivo
14694444	Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.	PT-causality	subj_studies subj_reduction subj_BRCA1 mRNA subj_protein subj_result subj_increased obj_increased obj_proliferation obj_BG-1 obj_ovarian cancer obj_cells obj_vitro obj_vivo
14701673	Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells.	CGE-increased	subj_FKHRL1 subj_induced subj_activity subj_Fas ligand promoter subj_Caov-3 subj_cells obj_Fas obj_ligand obj_promoter obj_Caov-3 obj_cells
14701673	Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells.	IGE-	subj_FKHRL1 subj_induced subj_activity subj_Fas ligand promoter subj_Caov-3 subj_cells obj_Fas obj_ligand obj_promoter obj_Caov-3 obj_cells
14701673	Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells.	CCS-unidentifiable	subj_FKHRL1 subj_induced subj_activity subj_Fas ligand promoter subj_Caov-3 subj_cells obj_Fas obj_ligand obj_promoter obj_Caov-3 obj_cells
14701673	Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells.	PT-	subj_FKHRL1 subj_induced subj_activity subj_Fas ligand promoter subj_Caov-3 subj_cells obj_Fas obj_ligand obj_promoter obj_Caov-3 obj_cells
14735192	Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer.	CGE-decreased	subj_ongoing subj_therapeutic subj_attempts subj_EGFR subj_inhibition subj_subgroups subj_patients obj_inhibition obj_subgroups obj_patients obj_prostate cancer
14735192	Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer.	IGE-	subj_ongoing subj_therapeutic subj_attempts subj_EGFR subj_inhibition subj_subgroups subj_patients obj_inhibition obj_subgroups obj_patients obj_prostate cancer
14735192	Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer.	CCS-unidentifiable	subj_ongoing subj_therapeutic subj_attempts subj_EGFR subj_inhibition subj_subgroups subj_patients obj_inhibition obj_subgroups obj_patients obj_prostate cancer
14735192	Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer.	PT-	subj_ongoing subj_therapeutic subj_attempts subj_EGFR subj_inhibition subj_subgroups subj_patients obj_inhibition obj_subgroups obj_patients obj_prostate cancer
14739059	Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.	CGE-increased	subj_tumors subj_elevated subj_serum subj_inhibin subj_levels subj_detected subj_patients obj_evaluation obj_management obj_nondysgerminomatous obj_ovarian germ cell tumors obj_elevated obj_serum obj_inhibin
14739059	Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.	IGE-unchanged	subj_tumors subj_elevated subj_serum subj_inhibin subj_levels subj_detected subj_patients obj_evaluation obj_management obj_nondysgerminomatous obj_ovarian germ cell tumors obj_elevated obj_serum obj_inhibin
14739059	Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.	CCS-normalTOcancer	subj_tumors subj_elevated subj_serum subj_inhibin subj_levels subj_detected subj_patients obj_evaluation obj_management obj_nondysgerminomatous obj_ovarian germ cell tumors obj_elevated obj_serum obj_inhibin
14739059	Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.	PT-observation	subj_tumors subj_elevated subj_serum subj_inhibin subj_levels subj_detected subj_patients obj_evaluation obj_management obj_nondysgerminomatous obj_ovarian germ cell tumors obj_elevated obj_serum obj_inhibin
14743504	These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.	CGE-decreased	subj_protein subj_genetic subj_epigenetic subj_BRCA1 gene subj_play subj_role subj_development obj_role obj_development obj_sporadic obj_ovarian carcinomas obj_serous obj_histology
14743504	These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.	IGE-unidentifiable	subj_protein subj_genetic subj_epigenetic subj_BRCA1 gene subj_play subj_role subj_development obj_role obj_development obj_sporadic obj_ovarian carcinomas obj_serous obj_histology
14743504	These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.	CCS-normalTOcancer	subj_protein subj_genetic subj_epigenetic subj_BRCA1 gene subj_play subj_role subj_development obj_role obj_development obj_sporadic obj_ovarian carcinomas obj_serous obj_histology
14743504	These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.	PT-causality	subj_protein subj_genetic subj_epigenetic subj_BRCA1 gene subj_play subj_role subj_development obj_role obj_development obj_sporadic obj_ovarian carcinomas obj_serous obj_histology
14744752	First, a comprehensive serial immunohistochemical analysis of primary and metastatic prostate cancer samples showed increased stage-specific expression of IL-11Ralpha during disease progression.	CGE-increased	subj_stage subj_specific subj_expression subj_IL-11Ralpha subj_disease subj_progression obj_analysis obj_primary obj_metastatic obj_prostate cancer obj_samples obj_increased obj_stage
14744752	First, a comprehensive serial immunohistochemical analysis of primary and metastatic prostate cancer samples showed increased stage-specific expression of IL-11Ralpha during disease progression.	IGE-unidentifiable	subj_stage subj_specific subj_expression subj_IL-11Ralpha subj_disease subj_progression obj_analysis obj_primary obj_metastatic obj_prostate cancer obj_samples obj_increased obj_stage
14744752	First, a comprehensive serial immunohistochemical analysis of primary and metastatic prostate cancer samples showed increased stage-specific expression of IL-11Ralpha during disease progression.	CCS-normalTOcancer	subj_stage subj_specific subj_expression subj_IL-11Ralpha subj_disease subj_progression obj_analysis obj_primary obj_metastatic obj_prostate cancer obj_samples obj_increased obj_stage
14744752	First, a comprehensive serial immunohistochemical analysis of primary and metastatic prostate cancer samples showed increased stage-specific expression of IL-11Ralpha during disease progression.	PT-observation	subj_stage subj_specific subj_expression subj_IL-11Ralpha subj_disease subj_progression obj_analysis obj_primary obj_metastatic obj_prostate cancer obj_samples obj_increased obj_stage
14744778	Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.	CGE-decreased	subj_molecular subj_events subj_loss subj_AP-2 subj_prostate subj_epithelium subj_implications obj_understanding obj_prevention obj_onset obj_prostate cancer
14744778	Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.	IGE-	subj_molecular subj_events subj_loss subj_AP-2 subj_prostate subj_epithelium subj_implications obj_understanding obj_prevention obj_onset obj_prostate cancer
14744778	Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.	CCS-unidentifiable	subj_molecular subj_events subj_loss subj_AP-2 subj_prostate subj_epithelium subj_implications obj_understanding obj_prevention obj_onset obj_prostate cancer
14744778	Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.	PT-	subj_molecular subj_events subj_loss subj_AP-2 subj_prostate subj_epithelium subj_implications obj_understanding obj_prevention obj_onset obj_prostate cancer
14749128	Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth.	CGE-decreased	subj_Inhibition subj_ILK subj_activity subj_inhibits subj_prostate obj_ILK obj_activity obj_inhibits obj_prostate tumor obj_angiogenesis obj_suppresses obj_tumor
14749128	Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth.	IGE-unidentifiable	subj_Inhibition subj_ILK subj_activity subj_inhibits subj_prostate obj_ILK obj_activity obj_inhibits obj_prostate tumor obj_angiogenesis obj_suppresses obj_tumor
14749128	Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth.	CCS-cancerTOnormal	subj_Inhibition subj_ILK subj_activity subj_inhibits subj_prostate obj_ILK obj_activity obj_inhibits obj_prostate tumor obj_angiogenesis obj_suppresses obj_tumor
14749128	Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth.	PT-causality	subj_Inhibition subj_ILK subj_activity subj_inhibits subj_prostate obj_ILK obj_activity obj_inhibits obj_prostate tumor obj_angiogenesis obj_suppresses obj_tumor
14766760	The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis.	CGE-decreased	subj_abrogation subj_JNK subj_activity subj_HIPK3 subj_expression subj_restore subj_interaction obj_interaction obj_increased obj_sensitivity obj_DU 145 obj_cells obj_Fas obj_receptor
14766760	The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis.	IGE-unidentifiable	subj_abrogation subj_JNK subj_activity subj_HIPK3 subj_expression subj_restore subj_interaction obj_interaction obj_increased obj_sensitivity obj_DU 145 obj_cells obj_Fas obj_receptor
14766760	The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis.	CCS-cancerTOnormal	subj_abrogation subj_JNK subj_activity subj_HIPK3 subj_expression subj_restore subj_interaction obj_interaction obj_increased obj_sensitivity obj_DU 145 obj_cells obj_Fas obj_receptor
14766760	The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis.	PT-causality	subj_abrogation subj_JNK subj_activity subj_HIPK3 subj_expression subj_restore subj_interaction obj_interaction obj_increased obj_sensitivity obj_DU 145 obj_cells obj_Fas obj_receptor
14961570	Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.	CGE-decreased	subj_I subj_dependent subj_Akt subj_ERK1/2 subj_activation subj_subsequently subj_reduces obj_activation obj_subsequently obj_reduces obj_ovarian cancer obj_cell obj_growth obj_invasion
14961570	Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.	IGE-unidentifiable	subj_I subj_dependent subj_Akt subj_ERK1/2 subj_activation subj_subsequently subj_reduces obj_activation obj_subsequently obj_reduces obj_ovarian cancer obj_cell obj_growth obj_invasion
14961570	Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.	CCS-cancerTOnormal	subj_I subj_dependent subj_Akt subj_ERK1/2 subj_activation subj_subsequently subj_reduces obj_activation obj_subsequently obj_reduces obj_ovarian cancer obj_cell obj_growth obj_invasion
14961570	Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.	PT-observation	subj_I subj_dependent subj_Akt subj_ERK1/2 subj_activation subj_subsequently subj_reduces obj_activation obj_subsequently obj_reduces obj_ovarian cancer obj_cell obj_growth obj_invasion
14971642	We have also shown that arsenite specifically induces HIF-1alpha, but not HIF-1beta, protein levels in prostate cancer cells in a mTOR-dependent manner.	CGE-increased	subj_We subj_arsenite subj_induces subj_HIF-1alpha subj_HIF-1beta subj_protein subj_levels obj_HIF-1beta obj_protein obj_levels obj_prostate cancer obj_cells obj_mTOR obj_dependent
14971642	We have also shown that arsenite specifically induces HIF-1alpha, but not HIF-1beta, protein levels in prostate cancer cells in a mTOR-dependent manner.	IGE-	subj_We subj_arsenite subj_induces subj_HIF-1alpha subj_HIF-1beta subj_protein subj_levels obj_HIF-1beta obj_protein obj_levels obj_prostate cancer obj_cells obj_mTOR obj_dependent
14971642	We have also shown that arsenite specifically induces HIF-1alpha, but not HIF-1beta, protein levels in prostate cancer cells in a mTOR-dependent manner.	CCS-unidentifiable	subj_We subj_arsenite subj_induces subj_HIF-1alpha subj_HIF-1beta subj_protein subj_levels obj_HIF-1beta obj_protein obj_levels obj_prostate cancer obj_cells obj_mTOR obj_dependent
14971642	We have also shown that arsenite specifically induces HIF-1alpha, but not HIF-1beta, protein levels in prostate cancer cells in a mTOR-dependent manner.	PT-	subj_We subj_arsenite subj_induces subj_HIF-1alpha subj_HIF-1beta subj_protein subj_levels obj_HIF-1beta obj_protein obj_levels obj_prostate cancer obj_cells obj_mTOR obj_dependent
14971644	Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.	CGE-increased	subj_induces subj_expression subj_HIF-1alpha subj_HIF-1beta subunit subj_DU145 subj_human subj_prostate obj_subunit obj_DU145 obj_human obj_prostate carcinoma obj_cells
14971644	Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.	IGE-	subj_induces subj_expression subj_HIF-1alpha subj_HIF-1beta subunit subj_DU145 subj_human subj_prostate obj_subunit obj_DU145 obj_human obj_prostate carcinoma obj_cells
14971644	Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.	CCS-unidentifiable	subj_induces subj_expression subj_HIF-1alpha subj_HIF-1beta subunit subj_DU145 subj_human subj_prostate obj_subunit obj_DU145 obj_human obj_prostate carcinoma obj_cells
14971644	Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.	PT-	subj_induces subj_expression subj_HIF-1alpha subj_HIF-1beta subunit subj_DU145 subj_human subj_prostate obj_subunit obj_DU145 obj_human obj_prostate carcinoma obj_cells
15020607	In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer.	CGE-increased	subj_progression subj_survival subj_women subj_HER2 subj_overexpressing subj_metastatic subj_breast obj_women obj_HER2 obj_overexpressing obj_metastatic breast cancer
15020607	In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer.	IGE-unidentifiable	subj_progression subj_survival subj_women subj_HER2 subj_overexpressing subj_metastatic subj_breast obj_women obj_HER2 obj_overexpressing obj_metastatic breast cancer
15020607	In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer.	CCS-normalTOcancer	subj_progression subj_survival subj_women subj_HER2 subj_overexpressing subj_metastatic subj_breast obj_women obj_HER2 obj_overexpressing obj_metastatic breast cancer
15020607	In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer.	PT-observation	subj_progression subj_survival subj_women subj_HER2 subj_overexpressing subj_metastatic subj_breast obj_women obj_HER2 obj_overexpressing obj_metastatic breast cancer
15026365	In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence.	CGE-increased	subj_cancer subj_demonstrated subj_regulation subj_SREBPs subj_downstream subj_effector subj_genes obj_cancer obj_clinical obj_specimens obj_prostate cancer obj_demonstrated obj_regulation obj_SREBPs
15026365	In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence.	IGE-unidentifiable	subj_cancer subj_demonstrated subj_regulation subj_SREBPs subj_downstream subj_effector subj_genes obj_cancer obj_clinical obj_specimens obj_prostate cancer obj_demonstrated obj_regulation obj_SREBPs
15026365	In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence.	CCS-normalTOcancer	subj_cancer subj_demonstrated subj_regulation subj_SREBPs subj_downstream subj_effector subj_genes obj_cancer obj_clinical obj_specimens obj_prostate cancer obj_demonstrated obj_regulation obj_SREBPs
15026365	In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence.	PT-observation	subj_cancer subj_demonstrated subj_regulation subj_SREBPs subj_downstream subj_effector subj_genes obj_cancer obj_clinical obj_specimens obj_prostate cancer obj_demonstrated obj_regulation obj_SREBPs
15040833	RESULTS: E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in MCF-7, T47-D cells, and HepG2 cells when transfected with ERalpha.	CGE-increased	subj_HepG2 subj_cells subj_transfected subj_ERalpha obj_activity obj_100 obj_% obj_MCF-7 obj_T47-D obj_cells obj_HepG2
15040833	RESULTS: E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in MCF-7, T47-D cells, and HepG2 cells when transfected with ERalpha.	IGE-	subj_HepG2 subj_cells subj_transfected subj_ERalpha obj_activity obj_100 obj_% obj_MCF-7 obj_T47-D obj_cells obj_HepG2
15040833	RESULTS: E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in MCF-7, T47-D cells, and HepG2 cells when transfected with ERalpha.	CCS-unidentifiable	subj_HepG2 subj_cells subj_transfected subj_ERalpha obj_activity obj_100 obj_% obj_MCF-7 obj_T47-D obj_cells obj_HepG2
15040833	RESULTS: E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in MCF-7, T47-D cells, and HepG2 cells when transfected with ERalpha.	PT-	subj_HepG2 subj_cells subj_transfected subj_ERalpha obj_activity obj_100 obj_% obj_MCF-7 obj_T47-D obj_cells obj_HepG2
15072561	In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner.	CGE-decreased	subj_HDAC subj_inhibitor subj_decreases subj_ERalpha subj_expression subj_dose subj_dependent obj_In obj_breast cancer obj_cell obj_lines obj_trichostatin
15072561	In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner.	IGE-	subj_HDAC subj_inhibitor subj_decreases subj_ERalpha subj_expression subj_dose subj_dependent obj_In obj_breast cancer obj_cell obj_lines obj_trichostatin
15072561	In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner.	CCS-unidentifiable	subj_HDAC subj_inhibitor subj_decreases subj_ERalpha subj_expression subj_dose subj_dependent obj_In obj_breast cancer obj_cell obj_lines obj_trichostatin
15072561	In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner.	PT-	subj_HDAC subj_inhibitor subj_decreases subj_ERalpha subj_expression subj_dose subj_dependent obj_In obj_breast cancer obj_cell obj_lines obj_trichostatin
15075673	In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.	CGE-increased	subj_Taxo subj_interfere subj_activation subj_E-cadherin subj_maspin subj_genes subj_5-AZA obj_MDA obj_MB-231 obj_breast carcinoma obj_cells obj_Taxo obj_interfere
15075673	In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.	IGE-	subj_Taxo subj_interfere subj_activation subj_E-cadherin subj_maspin subj_genes subj_5-AZA obj_MDA obj_MB-231 obj_breast carcinoma obj_cells obj_Taxo obj_interfere
15075673	In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.	CCS-unidentifiable	subj_Taxo subj_interfere subj_activation subj_E-cadherin subj_maspin subj_genes subj_5-AZA obj_MDA obj_MB-231 obj_breast carcinoma obj_cells obj_Taxo obj_interfere
15075673	In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.	PT-	subj_Taxo subj_interfere subj_activation subj_E-cadherin subj_maspin subj_genes subj_5-AZA obj_MDA obj_MB-231 obj_breast carcinoma obj_cells obj_Taxo obj_interfere
15113415	Functional studies suggest that CRBP downregulation contributes to breast tumor progression.	CGE-decreased	subj_studies subj_CRBP subj_downregulation subj_contributes subj_breast obj_CRBP obj_downregulation obj_contributes obj_breast tumor obj_progression
15113415	Functional studies suggest that CRBP downregulation contributes to breast tumor progression.	IGE-unidentifiable	subj_studies subj_CRBP subj_downregulation subj_contributes subj_breast obj_CRBP obj_downregulation obj_contributes obj_breast tumor obj_progression
15113415	Functional studies suggest that CRBP downregulation contributes to breast tumor progression.	CCS-normalTOcancer	subj_studies subj_CRBP subj_downregulation subj_contributes subj_breast obj_CRBP obj_downregulation obj_contributes obj_breast tumor obj_progression
15113415	Functional studies suggest that CRBP downregulation contributes to breast tumor progression.	PT-causality	subj_studies subj_CRBP subj_downregulation subj_contributes subj_breast obj_CRBP obj_downregulation obj_contributes obj_breast tumor obj_progression
15138597	In patients with ovarian cancer, the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH).	CGE-increased	subj_ovarian subj_cancer subj_increased subj_leptin subj_levels subj_circulating subj_follicle obj_patients obj_ovarian cancer obj_increased obj_leptin obj_levels
15138597	In patients with ovarian cancer, the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH).	IGE-	subj_ovarian subj_cancer subj_increased subj_leptin subj_levels subj_circulating subj_follicle obj_patients obj_ovarian cancer obj_increased obj_leptin obj_levels
15138597	In patients with ovarian cancer, the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH).	CCS-unidentifiable	subj_ovarian subj_cancer subj_increased subj_leptin subj_levels subj_circulating subj_follicle obj_patients obj_ovarian cancer obj_increased obj_leptin obj_levels
15138597	In patients with ovarian cancer, the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH).	PT-	subj_ovarian subj_cancer subj_increased subj_leptin subj_levels subj_circulating subj_follicle obj_patients obj_ovarian cancer obj_increased obj_leptin obj_levels
15162825	This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.	CGE-increased	subj_study subj_IL-18 subj_serum subj_levels subj_elevated obj_serum obj_levels obj_elevated obj_ovarian cancer obj_patients obj_correlated obj_survival
15162825	This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.	IGE-unchanged	subj_study subj_IL-18 subj_serum subj_levels subj_elevated obj_serum obj_levels obj_elevated obj_ovarian cancer obj_patients obj_correlated obj_survival
15162825	This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.	CCS-normalTOcancer	subj_study subj_IL-18 subj_serum subj_levels subj_elevated obj_serum obj_levels obj_elevated obj_ovarian cancer obj_patients obj_correlated obj_survival
15162825	This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.	PT-observation	subj_study subj_IL-18 subj_serum subj_levels subj_elevated obj_serum obj_levels obj_elevated obj_ovarian cancer obj_patients obj_correlated obj_survival
15193259	R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway.	CGE-decreased	subj_xenograft subj_growth subj_downregulation subj_cyclin D1 subj_expression subj_PPARgamma subj_pathway obj_LuCaP-35 obj_androgen obj_dependent obj_prostate cancer obj_xenograft obj_growth obj_downregulation
15193259	R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway.	IGE-unidentifiable	subj_xenograft subj_growth subj_downregulation subj_cyclin D1 subj_expression subj_PPARgamma subj_pathway obj_LuCaP-35 obj_androgen obj_dependent obj_prostate cancer obj_xenograft obj_growth obj_downregulation
15193259	R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway.	CCS-cancerTOnormal	subj_xenograft subj_growth subj_downregulation subj_cyclin D1 subj_expression subj_PPARgamma subj_pathway obj_LuCaP-35 obj_androgen obj_dependent obj_prostate cancer obj_xenograft obj_growth obj_downregulation
15193259	R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway.	PT-causality	subj_xenograft subj_growth subj_downregulation subj_cyclin D1 subj_expression subj_PPARgamma subj_pathway obj_LuCaP-35 obj_androgen obj_dependent obj_prostate cancer obj_xenograft obj_growth obj_downregulation
15297183	Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha.	CGE-increased	subj_dmPGE(2 subj_) subj_increase subj_VEGF subj_expression subj_HIF-1alpha obj_normoxic obj_conditions obj_treatment obj_ovarian cancer obj_cell obj_lines obj_dmPGE(2
15297183	Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha.	IGE-	subj_dmPGE(2 subj_) subj_increase subj_VEGF subj_expression subj_HIF-1alpha obj_normoxic obj_conditions obj_treatment obj_ovarian cancer obj_cell obj_lines obj_dmPGE(2
15297183	Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha.	CCS-unidentifiable	subj_dmPGE(2 subj_) subj_increase subj_VEGF subj_expression subj_HIF-1alpha obj_normoxic obj_conditions obj_treatment obj_ovarian cancer obj_cell obj_lines obj_dmPGE(2
15297183	Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha.	PT-	subj_dmPGE(2 subj_) subj_increase subj_VEGF subj_expression subj_HIF-1alpha obj_normoxic obj_conditions obj_treatment obj_ovarian cancer obj_cell obj_lines obj_dmPGE(2
15313907	Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.	CGE-decreased	subj_II subj_) subj_decreased subj_LF subj_8 subj_patients subj_( obj_analysis obj_breast cancer obj_profiling obj_arrays obj_revealed
15313907	Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.	IGE-unchanged	subj_II subj_) subj_decreased subj_LF subj_8 subj_patients subj_( obj_analysis obj_breast cancer obj_profiling obj_arrays obj_revealed
15313907	Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.	CCS-normalTOcancer	subj_II subj_) subj_decreased subj_LF subj_8 subj_patients subj_( obj_analysis obj_breast cancer obj_profiling obj_arrays obj_revealed
15313907	Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.	PT-observation	subj_II subj_) subj_decreased subj_LF subj_8 subj_patients subj_( obj_analysis obj_breast cancer obj_profiling obj_arrays obj_revealed
15326487	These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients.	CGE-increased	subj_prostate subj_increased subj_activity subj_SRD5A2 locus subj_prostate subj_cancer subj_progression obj_activity obj_SRD5A2 obj_locus obj_prostate cancer obj_progression obj_subset obj_patients
15326487	These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients.	IGE-unchanged	subj_prostate subj_increased subj_activity subj_SRD5A2 locus subj_prostate subj_cancer subj_progression obj_activity obj_SRD5A2 obj_locus obj_prostate cancer obj_progression obj_subset obj_patients
15326487	These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients.	CCS-normalTOcancer	subj_prostate subj_increased subj_activity subj_SRD5A2 locus subj_prostate subj_cancer subj_progression obj_activity obj_SRD5A2 obj_locus obj_prostate cancer obj_progression obj_subset obj_patients
15326487	These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients.	PT-observation	subj_prostate subj_increased subj_activity subj_SRD5A2 locus subj_prostate subj_cancer subj_progression obj_activity obj_SRD5A2 obj_locus obj_prostate cancer obj_progression obj_subset obj_patients
15336984	TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.	CGE-increased	subj_prostate subj_correlates subj_increased subj_TRPV6 subj_Ca2 subj_+ subj_channel obj_involved obj_process obj_TRPV6 obj_prostate cancer obj_: obj_cancer obj_growth
15336984	TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.	IGE-unidentifiable	subj_prostate subj_correlates subj_increased subj_TRPV6 subj_Ca2 subj_+ subj_channel obj_involved obj_process obj_TRPV6 obj_prostate cancer obj_: obj_cancer obj_growth
15336984	TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.	CCS-normalTOcancer	subj_prostate subj_correlates subj_increased subj_TRPV6 subj_Ca2 subj_+ subj_channel obj_involved obj_process obj_TRPV6 obj_prostate cancer obj_: obj_cancer obj_growth
15336984	TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.	PT-causality	subj_prostate subj_correlates subj_increased subj_TRPV6 subj_Ca2 subj_+ subj_channel obj_involved obj_process obj_TRPV6 obj_prostate cancer obj_: obj_cancer obj_growth
15359289	The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells.	CGE-increased	subj_EphA2 receptor tyrosine kinase subj_frequently subj_overexpressed subj_invasive obj_kinase obj_frequently obj_overexpressed obj_invasive breast cancer obj_cells
15359289	The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells.	IGE-unchanged	subj_EphA2 receptor tyrosine kinase subj_frequently subj_overexpressed subj_invasive obj_kinase obj_frequently obj_overexpressed obj_invasive breast cancer obj_cells
15359289	The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells.	CCS-normalTOcancer	subj_EphA2 receptor tyrosine kinase subj_frequently subj_overexpressed subj_invasive obj_kinase obj_frequently obj_overexpressed obj_invasive breast cancer obj_cells
15359289	The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells.	PT-observation	subj_EphA2 receptor tyrosine kinase subj_frequently subj_overexpressed subj_invasive obj_kinase obj_frequently obj_overexpressed obj_invasive breast cancer obj_cells
15368472	These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers.	CGE-increased	subj_studies subj_validate subj_TFF3 subj_overexpressed subj_subset subj_primary obj_subset obj_primary obj_metastic obj_prostate cancers
15368472	These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers.	IGE-unchanged	subj_studies subj_validate subj_TFF3 subj_overexpressed subj_subset subj_primary obj_subset obj_primary obj_metastic obj_prostate cancers
15368472	These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers.	CCS-normalTOcancer	subj_studies subj_validate subj_TFF3 subj_overexpressed subj_subset subj_primary obj_subset obj_primary obj_metastic obj_prostate cancers
15368472	These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers.	PT-observation	subj_studies subj_validate subj_TFF3 subj_overexpressed subj_subset subj_primary obj_subset obj_primary obj_metastic obj_prostate cancers
15382080	KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression.	CGE-decreased	subj_kinase subj_leading subj_suppression subj_uPA subj_expression obj_treatment obj_beneficial obj_ovarian cancer obj_patients obj_risk obj_peritoneal
15382080	KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression.	IGE-unidentifiable	subj_kinase subj_leading subj_suppression subj_uPA subj_expression obj_treatment obj_beneficial obj_ovarian cancer obj_patients obj_risk obj_peritoneal
15382080	KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression.	CCS-cancerTOnormal	subj_kinase subj_leading subj_suppression subj_uPA subj_expression obj_treatment obj_beneficial obj_ovarian cancer obj_patients obj_risk obj_peritoneal
15382080	KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression.	PT-causality	subj_kinase subj_leading subj_suppression subj_uPA subj_expression obj_treatment obj_beneficial obj_ovarian cancer obj_patients obj_risk obj_peritoneal
1541865	TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.	CGE-increased	subj_TAT subj_FDP subj_increased subj_cancer subj_dissemination obj_correlated obj_prognosis obj_patients obj_ovarian cancer
1541865	TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.	IGE-unidentifiable	subj_TAT subj_FDP subj_increased subj_cancer subj_dissemination obj_correlated obj_prognosis obj_patients obj_ovarian cancer
1541865	TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.	CCS-normalTOcancer	subj_TAT subj_FDP subj_increased subj_cancer subj_dissemination obj_correlated obj_prognosis obj_patients obj_ovarian cancer
1541865	TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.	PT-observation	subj_TAT subj_FDP subj_increased subj_cancer subj_dissemination obj_correlated obj_prognosis obj_patients obj_ovarian cancer
15520877	More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease.	CGE-increased	subj_interestingly subj_MMP-9 subj_expression subj_fibronectin subj_concentration obj_MMP-9 obj_MMP-2 obj_frequent obj_ovarian cancer obj_patients obj_developed obj_recurrent
15520877	More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease.	IGE-unidentifiable	subj_interestingly subj_MMP-9 subj_expression subj_fibronectin subj_concentration obj_MMP-9 obj_MMP-2 obj_frequent obj_ovarian cancer obj_patients obj_developed obj_recurrent
15520877	More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease.	CCS-normalTOcancer	subj_interestingly subj_MMP-9 subj_expression subj_fibronectin subj_concentration obj_MMP-9 obj_MMP-2 obj_frequent obj_ovarian cancer obj_patients obj_developed obj_recurrent
15520877	More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease.	PT-observation	subj_interestingly subj_MMP-9 subj_expression subj_fibronectin subj_concentration obj_MMP-9 obj_MMP-2 obj_frequent obj_ovarian cancer obj_patients obj_developed obj_recurrent
15523695	TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7.	CGE-increased	subj_GM6001 subj_inhibited subj_activation subj_proMMP-2 subj_increased subj_invasion subj_DOV13 obj_proMMP-2 obj_increased obj_invasion obj_DOV13 obj_cells obj_promoted obj_rhMMP-7
15523695	TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7.	IGE-unidentifiable	subj_GM6001 subj_inhibited subj_activation subj_proMMP-2 subj_increased subj_invasion subj_DOV13 obj_proMMP-2 obj_increased obj_invasion obj_DOV13 obj_cells obj_promoted obj_rhMMP-7
15523695	TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7.	CCS-normalTOcancer	subj_GM6001 subj_inhibited subj_activation subj_proMMP-2 subj_increased subj_invasion subj_DOV13 obj_proMMP-2 obj_increased obj_invasion obj_DOV13 obj_cells obj_promoted obj_rhMMP-7
15523695	TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7.	PT-observation	subj_GM6001 subj_inhibited subj_activation subj_proMMP-2 subj_increased subj_invasion subj_DOV13 obj_proMMP-2 obj_increased obj_invasion obj_DOV13 obj_cells obj_promoted obj_rhMMP-7
15528975	Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.	CGE-increased	subj_metalloproteinases subj_gene subj_( subj_TIMP subj_) subj_cell subj_lines obj_( obj_A2780cp obj_) obj_ovarian carcinoma obj_cell obj_lines obj_exposed
15528975	Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.	IGE-	subj_metalloproteinases subj_gene subj_( subj_TIMP subj_) subj_cell subj_lines obj_( obj_A2780cp obj_) obj_ovarian carcinoma obj_cell obj_lines obj_exposed
15528975	Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.	CCS-unidentifiable	subj_metalloproteinases subj_gene subj_( subj_TIMP subj_) subj_cell subj_lines obj_( obj_A2780cp obj_) obj_ovarian carcinoma obj_cell obj_lines obj_exposed
15528975	Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.	PT-	subj_metalloproteinases subj_gene subj_( subj_TIMP subj_) subj_cell subj_lines obj_( obj_A2780cp obj_) obj_ovarian carcinoma obj_cell obj_lines obj_exposed
15533896	The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention.	CGE-increased	subj_The subj_study subj_PPAR-gamma subj_activation subj_regulator subj_COX-2 obj_prostate obj_cells obj_target obj_prostate cancer obj_chemoprevention
15533896	The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention.	IGE-unidentifiable	subj_The subj_study subj_PPAR-gamma subj_activation subj_regulator subj_COX-2 obj_prostate obj_cells obj_target obj_prostate cancer obj_chemoprevention
15533896	The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention.	CCS-cancerTOnormal	subj_The subj_study subj_PPAR-gamma subj_activation subj_regulator subj_COX-2 obj_prostate obj_cells obj_target obj_prostate cancer obj_chemoprevention
15533896	The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention.	PT-causality	subj_The subj_study subj_PPAR-gamma subj_activation subj_regulator subj_COX-2 obj_prostate obj_cells obj_target obj_prostate cancer obj_chemoprevention
15609126	Increased frequency of long androgen receptor CAG repeats in male breast cancers.	CGE-increased	subj_frequency subj_androgen receptor CAG repeats subj_male subj_breast subj_cancers obj_receptor obj_CAG obj_repeats obj_male breast cancers obj_
15609126	Increased frequency of long androgen receptor CAG repeats in male breast cancers.	IGE-unchanged	subj_frequency subj_androgen receptor CAG repeats subj_male subj_breast subj_cancers obj_receptor obj_CAG obj_repeats obj_male breast cancers obj_
15609126	Increased frequency of long androgen receptor CAG repeats in male breast cancers.	CCS-normalTOcancer	subj_frequency subj_androgen receptor CAG repeats subj_male subj_breast subj_cancers obj_receptor obj_CAG obj_repeats obj_male breast cancers obj_
15609126	Increased frequency of long androgen receptor CAG repeats in male breast cancers.	PT-observation	subj_frequency subj_androgen receptor CAG repeats subj_male subj_breast subj_cancers obj_receptor obj_CAG obj_repeats obj_male breast cancers obj_
15638997	In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.	CGE-decreased	subj_explanation subj_telomerase subj_inhibition subj_androgen receptor subj_blockade subj_LNCaP subj_cells obj_activation obj_p53 obj_pathway obj_LNCaP obj_cells obj_vitro obj_sensitivity
15638997	In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.	IGE-	subj_explanation subj_telomerase subj_inhibition subj_androgen receptor subj_blockade subj_LNCaP subj_cells obj_activation obj_p53 obj_pathway obj_LNCaP obj_cells obj_vitro obj_sensitivity
15638997	In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.	CCS-unidentifiable	subj_explanation subj_telomerase subj_inhibition subj_androgen receptor subj_blockade subj_LNCaP subj_cells obj_activation obj_p53 obj_pathway obj_LNCaP obj_cells obj_vitro obj_sensitivity
15638997	In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.	PT-	subj_explanation subj_telomerase subj_inhibition subj_androgen receptor subj_blockade subj_LNCaP subj_cells obj_activation obj_p53 obj_pathway obj_LNCaP obj_cells obj_vitro obj_sensitivity
15643450	Angiogenic cytokines such as vascular endothelial growth factor (VEGF) have been identified in prostate cancer cells and tumours, and androgens appear to stimulate VEGF.	CGE-increased	subj_tumours subj_androgens subj_stimulate subj_VEGF obj_VEGF obj_) obj_identified obj_prostate cancer obj_cells obj_tumours obj_androgens
15643450	Angiogenic cytokines such as vascular endothelial growth factor (VEGF) have been identified in prostate cancer cells and tumours, and androgens appear to stimulate VEGF.	IGE-	subj_tumours subj_androgens subj_stimulate subj_VEGF obj_VEGF obj_) obj_identified obj_prostate cancer obj_cells obj_tumours obj_androgens
15643450	Angiogenic cytokines such as vascular endothelial growth factor (VEGF) have been identified in prostate cancer cells and tumours, and androgens appear to stimulate VEGF.	CCS-unidentifiable	subj_tumours subj_androgens subj_stimulate subj_VEGF obj_VEGF obj_) obj_identified obj_prostate cancer obj_cells obj_tumours obj_androgens
15643450	Angiogenic cytokines such as vascular endothelial growth factor (VEGF) have been identified in prostate cancer cells and tumours, and androgens appear to stimulate VEGF.	PT-	subj_tumours subj_androgens subj_stimulate subj_VEGF obj_VEGF obj_) obj_identified obj_prostate cancer obj_cells obj_tumours obj_androgens
15647830	Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.	CGE-increased	subj_Using subj_approach subj_regulation subj_ubiquitin carboxyl extension protein 1 subj_( subj_UBCEP-1 subj_) obj_UBCEP-1 obj_) obj_mRNA obj_prostate carcinoma obj_cells obj_compared obj_normal
15647830	Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.	IGE-unchanged	subj_Using subj_approach subj_regulation subj_ubiquitin carboxyl extension protein 1 subj_( subj_UBCEP-1 subj_) obj_UBCEP-1 obj_) obj_mRNA obj_prostate carcinoma obj_cells obj_compared obj_normal
15647830	Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.	CCS-normalTOcancer	subj_Using subj_approach subj_regulation subj_ubiquitin carboxyl extension protein 1 subj_( subj_UBCEP-1 subj_) obj_UBCEP-1 obj_) obj_mRNA obj_prostate carcinoma obj_cells obj_compared obj_normal
15647830	Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.	PT-observation	subj_Using subj_approach subj_regulation subj_ubiquitin carboxyl extension protein 1 subj_( subj_UBCEP-1 subj_) obj_UBCEP-1 obj_) obj_mRNA obj_prostate carcinoma obj_cells obj_compared obj_normal
15647840	DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.	CGE-decreased	subj_DHT subj_induced subj_E2F-1 protein subj_mRNA subj_expressions subj_inhibited obj_DHT obj_induced obj_growth obj_LNCaP obj_cells obj_decrease obj_E2F
15647840	DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.	IGE-unidentifiable	subj_DHT subj_induced subj_E2F-1 protein subj_mRNA subj_expressions subj_inhibited obj_DHT obj_induced obj_growth obj_LNCaP obj_cells obj_decrease obj_E2F
15647840	DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.	CCS-cancerTOnormal	subj_DHT subj_induced subj_E2F-1 protein subj_mRNA subj_expressions subj_inhibited obj_DHT obj_induced obj_growth obj_LNCaP obj_cells obj_decrease obj_E2F
15647840	DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.	PT-causality	subj_DHT subj_induced subj_E2F-1 protein subj_mRNA subj_expressions subj_inhibited obj_DHT obj_induced obj_growth obj_LNCaP obj_cells obj_decrease obj_E2F
15657352	Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.	CGE-increased	subj_TOS subj_Up subj_regulation subj_c-Jun-NH2-kinase subj_pathway subj_contributes subj_induction obj_tocopheryl obj_succinate obj_human obj_prostate cancer obj_cells obj_
15657352	Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.	IGE-unidentifiable	subj_TOS subj_Up subj_regulation subj_c-Jun-NH2-kinase subj_pathway subj_contributes subj_induction obj_tocopheryl obj_succinate obj_human obj_prostate cancer obj_cells obj_
15657352	Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.	CCS-cancerTOnormal	subj_TOS subj_Up subj_regulation subj_c-Jun-NH2-kinase subj_pathway subj_contributes subj_induction obj_tocopheryl obj_succinate obj_human obj_prostate cancer obj_cells obj_
15657352	Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.	PT-causality	subj_TOS subj_Up subj_regulation subj_c-Jun-NH2-kinase subj_pathway subj_contributes subj_induction obj_tocopheryl obj_succinate obj_human obj_prostate cancer obj_cells obj_
15688367	Overexpressing ID2 in the MDA-MB-468 breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.	CGE-increased	subj_ID2 subj_MDA subj_MB-468 subj_breast obj_ID2 obj_MDA obj_MB-468 obj_breast cancer obj_cell obj_generated obj_marked
15688367	Overexpressing ID2 in the MDA-MB-468 breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.	IGE-unidentifiable	subj_ID2 subj_MDA subj_MB-468 subj_breast obj_ID2 obj_MDA obj_MB-468 obj_breast cancer obj_cell obj_generated obj_marked
15688367	Overexpressing ID2 in the MDA-MB-468 breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.	CCS-cancerTOnormal	subj_ID2 subj_MDA subj_MB-468 subj_breast obj_ID2 obj_MDA obj_MB-468 obj_breast cancer obj_cell obj_generated obj_marked
15688367	Overexpressing ID2 in the MDA-MB-468 breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.	PT-causality	subj_ID2 subj_MDA subj_MB-468 subj_breast obj_ID2 obj_MDA obj_MB-468 obj_breast cancer obj_cell obj_generated obj_marked
15720809	Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.	CGE-increased	subj_PCa subj_progression subj_Overexpression subj_12/15-lipoxygenase subj_ortholog subj_human subj_15-lipoxygenase-1 obj_ortholog obj_human obj_15-lipoxygenase-1 obj_prostate tumors obj_TRAMP obj_mice obj_
15720809	Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.	IGE-unchanged	subj_PCa subj_progression subj_Overexpression subj_12/15-lipoxygenase subj_ortholog subj_human subj_15-lipoxygenase-1 obj_ortholog obj_human obj_15-lipoxygenase-1 obj_prostate tumors obj_TRAMP obj_mice obj_
15720809	Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.	CCS-normalTOcancer	subj_PCa subj_progression subj_Overexpression subj_12/15-lipoxygenase subj_ortholog subj_human subj_15-lipoxygenase-1 obj_ortholog obj_human obj_15-lipoxygenase-1 obj_prostate tumors obj_TRAMP obj_mice obj_
15720809	Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.	PT-observation	subj_PCa subj_progression subj_Overexpression subj_12/15-lipoxygenase subj_ortholog subj_human subj_15-lipoxygenase-1 obj_ortholog obj_human obj_15-lipoxygenase-1 obj_prostate tumors obj_TRAMP obj_mice obj_
15735018	These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.	CGE-decreased	subj_cancer subj_cells subj_blocking subj_bFGF subj_signaling subj_pathway obj_inhibits obj_malignant obj_phenotype obj_prostate cancer obj_cells obj_blocking obj_bFGF
15735018	These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.	IGE-unidentifiable	subj_cancer subj_cells subj_blocking subj_bFGF subj_signaling subj_pathway obj_inhibits obj_malignant obj_phenotype obj_prostate cancer obj_cells obj_blocking obj_bFGF
15735018	These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.	CCS-cancerTOnormal	subj_cancer subj_cells subj_blocking subj_bFGF subj_signaling subj_pathway obj_inhibits obj_malignant obj_phenotype obj_prostate cancer obj_cells obj_blocking obj_bFGF
15735018	These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.	PT-causality	subj_cancer subj_cells subj_blocking subj_bFGF subj_signaling subj_pathway obj_inhibits obj_malignant obj_phenotype obj_prostate cancer obj_cells obj_blocking obj_bFGF
15770517	Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy.	CGE-increased	subj_Overexpression subj_clusterin subj_LNCaP subj_cells subj_confers obj_Overexpression obj_clusterin obj_LNCaP obj_cells obj_confers obj_resistance
15770517	Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy.	IGE-unidentifiable	subj_Overexpression subj_clusterin subj_LNCaP subj_cells subj_confers obj_Overexpression obj_clusterin obj_LNCaP obj_cells obj_confers obj_resistance
15770517	Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy.	CCS-normalTOcancer	subj_Overexpression subj_clusterin subj_LNCaP subj_cells subj_confers obj_Overexpression obj_clusterin obj_LNCaP obj_cells obj_confers obj_resistance
15770517	Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy.	PT-causality	subj_Overexpression subj_clusterin subj_LNCaP subj_cells subj_confers obj_Overexpression obj_clusterin obj_LNCaP obj_cells obj_confers obj_resistance
15781636	LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines.	CGE-increased	subj_increased subj_COX-2 protein subj_expression subj_time- subj_concentration obj_ovarian obj_epithelial obj_cells obj_ovarian cancer obj_cell obj_lines
15781636	LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines.	IGE-	subj_increased subj_COX-2 protein subj_expression subj_time- subj_concentration obj_ovarian obj_epithelial obj_cells obj_ovarian cancer obj_cell obj_lines
15781636	LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines.	CCS-unidentifiable	subj_increased subj_COX-2 protein subj_expression subj_time- subj_concentration obj_ovarian obj_epithelial obj_cells obj_ovarian cancer obj_cell obj_lines
15781636	LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines.	PT-	subj_increased subj_COX-2 protein subj_expression subj_time- subj_concentration obj_ovarian obj_epithelial obj_cells obj_ovarian cancer obj_cell obj_lines
15790678	Androgen-sensitive LNCaP prostate cancer cells engineered to stably overexpress CDK6 display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.	CGE-increased	subj_engineered subj_stably subj_overexpress subj_CDK6 subj_display subj_increased subj_expression obj_Androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_engineered obj_stably
15790678	Androgen-sensitive LNCaP prostate cancer cells engineered to stably overexpress CDK6 display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.	IGE-unidentifiable	subj_engineered subj_stably subj_overexpress subj_CDK6 subj_display subj_increased subj_expression obj_Androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_engineered obj_stably
15790678	Androgen-sensitive LNCaP prostate cancer cells engineered to stably overexpress CDK6 display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.	CCS-normalTOcancer	subj_engineered subj_stably subj_overexpress subj_CDK6 subj_display subj_increased subj_expression obj_Androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_engineered obj_stably
15790678	Androgen-sensitive LNCaP prostate cancer cells engineered to stably overexpress CDK6 display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.	PT-causality	subj_engineered subj_stably subj_overexpress subj_CDK6 subj_display subj_increased subj_expression obj_Androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_engineered obj_stably
15833840	Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.	CGE-decreased	subj_3Ac subj_SL0101 subj_decreased subj_PSA subj_expression obj_expression obj_diagnostic obj_marker obj_prostate cancer obj_inhibiting obj_RSK obj_activity
15833840	Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.	IGE-	subj_3Ac subj_SL0101 subj_decreased subj_PSA subj_expression obj_expression obj_diagnostic obj_marker obj_prostate cancer obj_inhibiting obj_RSK obj_activity
15833840	Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.	CCS-unidentifiable	subj_3Ac subj_SL0101 subj_decreased subj_PSA subj_expression obj_expression obj_diagnostic obj_marker obj_prostate cancer obj_inhibiting obj_RSK obj_activity
15833840	Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.	PT-	subj_3Ac subj_SL0101 subj_decreased subj_PSA subj_expression obj_expression obj_diagnostic obj_marker obj_prostate cancer obj_inhibiting obj_RSK obj_activity
15837784	Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.	CGE-decreased	subj_cancer subj_Down subj_regulation subj_ATM protein subj_sensitizes subj_human subj_prostate obj_protein obj_sensitizes obj_human obj_prostate cancer obj_cells obj_radiation obj_induced
15837784	Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.	IGE-unidentifiable	subj_cancer subj_Down subj_regulation subj_ATM protein subj_sensitizes subj_human subj_prostate obj_protein obj_sensitizes obj_human obj_prostate cancer obj_cells obj_radiation obj_induced
15837784	Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.	CCS-cancerTOnormal	subj_cancer subj_Down subj_regulation subj_ATM protein subj_sensitizes subj_human subj_prostate obj_protein obj_sensitizes obj_human obj_prostate cancer obj_cells obj_radiation obj_induced
15837784	Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.	PT-causality	subj_cancer subj_Down subj_regulation subj_ATM protein subj_sensitizes subj_human subj_prostate obj_protein obj_sensitizes obj_human obj_prostate cancer obj_cells obj_radiation obj_induced
15867372	These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer.	CGE-increased	subj_protein subj_translation subj_leading subj_CSF-1 subj_overexpression subj_increased subj_metastatic obj_increased obj_metastatic obj_properties obj_ovarian cancer
15867372	These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer.	IGE-unidentifiable	subj_protein subj_translation subj_leading subj_CSF-1 subj_overexpression subj_increased subj_metastatic obj_increased obj_metastatic obj_properties obj_ovarian cancer
15867372	These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer.	CCS-normalTOcancer	subj_protein subj_translation subj_leading subj_CSF-1 subj_overexpression subj_increased subj_metastatic obj_increased obj_metastatic obj_properties obj_ovarian cancer
15867372	These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer.	PT-observation	subj_protein subj_translation subj_leading subj_CSF-1 subj_overexpression subj_increased subj_metastatic obj_increased obj_metastatic obj_properties obj_ovarian cancer
15868442	In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6).	CGE-increased	subj_In subj_ErbB2 subj_overexpression subj_increased subj_risk obj_2.1 obj_10.4 obj_) obj_breast cancer obj_death obj_( obj_RR
15868442	In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6).	IGE-unchanged	subj_In subj_ErbB2 subj_overexpression subj_increased subj_risk obj_2.1 obj_10.4 obj_) obj_breast cancer obj_death obj_( obj_RR
15868442	In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6).	CCS-normalTOcancer	subj_In subj_ErbB2 subj_overexpression subj_increased subj_risk obj_2.1 obj_10.4 obj_) obj_breast cancer obj_death obj_( obj_RR
15868442	In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6).	PT-observation	subj_In subj_ErbB2 subj_overexpression subj_increased subj_risk obj_2.1 obj_10.4 obj_) obj_breast cancer obj_death obj_( obj_RR
15894658	This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.	CGE-increased	subj_women subj_increasing subj_blood subj_SHBG subj_levels obj_gene obj_reduced obj_risk obj_breast cancer obj_postmenopausal obj_women obj_increasing
15894658	This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.	IGE-unidentifiable	subj_women subj_increasing subj_blood subj_SHBG subj_levels obj_gene obj_reduced obj_risk obj_breast cancer obj_postmenopausal obj_women obj_increasing
15894658	This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.	CCS-cancerTOnormal	subj_women subj_increasing subj_blood subj_SHBG subj_levels obj_gene obj_reduced obj_risk obj_breast cancer obj_postmenopausal obj_women obj_increasing
15894658	This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.	PT-observation	subj_women subj_increasing subj_blood subj_SHBG subj_levels obj_gene obj_reduced obj_risk obj_breast cancer obj_postmenopausal obj_women obj_increasing
15897876	CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.	CGE-increased	subj_CBX7 subj_overexpression subj_LNCaP subj_cells obj_overexpression obj_LNCaP obj_cells obj_slight obj_growth
15897876	CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.	IGE-unidentifiable	subj_CBX7 subj_overexpression subj_LNCaP subj_cells obj_overexpression obj_LNCaP obj_cells obj_slight obj_growth
15897876	CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.	CCS-normalTOcancer	subj_CBX7 subj_overexpression subj_LNCaP subj_cells obj_overexpression obj_LNCaP obj_cells obj_slight obj_growth
15897876	CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.	PT-causality	subj_CBX7 subj_overexpression subj_LNCaP subj_cells obj_overexpression obj_LNCaP obj_cells obj_slight obj_growth
15913739	Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.	CGE-decreased	subj_SKOV3 subj_cells subj_inhibition subj_Bcl-2 subj_abolished subj_delayed subj_entry obj_S obj_phase obj_Bcl-2-overexpressing obj_SKOV3 obj_cells obj_inhibition obj_Bcl-2
15913739	Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.	IGE-unidentifiable	subj_SKOV3 subj_cells subj_inhibition subj_Bcl-2 subj_abolished subj_delayed subj_entry obj_S obj_phase obj_Bcl-2-overexpressing obj_SKOV3 obj_cells obj_inhibition obj_Bcl-2
15913739	Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.	CCS-normalTOcancer	subj_SKOV3 subj_cells subj_inhibition subj_Bcl-2 subj_abolished subj_delayed subj_entry obj_S obj_phase obj_Bcl-2-overexpressing obj_SKOV3 obj_cells obj_inhibition obj_Bcl-2
15913739	Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.	PT-causality	subj_SKOV3 subj_cells subj_inhibition subj_Bcl-2 subj_abolished subj_delayed subj_entry obj_S obj_phase obj_Bcl-2-overexpressing obj_SKOV3 obj_cells obj_inhibition obj_Bcl-2
15947099	Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.	CGE-increased	subj_Similarly subj_activation subj_AR subj_phosphorylated subj_protein subj_kinase obj_B obj_Akt obj_reported obj_prostate cancer
15947099	Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.	IGE-unidentifiable	subj_Similarly subj_activation subj_AR subj_phosphorylated subj_protein subj_kinase obj_B obj_Akt obj_reported obj_prostate cancer
15947099	Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.	CCS-normalTOcancer	subj_Similarly subj_activation subj_AR subj_phosphorylated subj_protein subj_kinase obj_B obj_Akt obj_reported obj_prostate cancer
15947099	Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.	PT-observation	subj_Similarly subj_activation subj_AR subj_phosphorylated subj_protein subj_kinase obj_B obj_Akt obj_reported obj_prostate cancer
15958562	These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.	CGE-decreased	subj_findings subj_FoxM1 subj_depletion subj_cell subj_death obj_therapeutic obj_strategy obj_target obj_breast cancer
15958562	These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.	IGE-unidentifiable	subj_findings subj_FoxM1 subj_depletion subj_cell subj_death obj_therapeutic obj_strategy obj_target obj_breast cancer
15958562	These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.	CCS-cancerTOnormal	subj_findings subj_FoxM1 subj_depletion subj_cell subj_death obj_therapeutic obj_strategy obj_target obj_breast cancer
15958562	These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.	PT-causality	subj_findings subj_FoxM1 subj_depletion subj_cell subj_death obj_therapeutic obj_strategy obj_target obj_breast cancer
15982318	We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer.	CGE-increased	subj_p63 subj_discovery subj_overexpression subj_alpha-methylacyl coenzyme A racemase subj_( subj_AMACR subj_) obj_( obj_AMACR obj_) obj_prostate cancer
15982318	We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer.	IGE-unchanged	subj_p63 subj_discovery subj_overexpression subj_alpha-methylacyl coenzyme A racemase subj_( subj_AMACR subj_) obj_( obj_AMACR obj_) obj_prostate cancer
15982318	We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer.	CCS-normalTOcancer	subj_p63 subj_discovery subj_overexpression subj_alpha-methylacyl coenzyme A racemase subj_( subj_AMACR subj_) obj_( obj_AMACR obj_) obj_prostate cancer
15982318	We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer.	PT-observation	subj_p63 subj_discovery subj_overexpression subj_alpha-methylacyl coenzyme A racemase subj_( subj_AMACR subj_) obj_( obj_AMACR obj_) obj_prostate cancer
16044418	Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells.	CGE-increased	subj_/ subj_overexpression subj_Akt subj_COX-2 subj_MMP-9 subj_cells obj_studies obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_demonstrated
16044418	Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells.	IGE-	subj_/ subj_overexpression subj_Akt subj_COX-2 subj_MMP-9 subj_cells obj_studies obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_demonstrated
16044418	Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells.	CCS-unidentifiable	subj_/ subj_overexpression subj_Akt subj_COX-2 subj_MMP-9 subj_cells obj_studies obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_demonstrated
16044418	Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells.	PT-	subj_/ subj_overexpression subj_Akt subj_COX-2 subj_MMP-9 subj_cells obj_studies obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_demonstrated
16049707	Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.	CGE-increased	subj_) subj_increase subj_p21 subj_hypophosphorylated retinoblastoma proteins subj_expression subj_ obj_inhibition obj_cell obj_death obj_prostatic carcinoma obj_cells obj_( obj_PC-3
16049707	Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.	IGE-unidentifiable	subj_) subj_increase subj_p21 subj_hypophosphorylated retinoblastoma proteins subj_expression subj_ obj_inhibition obj_cell obj_death obj_prostatic carcinoma obj_cells obj_( obj_PC-3
16049707	Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.	CCS-cancerTOnormal	subj_) subj_increase subj_p21 subj_hypophosphorylated retinoblastoma proteins subj_expression subj_ obj_inhibition obj_cell obj_death obj_prostatic carcinoma obj_cells obj_( obj_PC-3
16049707	Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.	PT-observation	subj_) subj_increase subj_p21 subj_hypophosphorylated retinoblastoma proteins subj_expression subj_ obj_inhibition obj_cell obj_death obj_prostatic carcinoma obj_cells obj_( obj_PC-3
16086871	-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells.	CGE-decreased	subj_Survivin subj_reduce subj_expression subj_Survivin gene subj_induce subj_apoptosis subj_SKOV3 obj_gene obj_induce obj_apoptosis obj_SKOV3 obj_SKOV3/ADM obj_cells
16086871	-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells.	IGE-unidentifiable	subj_Survivin subj_reduce subj_expression subj_Survivin gene subj_induce subj_apoptosis subj_SKOV3 obj_gene obj_induce obj_apoptosis obj_SKOV3 obj_SKOV3/ADM obj_cells
16086871	-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells.	CCS-cancerTOnormal	subj_Survivin subj_reduce subj_expression subj_Survivin gene subj_induce subj_apoptosis subj_SKOV3 obj_gene obj_induce obj_apoptosis obj_SKOV3 obj_SKOV3/ADM obj_cells
16086871	-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells.	PT-observation	subj_Survivin subj_reduce subj_expression subj_Survivin gene subj_induce subj_apoptosis subj_SKOV3 obj_gene obj_induce obj_apoptosis obj_SKOV3 obj_SKOV3/ADM obj_cells
16093247	Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer.	CGE-decreased	subj_Knockdown subj_TRAIL receptor 4 subj_RNA subj_interference subj_ectopic obj_1,25-dihydroxyvitamin obj_D3 obj_apoptosis obj_ovarian cancer
16093247	Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer.	IGE-unidentifiable	subj_Knockdown subj_TRAIL receptor 4 subj_RNA subj_interference subj_ectopic obj_1,25-dihydroxyvitamin obj_D3 obj_apoptosis obj_ovarian cancer
16093247	Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer.	CCS-cancerTOnormal	subj_Knockdown subj_TRAIL receptor 4 subj_RNA subj_interference subj_ectopic obj_1,25-dihydroxyvitamin obj_D3 obj_apoptosis obj_ovarian cancer
16093247	Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer.	PT-causality	subj_Knockdown subj_TRAIL receptor 4 subj_RNA subj_interference subj_ectopic obj_1,25-dihydroxyvitamin obj_D3 obj_apoptosis obj_ovarian cancer
16115918	Cytochrome P450 1B1 (CYP1B1), a dioxin inducible member of the CYP supergene family, is overexpressed in various human malignancies including prostate cancer.	CGE-increased	subj_Cytochrome P450 1B1 (CYP1B1) subj_dioxin subj_inducible subj_CYP obj_human obj_malignancies obj_including obj_prostate cancer
16115918	Cytochrome P450 1B1 (CYP1B1), a dioxin inducible member of the CYP supergene family, is overexpressed in various human malignancies including prostate cancer.	IGE-unchanged	subj_Cytochrome P450 1B1 (CYP1B1) subj_dioxin subj_inducible subj_CYP obj_human obj_malignancies obj_including obj_prostate cancer
16115918	Cytochrome P450 1B1 (CYP1B1), a dioxin inducible member of the CYP supergene family, is overexpressed in various human malignancies including prostate cancer.	CCS-normalTOcancer	subj_Cytochrome P450 1B1 (CYP1B1) subj_dioxin subj_inducible subj_CYP obj_human obj_malignancies obj_including obj_prostate cancer
16115918	Cytochrome P450 1B1 (CYP1B1), a dioxin inducible member of the CYP supergene family, is overexpressed in various human malignancies including prostate cancer.	PT-observation	subj_Cytochrome P450 1B1 (CYP1B1) subj_dioxin subj_inducible subj_CYP obj_human obj_malignancies obj_including obj_prostate cancer
16136053	Transfecting A2780 cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells.	CGE-increased	subj_A2780 subj_cells subj_active subj_Notch 1-IC subj_proliferative subj_colony subj_formation obj_A2780 obj_cells obj_active obj_Notch
16136053	Transfecting A2780 cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells.	IGE-unidentifiable	subj_A2780 subj_cells subj_active subj_Notch 1-IC subj_proliferative subj_colony subj_formation obj_A2780 obj_cells obj_active obj_Notch
16136053	Transfecting A2780 cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells.	CCS-normalTOcancer	subj_A2780 subj_cells subj_active subj_Notch 1-IC subj_proliferative subj_colony subj_formation obj_A2780 obj_cells obj_active obj_Notch
16136053	Transfecting A2780 cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells.	PT-causality	subj_A2780 subj_cells subj_active subj_Notch 1-IC subj_proliferative subj_colony subj_formation obj_A2780 obj_cells obj_active obj_Notch
16145051	These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.	CGE-increased	subj_These subj_support subj_hypothesis subj_EMSY subj_overexpression subj_play subj_role obj_role obj_genesis obj_human obj_breast cancer
16145051	These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.	IGE-unchanged	subj_These subj_support subj_hypothesis subj_EMSY subj_overexpression subj_play subj_role obj_role obj_genesis obj_human obj_breast cancer
16145051	These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.	CCS-normalTOcancer	subj_These subj_support subj_hypothesis subj_EMSY subj_overexpression subj_play subj_role obj_role obj_genesis obj_human obj_breast cancer
16145051	These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.	PT-causality	subj_These subj_support subj_hypothesis subj_EMSY subj_overexpression subj_play subj_role obj_role obj_genesis obj_human obj_breast cancer
16176813	While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.	CGE-increased	subj_Bcl subj_X(L subj_) subj_Hsp 70 subj_90 subj_increased subj_expression obj_3 obj_human obj_canine obj_mammary tumor obj_tissues obj_compared obj_adjacent
16176813	While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.	IGE-unchanged	subj_Bcl subj_X(L subj_) subj_Hsp 70 subj_90 subj_increased subj_expression obj_3 obj_human obj_canine obj_mammary tumor obj_tissues obj_compared obj_adjacent
16176813	While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.	CCS-normalTOcancer	subj_Bcl subj_X(L subj_) subj_Hsp 70 subj_90 subj_increased subj_expression obj_3 obj_human obj_canine obj_mammary tumor obj_tissues obj_compared obj_adjacent
16176813	While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.	PT-observation	subj_Bcl subj_X(L subj_) subj_Hsp 70 subj_90 subj_increased subj_expression obj_3 obj_human obj_canine obj_mammary tumor obj_tissues obj_compared obj_adjacent
16217764	IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer.	CGE-increased	subj_IL-18 subj_FGF-2 proteins subj_elevated subj_tumor subj_tissues obj_p<0.05 obj_) obj_patients obj_ovarian cancer
16217764	IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer.	IGE-unchanged	subj_IL-18 subj_FGF-2 proteins subj_elevated subj_tumor subj_tissues obj_p<0.05 obj_) obj_patients obj_ovarian cancer
16217764	IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer.	CCS-normalTOcancer	subj_IL-18 subj_FGF-2 proteins subj_elevated subj_tumor subj_tissues obj_p<0.05 obj_) obj_patients obj_ovarian cancer
16217764	IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer.	PT-observation	subj_IL-18 subj_FGF-2 proteins subj_elevated subj_tumor subj_tissues obj_p<0.05 obj_) obj_patients obj_ovarian cancer
16230405	Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts.	CGE-decreased	subj_Inhibition subj_LPAAT-beta subj_enhanced subj_survival subj_mice obj_survival obj_mice obj_bearing obj_ovarian tumor obj_xenografts
16230405	Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts.	IGE-	subj_Inhibition subj_LPAAT-beta subj_enhanced subj_survival subj_mice obj_survival obj_mice obj_bearing obj_ovarian tumor obj_xenografts
16230405	Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts.	CCS-unidentifiable	subj_Inhibition subj_LPAAT-beta subj_enhanced subj_survival subj_mice obj_survival obj_mice obj_bearing obj_ovarian tumor obj_xenografts
16230405	Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts.	PT-	subj_Inhibition subj_LPAAT-beta subj_enhanced subj_survival subj_mice obj_survival obj_mice obj_bearing obj_ovarian tumor obj_xenografts
16234819	In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.	CGE-increased	subj_sVEGFR-1 subj_increased subj_secreted subj_VEGF subj_decreased subj_ratio subj_sVEGFR-1/VEGF obj_sVEGFR-1/VEGF obj_MCF-7 obj_human obj_breast cancer obj_cells
16234819	In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.	IGE-	subj_sVEGFR-1 subj_increased subj_secreted subj_VEGF subj_decreased subj_ratio subj_sVEGFR-1/VEGF obj_sVEGFR-1/VEGF obj_MCF-7 obj_human obj_breast cancer obj_cells
16234819	In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.	CCS-unidentifiable	subj_sVEGFR-1 subj_increased subj_secreted subj_VEGF subj_decreased subj_ratio subj_sVEGFR-1/VEGF obj_sVEGFR-1/VEGF obj_MCF-7 obj_human obj_breast cancer obj_cells
16234819	In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.	PT-	subj_sVEGFR-1 subj_increased subj_secreted subj_VEGF subj_decreased subj_ratio subj_sVEGFR-1/VEGF obj_sVEGFR-1/VEGF obj_MCF-7 obj_human obj_breast cancer obj_cells
16299254	The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.	CGE-decreased	subj_data subj_LY294002 subj_inhibits subj_vascular endothelial growth factor subj_( subj_VEGF subj_) obj_protein obj_expression obj_release obj_ovarian carcinoma obj_LY294002 obj_blocks obj_VEGF
16299254	The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.	IGE-unidentifiable	subj_data subj_LY294002 subj_inhibits subj_vascular endothelial growth factor subj_( subj_VEGF subj_) obj_protein obj_expression obj_release obj_ovarian carcinoma obj_LY294002 obj_blocks obj_VEGF
16299254	The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.	CCS-cancerTOnormal	subj_data subj_LY294002 subj_inhibits subj_vascular endothelial growth factor subj_( subj_VEGF subj_) obj_protein obj_expression obj_release obj_ovarian carcinoma obj_LY294002 obj_blocks obj_VEGF
16299254	The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.	PT-observation	subj_data subj_LY294002 subj_inhibits subj_vascular endothelial growth factor subj_( subj_VEGF subj_) obj_protein obj_expression obj_release obj_ovarian carcinoma obj_LY294002 obj_blocks obj_VEGF
16299799	Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.	CGE-increased	subj_marker subj_CaP. subj_Overexpression subj_PIM-1 subj_potential subj_biomarker subj_prostate obj_PIM-1 obj_potential obj_biomarker obj_prostate carcinoma obj_
16299799	Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.	IGE-unchanged	subj_marker subj_CaP. subj_Overexpression subj_PIM-1 subj_potential subj_biomarker subj_prostate obj_PIM-1 obj_potential obj_biomarker obj_prostate carcinoma obj_
16299799	Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.	CCS-normalTOcancer	subj_marker subj_CaP. subj_Overexpression subj_PIM-1 subj_potential subj_biomarker subj_prostate obj_PIM-1 obj_potential obj_biomarker obj_prostate carcinoma obj_
16299799	Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.	PT-observation	subj_marker subj_CaP. subj_Overexpression subj_PIM-1 subj_potential subj_biomarker subj_prostate obj_PIM-1 obj_potential obj_biomarker obj_prostate carcinoma obj_
16302272	Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.	CGE-increased	subj_cancer subj_models subj_revealed subj_androgen receptor subj_frequently subj_upregulated subj_implicated obj_Experimental obj_prostate cancer obj_models obj_revealed obj_androgen
16302272	Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.	IGE-unidentifiable	subj_cancer subj_models subj_revealed subj_androgen receptor subj_frequently subj_upregulated subj_implicated obj_Experimental obj_prostate cancer obj_models obj_revealed obj_androgen
16302272	Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.	CCS-normalTOcancer	subj_cancer subj_models subj_revealed subj_androgen receptor subj_frequently subj_upregulated subj_implicated obj_Experimental obj_prostate cancer obj_models obj_revealed obj_androgen
16302272	Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.	PT-causality	subj_cancer subj_models subj_revealed subj_androgen receptor subj_frequently subj_upregulated subj_implicated obj_Experimental obj_prostate cancer obj_models obj_revealed obj_androgen
16316409	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	CGE-increased	subj_cells subj_regulating subj_expression subj_CRABPI subj_localized subj_sequestration subj_retinoids obj_partially obj_reverse obj_differentiation obj_prostate cancer obj_cells obj_regulating obj_expression
16316409	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	IGE-unidentifiable	subj_cells subj_regulating subj_expression subj_CRABPI subj_localized subj_sequestration subj_retinoids obj_partially obj_reverse obj_differentiation obj_prostate cancer obj_cells obj_regulating obj_expression
16316409	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	CCS-cancerTOnormal	subj_cells subj_regulating subj_expression subj_CRABPI subj_localized subj_sequestration subj_retinoids obj_partially obj_reverse obj_differentiation obj_prostate cancer obj_cells obj_regulating obj_expression
16316409	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	PT-causality	subj_cells subj_regulating subj_expression subj_CRABPI subj_localized subj_sequestration subj_retinoids obj_partially obj_reverse obj_differentiation obj_prostate cancer obj_cells obj_regulating obj_expression
16370564	Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.	CGE-increased	subj_marked subj_ascites subj_elevated subj_CA-125 subj_levels subj_ obj_Graves obj_' obj_disease obj_benign struma ovarii obj_patient obj_marked obj_ascites
16370564	Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.	IGE-unchanged	subj_marked subj_ascites subj_elevated subj_CA-125 subj_levels subj_ obj_Graves obj_' obj_disease obj_benign struma ovarii obj_patient obj_marked obj_ascites
16370564	Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.	CCS-normalTOcancer	subj_marked subj_ascites subj_elevated subj_CA-125 subj_levels subj_ obj_Graves obj_' obj_disease obj_benign struma ovarii obj_patient obj_marked obj_ascites
16370564	Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.	PT-observation	subj_marked subj_ascites subj_elevated subj_CA-125 subj_levels subj_ obj_Graves obj_' obj_disease obj_benign struma ovarii obj_patient obj_marked obj_ascites
16427044	Strikingly, IFN-gamma-induced apoptosis and growth inhibition of M12 cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).	CGE-decreased	subj_constitutive subj_tyrosine subj_phosphorylated subj_STAT3 subj_( subj_pY subj_STAT3 obj_apoptosis obj_growth obj_inhibition obj_M12 obj_cells obj_persistent obj_suppression
16427044	Strikingly, IFN-gamma-induced apoptosis and growth inhibition of M12 cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).	IGE-unidentifiable	subj_constitutive subj_tyrosine subj_phosphorylated subj_STAT3 subj_( subj_pY subj_STAT3 obj_apoptosis obj_growth obj_inhibition obj_M12 obj_cells obj_persistent obj_suppression
16427044	Strikingly, IFN-gamma-induced apoptosis and growth inhibition of M12 cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).	CCS-cancerTOnormal	subj_constitutive subj_tyrosine subj_phosphorylated subj_STAT3 subj_( subj_pY subj_STAT3 obj_apoptosis obj_growth obj_inhibition obj_M12 obj_cells obj_persistent obj_suppression
16427044	Strikingly, IFN-gamma-induced apoptosis and growth inhibition of M12 cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).	PT-observation	subj_constitutive subj_tyrosine subj_phosphorylated subj_STAT3 subj_( subj_pY subj_STAT3 obj_apoptosis obj_growth obj_inhibition obj_M12 obj_cells obj_persistent obj_suppression
16464948	The insLQ polymorphism increases LHR activity, thereby shortening breast cancer disease-free survival, probably by increasing estrogen exposure in female carriers.	CGE-increased	subj_insLQ subj_polymorphism subj_increases subj_LHR subj_activity subj_shortening subj_breast obj_LHR obj_activity obj_shortening obj_breast cancer obj_disease obj_survival obj_increasing
16464948	The insLQ polymorphism increases LHR activity, thereby shortening breast cancer disease-free survival, probably by increasing estrogen exposure in female carriers.	IGE-	subj_insLQ subj_polymorphism subj_increases subj_LHR subj_activity subj_shortening subj_breast obj_LHR obj_activity obj_shortening obj_breast cancer obj_disease obj_survival obj_increasing
16464948	The insLQ polymorphism increases LHR activity, thereby shortening breast cancer disease-free survival, probably by increasing estrogen exposure in female carriers.	CCS-unidentifiable	subj_insLQ subj_polymorphism subj_increases subj_LHR subj_activity subj_shortening subj_breast obj_LHR obj_activity obj_shortening obj_breast cancer obj_disease obj_survival obj_increasing
16464948	The insLQ polymorphism increases LHR activity, thereby shortening breast cancer disease-free survival, probably by increasing estrogen exposure in female carriers.	PT-	subj_insLQ subj_polymorphism subj_increases subj_LHR subj_activity subj_shortening subj_breast obj_LHR obj_activity obj_shortening obj_breast cancer obj_disease obj_survival obj_increasing
16489002	ErbB2 overexpression in breast tumors results in increased metastasis and angiogenesis and reduced survival.	CGE-increased	subj_ErbB2 subj_overexpression subj_breast subj_tumors obj_overexpression obj_breast tumors obj_increased obj_metastasis obj_angiogenesis
16489002	ErbB2 overexpression in breast tumors results in increased metastasis and angiogenesis and reduced survival.	IGE-unidentifiable	subj_ErbB2 subj_overexpression subj_breast subj_tumors obj_overexpression obj_breast tumors obj_increased obj_metastasis obj_angiogenesis
16489002	ErbB2 overexpression in breast tumors results in increased metastasis and angiogenesis and reduced survival.	CCS-normalTOcancer	subj_ErbB2 subj_overexpression subj_breast subj_tumors obj_overexpression obj_breast tumors obj_increased obj_metastasis obj_angiogenesis
16489002	ErbB2 overexpression in breast tumors results in increased metastasis and angiogenesis and reduced survival.	PT-causality	subj_ErbB2 subj_overexpression subj_breast subj_tumors obj_overexpression obj_breast tumors obj_increased obj_metastasis obj_angiogenesis
16491480	AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated.	CGE-increased	subj_expression subj_AMACR subj_elevated subj_PSGR subj_and/or subj_PSGR2 subj_elevated obj_AMACR obj_single obj_marker obj_prostate cancer obj_7 obj_59 obj_total
16491480	AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated.	IGE-unchanged	subj_expression subj_AMACR subj_elevated subj_PSGR subj_and/or subj_PSGR2 subj_elevated obj_AMACR obj_single obj_marker obj_prostate cancer obj_7 obj_59 obj_total
16491480	AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated.	CCS-normalTOcancer	subj_expression subj_AMACR subj_elevated subj_PSGR subj_and/or subj_PSGR2 subj_elevated obj_AMACR obj_single obj_marker obj_prostate cancer obj_7 obj_59 obj_total
16491480	AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated.	PT-observation	subj_expression subj_AMACR subj_elevated subj_PSGR subj_and/or subj_PSGR2 subj_elevated obj_AMACR obj_single obj_marker obj_prostate cancer obj_7 obj_59 obj_total
16501249	A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial breast cancer risk.	CGE-decreased	subj_/ subj_duplication subj_reduced subj_p53 subj_expression subj_familial subj_breast obj_reduced obj_p53 obj_expression obj_familial breast cancer obj_risk
16501249	A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial breast cancer risk.	IGE-	subj_/ subj_duplication subj_reduced subj_p53 subj_expression subj_familial subj_breast obj_reduced obj_p53 obj_expression obj_familial breast cancer obj_risk
16501249	A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial breast cancer risk.	CCS-unidentifiable	subj_/ subj_duplication subj_reduced subj_p53 subj_expression subj_familial subj_breast obj_reduced obj_p53 obj_expression obj_familial breast cancer obj_risk
16501249	A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial breast cancer risk.	PT-	subj_/ subj_duplication subj_reduced subj_p53 subj_expression subj_familial subj_breast obj_reduced obj_p53 obj_expression obj_familial breast cancer obj_risk
16510571	Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth.	CGE-decreased	subj_Furthermore subj_knockdown subj_cyclin D1 subj_breast subj_carcinoma subj_cells obj_knockdown obj_cyclin obj_D1 obj_breast carcinoma obj_cells obj_led obj_reduction
16510571	Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth.	IGE-unidentifiable	subj_Furthermore subj_knockdown subj_cyclin D1 subj_breast subj_carcinoma subj_cells obj_knockdown obj_cyclin obj_D1 obj_breast carcinoma obj_cells obj_led obj_reduction
16510571	Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth.	CCS-cancerTOnormal	subj_Furthermore subj_knockdown subj_cyclin D1 subj_breast subj_carcinoma subj_cells obj_knockdown obj_cyclin obj_D1 obj_breast carcinoma obj_cells obj_led obj_reduction
16510571	Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth.	PT-causality	subj_Furthermore subj_knockdown subj_cyclin D1 subj_breast subj_carcinoma subj_cells obj_knockdown obj_cyclin obj_D1 obj_breast carcinoma obj_cells obj_led obj_reduction
16552954	[Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].	CGE-increased	subj_endothelial subj_progenitor subj_cells subj_TRAIL gene subj_transfection subj_ovarian subj_carcinoma obj_TRAIL obj_gene obj_transfection obj_ovarian carcinoma obj_xenografts obj_nude obj_mice
16552954	[Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].	IGE-unidentifiable	subj_endothelial subj_progenitor subj_cells subj_TRAIL gene subj_transfection subj_ovarian subj_carcinoma obj_TRAIL obj_gene obj_transfection obj_ovarian carcinoma obj_xenografts obj_nude obj_mice
16552954	[Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].	CCS-cancerTOnormal	subj_endothelial subj_progenitor subj_cells subj_TRAIL gene subj_transfection subj_ovarian subj_carcinoma obj_TRAIL obj_gene obj_transfection obj_ovarian carcinoma obj_xenografts obj_nude obj_mice
16552954	[Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].	PT-observation	subj_endothelial subj_progenitor subj_cells subj_TRAIL gene subj_transfection subj_ovarian subj_carcinoma obj_TRAIL obj_gene obj_transfection obj_ovarian carcinoma obj_xenografts obj_nude obj_mice
16584837	Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.	CGE-increased	subj_: subj_increased subj_expression subj_AKT subj_advanced subj_ovarian subj_cancer obj_expression obj_AKT obj_advanced obj_ovarian cancer obj_
16584837	Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.	IGE-unidentifiable	subj_: subj_increased subj_expression subj_AKT subj_advanced subj_ovarian subj_cancer obj_expression obj_AKT obj_advanced obj_ovarian cancer obj_
16584837	Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.	CCS-normalTOcancer	subj_: subj_increased subj_expression subj_AKT subj_advanced subj_ovarian subj_cancer obj_expression obj_AKT obj_advanced obj_ovarian cancer obj_
16584837	Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.	PT-observation	subj_: subj_increased subj_expression subj_AKT subj_advanced subj_ovarian subj_cancer obj_expression obj_AKT obj_advanced obj_ovarian cancer obj_
16601286	We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma.	CGE-increased	subj_conclude subj_elevated subj_expression subj_AKR1C3 subj_highly subj_prostate subj_carcinoma obj_expression obj_AKR1C3 obj_highly obj_prostate carcinoma
16601286	We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma.	IGE-unchanged	subj_conclude subj_elevated subj_expression subj_AKR1C3 subj_highly subj_prostate subj_carcinoma obj_expression obj_AKR1C3 obj_highly obj_prostate carcinoma
16601286	We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma.	CCS-normalTOcancer	subj_conclude subj_elevated subj_expression subj_AKR1C3 subj_highly subj_prostate subj_carcinoma obj_expression obj_AKR1C3 obj_highly obj_prostate carcinoma
16601286	We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma.	PT-observation	subj_conclude subj_elevated subj_expression subj_AKR1C3 subj_highly subj_prostate subj_carcinoma obj_expression obj_AKR1C3 obj_highly obj_prostate carcinoma
16609016	Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P < 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression.	CGE-increased	subj_analysis subj_confirmed subj_increased subj_RPL19 subj_expression subj_highly subj_predictive obj_RPL19 obj_sensitive obj_predictor obj_prostate cancer obj_progression
16609016	Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P < 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression.	IGE-	subj_analysis subj_confirmed subj_increased subj_RPL19 subj_expression subj_highly subj_predictive obj_RPL19 obj_sensitive obj_predictor obj_prostate cancer obj_progression
16609016	Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P < 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression.	CCS-unidentifiable	subj_analysis subj_confirmed subj_increased subj_RPL19 subj_expression subj_highly subj_predictive obj_RPL19 obj_sensitive obj_predictor obj_prostate cancer obj_progression
16609016	Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P < 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression.	PT-	subj_analysis subj_confirmed subj_increased subj_RPL19 subj_expression subj_highly subj_predictive obj_RPL19 obj_sensitive obj_predictor obj_prostate cancer obj_progression
16630134	MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.	CGE-increased	subj_MTA1 subj_overexpression subj_correlates subj_tumor obj_grade obj_angiogenesis obj_human obj_breast cancers obj_
16630134	MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.	IGE-unchanged	subj_MTA1 subj_overexpression subj_correlates subj_tumor obj_grade obj_angiogenesis obj_human obj_breast cancers obj_
16630134	MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.	CCS-normalTOcancer	subj_MTA1 subj_overexpression subj_correlates subj_tumor obj_grade obj_angiogenesis obj_human obj_breast cancers obj_
16630134	MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.	PT-causality	subj_MTA1 subj_overexpression subj_correlates subj_tumor obj_grade obj_angiogenesis obj_human obj_breast cancers obj_
16643892	MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin.	CGE-increased	subj_cell subj_membranes subj_induced subj_plasmin subj_generation subj_time subj_dependent obj_MDA-MB231 obj_cell obj_membranes obj_induced
16643892	MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin.	IGE-	subj_cell subj_membranes subj_induced subj_plasmin subj_generation subj_time subj_dependent obj_MDA-MB231 obj_cell obj_membranes obj_induced
16643892	MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin.	CCS-unidentifiable	subj_cell subj_membranes subj_induced subj_plasmin subj_generation subj_time subj_dependent obj_MDA-MB231 obj_cell obj_membranes obj_induced
16643892	MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin.	PT-	subj_cell subj_membranes subj_induced subj_plasmin subj_generation subj_time subj_dependent obj_MDA-MB231 obj_cell obj_membranes obj_induced
16734726	Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers.	CGE-increased	subj_homolog subj_2 subj_( subj_EZH2 subj_) subj_protein subj_repressor obj_reported obj_biological obj_malignancy obj_prostate cancer obj_cancers
16734726	Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers.	IGE-unchanged	subj_homolog subj_2 subj_( subj_EZH2 subj_) subj_protein subj_repressor obj_reported obj_biological obj_malignancy obj_prostate cancer obj_cancers
16734726	Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers.	CCS-normalTOcancer	subj_homolog subj_2 subj_( subj_EZH2 subj_) subj_protein subj_repressor obj_reported obj_biological obj_malignancy obj_prostate cancer obj_cancers
16734726	Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers.	PT-observation	subj_homolog subj_2 subj_( subj_EZH2 subj_) subj_protein subj_repressor obj_reported obj_biological obj_malignancy obj_prostate cancer obj_cancers
16755107	Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.	CGE-decreased	subj_cancer subj_suggesting subj_inhibition subj_Akt subj_increase subj_efficacy subj_endocrine obj_resistance obj_endocrine obj_therapy obj_breast cancer obj_suggesting obj_inhibition obj_Akt
16755107	Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.	IGE-unidentifiable	subj_cancer subj_suggesting subj_inhibition subj_Akt subj_increase subj_efficacy subj_endocrine obj_resistance obj_endocrine obj_therapy obj_breast cancer obj_suggesting obj_inhibition obj_Akt
16755107	Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.	CCS-cancerTOnormal	subj_cancer subj_suggesting subj_inhibition subj_Akt subj_increase subj_efficacy subj_endocrine obj_resistance obj_endocrine obj_therapy obj_breast cancer obj_suggesting obj_inhibition obj_Akt
16755107	Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.	PT-causality	subj_cancer subj_suggesting subj_inhibition subj_Akt subj_increase subj_efficacy subj_endocrine obj_resistance obj_endocrine obj_therapy obj_breast cancer obj_suggesting obj_inhibition obj_Akt
16763719	In flow cytometry, 9-cis RA treatment caused accumulation of cells in the G(1) phase of the cell cycle and a fewer cells pass through to G(2)/M.
CONCLUSION: Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.	CGE-increased	subj_mitosis subj_upregulate subj_expression subj_human homeobox gene NKX3.1 subj_play subj_role subj_prostate obj_differentiating obj_agent obj_arrest obj_prostate cancer obj_cells obj_G(1 obj_)
16763719	In flow cytometry, 9-cis RA treatment caused accumulation of cells in the G(1) phase of the cell cycle and a fewer cells pass through to G(2)/M.
CONCLUSION: Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.	IGE-unidentifiable	subj_mitosis subj_upregulate subj_expression subj_human homeobox gene NKX3.1 subj_play subj_role subj_prostate obj_differentiating obj_agent obj_arrest obj_prostate cancer obj_cells obj_G(1 obj_)
16763719	In flow cytometry, 9-cis RA treatment caused accumulation of cells in the G(1) phase of the cell cycle and a fewer cells pass through to G(2)/M.
CONCLUSION: Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.	CCS-cancerTOnormal	subj_mitosis subj_upregulate subj_expression subj_human homeobox gene NKX3.1 subj_play subj_role subj_prostate obj_differentiating obj_agent obj_arrest obj_prostate cancer obj_cells obj_G(1 obj_)
16763719	In flow cytometry, 9-cis RA treatment caused accumulation of cells in the G(1) phase of the cell cycle and a fewer cells pass through to G(2)/M.
CONCLUSION: Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.	PT-causality	subj_mitosis subj_upregulate subj_expression subj_human homeobox gene NKX3.1 subj_play subj_role subj_prostate obj_differentiating obj_agent obj_arrest obj_prostate cancer obj_cells obj_G(1 obj_)
16809439	From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.	CGE-decreased	subj_actions subj_specific subj_blockade subj_FASN subj_activity subj_provide subj_protective obj_carcinoma obj_tamoxifen obj_based obj_breast cancer obj_therapy
16809439	From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.	IGE-unidentifiable	subj_actions subj_specific subj_blockade subj_FASN subj_activity subj_provide subj_protective obj_carcinoma obj_tamoxifen obj_based obj_breast cancer obj_therapy
16809439	From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.	CCS-cancerTOnormal	subj_actions subj_specific subj_blockade subj_FASN subj_activity subj_provide subj_protective obj_carcinoma obj_tamoxifen obj_based obj_breast cancer obj_therapy
16809439	From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.	PT-causality	subj_actions subj_specific subj_blockade subj_FASN subj_activity subj_provide subj_protective obj_carcinoma obj_tamoxifen obj_based obj_breast cancer obj_therapy
16818616	Transfection-mediated WWOX overexpression in DU145 cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.	CGE-increased	subj_= subj_0.0012 subj_) subj_WWOX subj_overexpression subj_infection subj_Ad obj_mediated obj_WWOX obj_overexpression obj_DU145 obj_cells obj_suppressed obj_colony
16818616	Transfection-mediated WWOX overexpression in DU145 cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.	IGE-unidentifiable	subj_= subj_0.0012 subj_) subj_WWOX subj_overexpression subj_infection subj_Ad obj_mediated obj_WWOX obj_overexpression obj_DU145 obj_cells obj_suppressed obj_colony
16818616	Transfection-mediated WWOX overexpression in DU145 cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.	CCS-cancerTOnormal	subj_= subj_0.0012 subj_) subj_WWOX subj_overexpression subj_infection subj_Ad obj_mediated obj_WWOX obj_overexpression obj_DU145 obj_cells obj_suppressed obj_colony
16818616	Transfection-mediated WWOX overexpression in DU145 cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.	PT-causality	subj_= subj_0.0012 subj_) subj_WWOX subj_overexpression subj_infection subj_Ad obj_mediated obj_WWOX obj_overexpression obj_DU145 obj_cells obj_suppressed obj_colony
16818637	Our findings suggest that blockage of osteopontin and/or COX-2 is a promising therapeutic approach for the inhibition of prostate tumor progression and angiogenesis.	CGE-decreased	subj_findings subj_blockage subj_osteopontin subj_and/or subj_COX-2 subj_promising obj_therapeutic obj_approach obj_inhibition obj_prostate tumor obj_progression obj_angiogenesis
16818637	Our findings suggest that blockage of osteopontin and/or COX-2 is a promising therapeutic approach for the inhibition of prostate tumor progression and angiogenesis.	IGE-unidentifiable	subj_findings subj_blockage subj_osteopontin subj_and/or subj_COX-2 subj_promising obj_therapeutic obj_approach obj_inhibition obj_prostate tumor obj_progression obj_angiogenesis
16818637	Our findings suggest that blockage of osteopontin and/or COX-2 is a promising therapeutic approach for the inhibition of prostate tumor progression and angiogenesis.	CCS-cancerTOnormal	subj_findings subj_blockage subj_osteopontin subj_and/or subj_COX-2 subj_promising obj_therapeutic obj_approach obj_inhibition obj_prostate tumor obj_progression obj_angiogenesis
16818637	Our findings suggest that blockage of osteopontin and/or COX-2 is a promising therapeutic approach for the inhibition of prostate tumor progression and angiogenesis.	PT-causality	subj_findings subj_blockage subj_osteopontin subj_and/or subj_COX-2 subj_promising obj_therapeutic obj_approach obj_inhibition obj_prostate tumor obj_progression obj_angiogenesis
16825507	Electrophoretic mobility shift assays showed that increased binding affinity of Sp1 to the promoter with -202G and +20A. Interestingly, ovarian cancer patients (n = 42) with G-A/G-A homozygous genotype had increased expression of LTBP-1 and apparently poorer survival than those with other genotypes (P = 0.02).	CGE-increased	subj_genotype subj_increased subj_expression subj_LTBP-1 subj_poorer subj_survival subj_genotypes obj_+ obj_20A. obj_Interestingly obj_ovarian cancer obj_patients obj_( obj_=
16825507	Electrophoretic mobility shift assays showed that increased binding affinity of Sp1 to the promoter with -202G and +20A. Interestingly, ovarian cancer patients (n = 42) with G-A/G-A homozygous genotype had increased expression of LTBP-1 and apparently poorer survival than those with other genotypes (P = 0.02).	IGE-unidentifiable	subj_genotype subj_increased subj_expression subj_LTBP-1 subj_poorer subj_survival subj_genotypes obj_+ obj_20A. obj_Interestingly obj_ovarian cancer obj_patients obj_( obj_=
16825507	Electrophoretic mobility shift assays showed that increased binding affinity of Sp1 to the promoter with -202G and +20A. Interestingly, ovarian cancer patients (n = 42) with G-A/G-A homozygous genotype had increased expression of LTBP-1 and apparently poorer survival than those with other genotypes (P = 0.02).	CCS-normalTOcancer	subj_genotype subj_increased subj_expression subj_LTBP-1 subj_poorer subj_survival subj_genotypes obj_+ obj_20A. obj_Interestingly obj_ovarian cancer obj_patients obj_( obj_=
16825507	Electrophoretic mobility shift assays showed that increased binding affinity of Sp1 to the promoter with -202G and +20A. Interestingly, ovarian cancer patients (n = 42) with G-A/G-A homozygous genotype had increased expression of LTBP-1 and apparently poorer survival than those with other genotypes (P = 0.02).	PT-observation	subj_genotype subj_increased subj_expression subj_LTBP-1 subj_poorer subj_survival subj_genotypes obj_+ obj_20A. obj_Interestingly obj_ovarian cancer obj_patients obj_( obj_=
16954434	Oestrogen receptor-alpha (ERalpha) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERalpha activity.	CGE-decreased	subj_designed subj_inhibit subj_prevent subj_ERalpha subj_activity obj_) obj_prognostic obj_marker obj_breast cancer obj_endocrine obj_therapies obj_designed
16954434	Oestrogen receptor-alpha (ERalpha) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERalpha activity.	IGE-up-regulated	subj_designed subj_inhibit subj_prevent subj_ERalpha subj_activity obj_) obj_prognostic obj_marker obj_breast cancer obj_endocrine obj_therapies obj_designed
16954434	Oestrogen receptor-alpha (ERalpha) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERalpha activity.	CCS-cancerTOnormal	subj_designed subj_inhibit subj_prevent subj_ERalpha subj_activity obj_) obj_prognostic obj_marker obj_breast cancer obj_endocrine obj_therapies obj_designed
16954434	Oestrogen receptor-alpha (ERalpha) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERalpha activity.	PT-causality	subj_designed subj_inhibit subj_prevent subj_ERalpha subj_activity obj_) obj_prognostic obj_marker obj_breast cancer obj_endocrine obj_therapies obj_designed
1696386	Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues.	CGE-increased	subj_cell subj_elevated subj_amplification subj_c-Ki-ras subj_compared subj_human subj_fibroblast obj_cells obj_NIH obj_: obj_OVCAR-3 obj_cancer obj_cell obj_elevated
1696386	Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues.	IGE-unchanged	subj_cell subj_elevated subj_amplification subj_c-Ki-ras subj_compared subj_human subj_fibroblast obj_cells obj_NIH obj_: obj_OVCAR-3 obj_cancer obj_cell obj_elevated
1696386	Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues.	CCS-normalTOcancer	subj_cell subj_elevated subj_amplification subj_c-Ki-ras subj_compared subj_human subj_fibroblast obj_cells obj_NIH obj_: obj_OVCAR-3 obj_cancer obj_cell obj_elevated
1696386	Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues.	PT-observation	subj_cell subj_elevated subj_amplification subj_c-Ki-ras subj_compared subj_human subj_fibroblast obj_cells obj_NIH obj_: obj_OVCAR-3 obj_cancer obj_cell obj_elevated
16982748	Furthermore, elevated [Ca2+]o triggered activation of the Akt signaling pathway and enhanced PC-3 cell attachment.	CGE-increased	subj_Ca2+]o subj_triggered subj_activation subj_Akt subj_signaling subj_pathway subj_enhanced obj_signaling obj_pathway obj_enhanced obj_PC-3 obj_cell obj_attachment
16982748	Furthermore, elevated [Ca2+]o triggered activation of the Akt signaling pathway and enhanced PC-3 cell attachment.	IGE-	subj_Ca2+]o subj_triggered subj_activation subj_Akt subj_signaling subj_pathway subj_enhanced obj_signaling obj_pathway obj_enhanced obj_PC-3 obj_cell obj_attachment
16982748	Furthermore, elevated [Ca2+]o triggered activation of the Akt signaling pathway and enhanced PC-3 cell attachment.	CCS-unidentifiable	subj_Ca2+]o subj_triggered subj_activation subj_Akt subj_signaling subj_pathway subj_enhanced obj_signaling obj_pathway obj_enhanced obj_PC-3 obj_cell obj_attachment
16982748	Furthermore, elevated [Ca2+]o triggered activation of the Akt signaling pathway and enhanced PC-3 cell attachment.	PT-	subj_Ca2+]o subj_triggered subj_activation subj_Akt subj_signaling subj_pathway subj_enhanced obj_signaling obj_pathway obj_enhanced obj_PC-3 obj_cell obj_attachment
17003780	Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.	CGE-increased	subj_Together subj_data subj_strong subj_Tiam1 subj_overexpression subj_relative subj_benign obj_decreased obj_DFS obj_patients obj_prostate cancer
17003780	Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.	IGE-	subj_Together subj_data subj_strong subj_Tiam1 subj_overexpression subj_relative subj_benign obj_decreased obj_DFS obj_patients obj_prostate cancer
17003780	Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.	CCS-unidentifiable	subj_Together subj_data subj_strong subj_Tiam1 subj_overexpression subj_relative subj_benign obj_decreased obj_DFS obj_patients obj_prostate cancer
17003780	Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.	PT-	subj_Together subj_data subj_strong subj_Tiam1 subj_overexpression subj_relative subj_benign obj_decreased obj_DFS obj_patients obj_prostate cancer
17022003	serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human PC-3 prostate cancer cells in vitro and induces apoptosis as shown by activation of caspase 3 and the induction of DNA fragmentation.	CGE-increased	subj_induces subj_apoptosis subj_activation subj_caspase 3 subj_induction subj_DNA subj_fragmentation obj_resistant obj_human obj_PC-3 obj_prostate cancer obj_cells obj_vitro obj_induces
17022003	serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human PC-3 prostate cancer cells in vitro and induces apoptosis as shown by activation of caspase 3 and the induction of DNA fragmentation.	IGE-unidentifiable	subj_induces subj_apoptosis subj_activation subj_caspase 3 subj_induction subj_DNA subj_fragmentation obj_resistant obj_human obj_PC-3 obj_prostate cancer obj_cells obj_vitro obj_induces
17022003	serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human PC-3 prostate cancer cells in vitro and induces apoptosis as shown by activation of caspase 3 and the induction of DNA fragmentation.	CCS-cancerTOnormal	subj_induces subj_apoptosis subj_activation subj_caspase 3 subj_induction subj_DNA subj_fragmentation obj_resistant obj_human obj_PC-3 obj_prostate cancer obj_cells obj_vitro obj_induces
17022003	serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human PC-3 prostate cancer cells in vitro and induces apoptosis as shown by activation of caspase 3 and the induction of DNA fragmentation.	PT-causality	subj_induces subj_apoptosis subj_activation subj_caspase 3 subj_induction subj_DNA subj_fragmentation obj_resistant obj_human obj_PC-3 obj_prostate cancer obj_cells obj_vitro obj_induces
17045920	This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.	CGE-increased	subj_production subj_H2O2 subj_activation subj_AKT subj_p70S6K1 subj_human subj_ovarian obj_AKT obj_p70S6K1 obj_human obj_ovarian cancer obj_cells
17045920	This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.	IGE-	subj_production subj_H2O2 subj_activation subj_AKT subj_p70S6K1 subj_human subj_ovarian obj_AKT obj_p70S6K1 obj_human obj_ovarian cancer obj_cells
17045920	This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.	CCS-unidentifiable	subj_production subj_H2O2 subj_activation subj_AKT subj_p70S6K1 subj_human subj_ovarian obj_AKT obj_p70S6K1 obj_human obj_ovarian cancer obj_cells
17045920	This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.	PT-	subj_production subj_H2O2 subj_activation subj_AKT subj_p70S6K1 subj_human subj_ovarian obj_AKT obj_p70S6K1 obj_human obj_ovarian cancer obj_cells
17079470	Activation of ATF2, which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in MCF10A cells.	CGE-increased	subj_Activation subj_ATF2 subj_depended subj_p38 subj_activity obj_invasive obj_migrative obj_phenotypes obj_MCF10A obj_cells
17079470	Activation of ATF2, which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in MCF10A cells.	IGE-unidentifiable	subj_Activation subj_ATF2 subj_depended subj_p38 subj_activity obj_invasive obj_migrative obj_phenotypes obj_MCF10A obj_cells
17079470	Activation of ATF2, which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in MCF10A cells.	CCS-normalTOcancer	subj_Activation subj_ATF2 subj_depended subj_p38 subj_activity obj_invasive obj_migrative obj_phenotypes obj_MCF10A obj_cells
17079470	Activation of ATF2, which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in MCF10A cells.	PT-causality	subj_Activation subj_ATF2 subj_depended subj_p38 subj_activity obj_invasive obj_migrative obj_phenotypes obj_MCF10A obj_cells
17092940	Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.	CGE-increased	subj_promotes subj_actin subj_polymerization subj_ErbB2 subj_activation subj_leading subj_beta obj_regulation obj_cell obj_migration obj_ovarian tumor obj_cells obj_
17092940	Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.	IGE-unidentifiable	subj_promotes subj_actin subj_polymerization subj_ErbB2 subj_activation subj_leading subj_beta obj_regulation obj_cell obj_migration obj_ovarian tumor obj_cells obj_
17092940	Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.	CCS-normalTOcancer	subj_promotes subj_actin subj_polymerization subj_ErbB2 subj_activation subj_leading subj_beta obj_regulation obj_cell obj_migration obj_ovarian tumor obj_cells obj_
17092940	Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.	PT-causality	subj_promotes subj_actin subj_polymerization subj_ErbB2 subj_activation subj_leading subj_beta obj_regulation obj_cell obj_migration obj_ovarian tumor obj_cells obj_
17118344	Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.	CGE-increased	subj_CHK2-knockout subj_HCT116 subj_cells subj_CHK2 subj_activation subj_contributes subj_control obj_Furthermore obj_ovarian cancer obj_cell obj_lines obj_expressing
17118344	Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.	IGE-	subj_CHK2-knockout subj_HCT116 subj_cells subj_CHK2 subj_activation subj_contributes subj_control obj_Furthermore obj_ovarian cancer obj_cell obj_lines obj_expressing
17118344	Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.	CCS-unidentifiable	subj_CHK2-knockout subj_HCT116 subj_cells subj_CHK2 subj_activation subj_contributes subj_control obj_Furthermore obj_ovarian cancer obj_cell obj_lines obj_expressing
17118344	Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.	PT-	subj_CHK2-knockout subj_HCT116 subj_cells subj_CHK2 subj_activation subj_contributes subj_control obj_Furthermore obj_ovarian cancer obj_cell obj_lines obj_expressing
17134822	Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.	CGE-increased	subj_Polycomb-group oncogenes EZH2 subj_BMI1 subj_RING1 subj_overexpressed obj_BMI1 obj_RING1 obj_overexpressed obj_prostate cancer obj_adverse obj_pathologic obj_clinical
17134822	Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.	IGE-unchanged	subj_Polycomb-group oncogenes EZH2 subj_BMI1 subj_RING1 subj_overexpressed obj_BMI1 obj_RING1 obj_overexpressed obj_prostate cancer obj_adverse obj_pathologic obj_clinical
17134822	Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.	CCS-normalTOcancer	subj_Polycomb-group oncogenes EZH2 subj_BMI1 subj_RING1 subj_overexpressed obj_BMI1 obj_RING1 obj_overexpressed obj_prostate cancer obj_adverse obj_pathologic obj_clinical
17134822	Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.	PT-observation	subj_Polycomb-group oncogenes EZH2 subj_BMI1 subj_RING1 subj_overexpressed obj_BMI1 obj_RING1 obj_overexpressed obj_prostate cancer obj_adverse obj_pathologic obj_clinical
17143532	Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.	CGE-increased	subj_cell subj_proliferation subj_upregulation subj_BRCA2 subj_ obj_/ obj_ERK obj_inhibits obj_prostate cancer obj_cell obj_proliferation obj_upregulation
17143532	Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.	IGE-unidentifiable	subj_cell subj_proliferation subj_upregulation subj_BRCA2 subj_ obj_/ obj_ERK obj_inhibits obj_prostate cancer obj_cell obj_proliferation obj_upregulation
17143532	Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.	CCS-cancerTOnormal	subj_cell subj_proliferation subj_upregulation subj_BRCA2 subj_ obj_/ obj_ERK obj_inhibits obj_prostate cancer obj_cell obj_proliferation obj_upregulation
17143532	Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.	PT-causality	subj_cell subj_proliferation subj_upregulation subj_BRCA2 subj_ obj_/ obj_ERK obj_inhibits obj_prostate cancer obj_cell obj_proliferation obj_upregulation
17145775	The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.	CGE-increased	subj_multidrug transporter breast cancer resistance protein subj_( subj_BCRP subj_/ obj_multidrug obj_transporter obj_breast cancer obj_resistance obj_protein obj_(
17145775	The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.	IGE-	subj_multidrug transporter breast cancer resistance protein subj_( subj_BCRP subj_/ obj_multidrug obj_transporter obj_breast cancer obj_resistance obj_protein obj_(
17145775	The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.	CCS-unidentifiable	subj_multidrug transporter breast cancer resistance protein subj_( subj_BCRP subj_/ obj_multidrug obj_transporter obj_breast cancer obj_resistance obj_protein obj_(
17145775	The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.	PT-	subj_multidrug transporter breast cancer resistance protein subj_( subj_BCRP subj_/ obj_multidrug obj_transporter obj_breast cancer obj_resistance obj_protein obj_(
17203235	In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.	CGE-increased	subj_morphogenetic subj_protein subj_receptors subj_BMPR-IB subj_BMPR subj_II subj_prostate obj_IB obj_BMPR obj_II obj_prostate cancer obj_cells obj_vitro obj_vivo
17203235	In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.	IGE-	subj_morphogenetic subj_protein subj_receptors subj_BMPR-IB subj_BMPR subj_II subj_prostate obj_IB obj_BMPR obj_II obj_prostate cancer obj_cells obj_vitro obj_vivo
17203235	In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.	CCS-unidentifiable	subj_morphogenetic subj_protein subj_receptors subj_BMPR-IB subj_BMPR subj_II subj_prostate obj_IB obj_BMPR obj_II obj_prostate cancer obj_cells obj_vitro obj_vivo
17203235	In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.	PT-	subj_morphogenetic subj_protein subj_receptors subj_BMPR-IB subj_BMPR subj_II subj_prostate obj_IB obj_BMPR obj_II obj_prostate cancer obj_cells obj_vitro obj_vivo
17276501	We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin.	CGE-decreased	subj_carcinoma subj_cells subj_loss subj_ERK subj_activation subj_response subj_cisplatin obj_cisplatin obj_resistance obj_OAW42-R obj_ovarian carcinoma obj_cells obj_loss obj_ERK
17276501	We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin.	IGE-unidentifiable	subj_carcinoma subj_cells subj_loss subj_ERK subj_activation subj_response subj_cisplatin obj_cisplatin obj_resistance obj_OAW42-R obj_ovarian carcinoma obj_cells obj_loss obj_ERK
17276501	We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin.	CCS-cancerTOnormal	subj_carcinoma subj_cells subj_loss subj_ERK subj_activation subj_response subj_cisplatin obj_cisplatin obj_resistance obj_OAW42-R obj_ovarian carcinoma obj_cells obj_loss obj_ERK
17276501	We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin.	PT-observation	subj_carcinoma subj_cells subj_loss subj_ERK subj_activation subj_response subj_cisplatin obj_cisplatin obj_resistance obj_OAW42-R obj_ovarian carcinoma obj_cells obj_loss obj_ERK
17285121	MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage.	CGE-increased	subj_A2780 subj_cells subj_illustrated subj_p53 subj_accumulation subj_activation subj_caspase-9 obj_apoptotic obj_pathway obj_normal obj_A2780 obj_cells obj_illustrated obj_p53
17285121	MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage.	IGE-	subj_A2780 subj_cells subj_illustrated subj_p53 subj_accumulation subj_activation subj_caspase-9 obj_apoptotic obj_pathway obj_normal obj_A2780 obj_cells obj_illustrated obj_p53
17285121	MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage.	CCS-unidentifiable	subj_A2780 subj_cells subj_illustrated subj_p53 subj_accumulation subj_activation subj_caspase-9 obj_apoptotic obj_pathway obj_normal obj_A2780 obj_cells obj_illustrated obj_p53
17285121	MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage.	PT-	subj_A2780 subj_cells subj_illustrated subj_p53 subj_accumulation subj_activation subj_caspase-9 obj_apoptotic obj_pathway obj_normal obj_A2780 obj_cells obj_illustrated obj_p53
17317102	In breast cancer cells overexpressing ErbB2, Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.	CGE-increased	subj_cancer subj_cells subj_overexpressing subj_ErbB2 subj_Erk5 subj_dual subj_phosphorylation obj_breast cancer obj_cells obj_overexpressing obj_ErbB2
17317102	In breast cancer cells overexpressing ErbB2, Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.	IGE-unidentifiable	subj_cancer subj_cells subj_overexpressing subj_ErbB2 subj_Erk5 subj_dual subj_phosphorylation obj_breast cancer obj_cells obj_overexpressing obj_ErbB2
17317102	In breast cancer cells overexpressing ErbB2, Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.	CCS-normalTOcancer	subj_cancer subj_cells subj_overexpressing subj_ErbB2 subj_Erk5 subj_dual subj_phosphorylation obj_breast cancer obj_cells obj_overexpressing obj_ErbB2
17317102	In breast cancer cells overexpressing ErbB2, Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.	PT-observation	subj_cancer subj_cells subj_overexpressing subj_ErbB2 subj_Erk5 subj_dual subj_phosphorylation obj_breast cancer obj_cells obj_overexpressing obj_ErbB2
17331422	Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3.	CGE-increased	subj_Transfection subj_HER-2 siRNA subj_conducted subj_lipofectamine subj_2000 obj_conducted obj_lipofectamine obj_2000 obj_ovarian carcinoma obj_cell obj_SKOV3
17331422	Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3.	IGE-	subj_Transfection subj_HER-2 siRNA subj_conducted subj_lipofectamine subj_2000 obj_conducted obj_lipofectamine obj_2000 obj_ovarian carcinoma obj_cell obj_SKOV3
17331422	Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3.	CCS-unidentifiable	subj_Transfection subj_HER-2 siRNA subj_conducted subj_lipofectamine subj_2000 obj_conducted obj_lipofectamine obj_2000 obj_ovarian carcinoma obj_cell obj_SKOV3
17331422	Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3.	PT-	subj_Transfection subj_HER-2 siRNA subj_conducted subj_lipofectamine subj_2000 obj_conducted obj_lipofectamine obj_2000 obj_ovarian carcinoma obj_cell obj_SKOV3
17342334	It was found that there were both significant overexpression of Wnt5A and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and breast tumor cells.	CGE-increased	subj_It subj_overexpression subj_Wnt5A subj_underexpression subj_Wnt10B subj_metastasis obj_finite obj_life obj_span obj_breast cancer obj_cells obj_compared obj_finite
17342334	It was found that there were both significant overexpression of Wnt5A and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and breast tumor cells.	IGE-unchanged	subj_It subj_overexpression subj_Wnt5A subj_underexpression subj_Wnt10B subj_metastasis obj_finite obj_life obj_span obj_breast cancer obj_cells obj_compared obj_finite
17342334	It was found that there were both significant overexpression of Wnt5A and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and breast tumor cells.	CCS-normalTOcancer	subj_It subj_overexpression subj_Wnt5A subj_underexpression subj_Wnt10B subj_metastasis obj_finite obj_life obj_span obj_breast cancer obj_cells obj_compared obj_finite
17342334	It was found that there were both significant overexpression of Wnt5A and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and breast tumor cells.	PT-observation	subj_It subj_overexpression subj_Wnt5A subj_underexpression subj_Wnt10B subj_metastasis obj_finite obj_life obj_span obj_breast cancer obj_cells obj_compared obj_finite
17352242	The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.	CGE-decreased	subj_MMP-9 subj_levels subj_decreased subj_time obj_anti obj_IL-6 obj_antibodies obj_SKOV-3 obj_cell obj_cultures obj_decreased
17352242	The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.	IGE-	subj_MMP-9 subj_levels subj_decreased subj_time obj_anti obj_IL-6 obj_antibodies obj_SKOV-3 obj_cell obj_cultures obj_decreased
17352242	The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.	CCS-unidentifiable	subj_MMP-9 subj_levels subj_decreased subj_time obj_anti obj_IL-6 obj_antibodies obj_SKOV-3 obj_cell obj_cultures obj_decreased
17352242	The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.	PT-	subj_MMP-9 subj_levels subj_decreased subj_time obj_anti obj_IL-6 obj_antibodies obj_SKOV-3 obj_cell obj_cultures obj_decreased
17363494	Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis.	CGE-increased	subj_Overexpression subj_CK2alpha subj_protected subj_prostatic subj_cancer obj_Overexpression obj_CK2alpha obj_protected obj_prostatic cancer obj_cells obj_resveratrol- obj_EGCG
17363494	Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis.	IGE-unidentifiable	subj_Overexpression subj_CK2alpha subj_protected subj_prostatic subj_cancer obj_Overexpression obj_CK2alpha obj_protected obj_prostatic cancer obj_cells obj_resveratrol- obj_EGCG
17363494	Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis.	CCS-normalTOcancer	subj_Overexpression subj_CK2alpha subj_protected subj_prostatic subj_cancer obj_Overexpression obj_CK2alpha obj_protected obj_prostatic cancer obj_cells obj_resveratrol- obj_EGCG
17363494	Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis.	PT-causality	subj_Overexpression subj_CK2alpha subj_protected subj_prostatic subj_cancer obj_Overexpression obj_CK2alpha obj_protected obj_prostatic cancer obj_cells obj_resveratrol- obj_EGCG
17409410	Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.	CGE-increased	subj_Six1 subj_overexpressed subj_50 subj_% obj_III obj_IV obj_) obj_ovarian carcinomas obj_examined obj_late obj_stage
17409410	Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.	IGE-unchanged	subj_Six1 subj_overexpressed subj_50 subj_% obj_III obj_IV obj_) obj_ovarian carcinomas obj_examined obj_late obj_stage
17409410	Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.	CCS-normalTOcancer	subj_Six1 subj_overexpressed subj_50 subj_% obj_III obj_IV obj_) obj_ovarian carcinomas obj_examined obj_late obj_stage
17409410	Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.	PT-observation	subj_Six1 subj_overexpressed subj_50 subj_% obj_III obj_IV obj_) obj_ovarian carcinomas obj_examined obj_late obj_stage
17409433	Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of prostate cancer cells independently of COX inhibition.	CGE-decreased	subj_cancer subj_cells subj_independently subj_COX subj_inhibition obj_p75(NTR)-dependent obj_decreased obj_survival obj_prostate cancer obj_cells obj_independently obj_COX
17409433	Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of prostate cancer cells independently of COX inhibition.	IGE-	subj_cancer subj_cells subj_independently subj_COX subj_inhibition obj_p75(NTR)-dependent obj_decreased obj_survival obj_prostate cancer obj_cells obj_independently obj_COX
17409433	Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of prostate cancer cells independently of COX inhibition.	CCS-unidentifiable	subj_cancer subj_cells subj_independently subj_COX subj_inhibition obj_p75(NTR)-dependent obj_decreased obj_survival obj_prostate cancer obj_cells obj_independently obj_COX
17409433	Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of prostate cancer cells independently of COX inhibition.	PT-	subj_cancer subj_cells subj_independently subj_COX subj_inhibition obj_p75(NTR)-dependent obj_decreased obj_survival obj_prostate cancer obj_cells obj_independently obj_COX
17415999	On the contrary, transfection with GID5-6 to downregulate GSK-3beta activity decreased the BrdU incorporation in SKOV3 cells, compared with that in GID5-6LP, which is a control vector of GID5-6.	CGE-increased	subj_On subj_contrary subj_transfection subj_GID5-6 subj_downregulate subj_GSK-3beta subj_activity obj_decreased obj_BrdU obj_incorporation obj_SKOV3 obj_cells obj_compared obj_GID5
17415999	On the contrary, transfection with GID5-6 to downregulate GSK-3beta activity decreased the BrdU incorporation in SKOV3 cells, compared with that in GID5-6LP, which is a control vector of GID5-6.	IGE-	subj_On subj_contrary subj_transfection subj_GID5-6 subj_downregulate subj_GSK-3beta subj_activity obj_decreased obj_BrdU obj_incorporation obj_SKOV3 obj_cells obj_compared obj_GID5
17415999	On the contrary, transfection with GID5-6 to downregulate GSK-3beta activity decreased the BrdU incorporation in SKOV3 cells, compared with that in GID5-6LP, which is a control vector of GID5-6.	CCS-unidentifiable	subj_On subj_contrary subj_transfection subj_GID5-6 subj_downregulate subj_GSK-3beta subj_activity obj_decreased obj_BrdU obj_incorporation obj_SKOV3 obj_cells obj_compared obj_GID5
17415999	On the contrary, transfection with GID5-6 to downregulate GSK-3beta activity decreased the BrdU incorporation in SKOV3 cells, compared with that in GID5-6LP, which is a control vector of GID5-6.	PT-	subj_On subj_contrary subj_transfection subj_GID5-6 subj_downregulate subj_GSK-3beta subj_activity obj_decreased obj_BrdU obj_incorporation obj_SKOV3 obj_cells obj_compared obj_GID5
17426117	Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.	CGE-decreased	subj_Reduction subj_AR subj_expression subj_androgen subj_sensitive obj_expression obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_LNCaP
17426117	Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.	IGE-unidentifiable	subj_Reduction subj_AR subj_expression subj_androgen subj_sensitive obj_expression obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_LNCaP
17426117	Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.	CCS-cancerTOnormal	subj_Reduction subj_AR subj_expression subj_androgen subj_sensitive obj_expression obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_LNCaP
17426117	Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.	PT-causality	subj_Reduction subj_AR subj_expression subj_androgen subj_sensitive obj_expression obj_androgen obj_sensitive obj_prostate cancer obj_cell obj_lines obj_LNCaP
17470361	These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.	CGE-increased	subj_cells subj_HIF-1 subj_expression subj_VEGF subj_transcriptional subj_activation obj_anti obj_tumor obj_activity obj_ovarian cancer obj_cells obj_HIF-1 obj_expression
17470361	These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.	IGE-unidentifiable	subj_cells subj_HIF-1 subj_expression subj_VEGF subj_transcriptional subj_activation obj_anti obj_tumor obj_activity obj_ovarian cancer obj_cells obj_HIF-1 obj_expression
17470361	These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.	CCS-cancerTOnormal	subj_cells subj_HIF-1 subj_expression subj_VEGF subj_transcriptional subj_activation obj_anti obj_tumor obj_activity obj_ovarian cancer obj_cells obj_HIF-1 obj_expression
17470361	These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.	PT-causality	subj_cells subj_HIF-1 subj_expression subj_VEGF subj_transcriptional subj_activation obj_anti obj_tumor obj_activity obj_ovarian cancer obj_cells obj_HIF-1 obj_expression
17481580	Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.	CGE-increased	subj_discovered subj_proto subj_isoform subj_gal8g subj_upregulated subj_LNCaP subj_cells obj_isoform obj_gal8 obj_upregulated obj_LNCaP obj_cells obj_compared obj_PrEC
17481580	Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.	IGE-unchanged	subj_discovered subj_proto subj_isoform subj_gal8g subj_upregulated subj_LNCaP subj_cells obj_isoform obj_gal8 obj_upregulated obj_LNCaP obj_cells obj_compared obj_PrEC
17481580	Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.	CCS-normalTOcancer	subj_discovered subj_proto subj_isoform subj_gal8g subj_upregulated subj_LNCaP subj_cells obj_isoform obj_gal8 obj_upregulated obj_LNCaP obj_cells obj_compared obj_PrEC
17481580	Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.	PT-observation	subj_discovered subj_proto subj_isoform subj_gal8g subj_upregulated subj_LNCaP subj_cells obj_isoform obj_gal8 obj_upregulated obj_LNCaP obj_cells obj_compared obj_PrEC
17513602	Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.	CGE-increased	subj_expression subj_cyclin B1 subj_sensitizes subj_prostate subj_cancer obj_cyclin obj_B1 obj_sensitizes obj_prostate cancer obj_cells obj_apoptosis obj_induced
17513602	Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.	IGE-unidentifiable	subj_expression subj_cyclin B1 subj_sensitizes subj_prostate subj_cancer obj_cyclin obj_B1 obj_sensitizes obj_prostate cancer obj_cells obj_apoptosis obj_induced
17513602	Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.	CCS-cancerTOnormal	subj_expression subj_cyclin B1 subj_sensitizes subj_prostate subj_cancer obj_cyclin obj_B1 obj_sensitizes obj_prostate cancer obj_cells obj_apoptosis obj_induced
17513602	Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.	PT-causality	subj_expression subj_cyclin B1 subj_sensitizes subj_prostate subj_cancer obj_cyclin obj_B1 obj_sensitizes obj_prostate cancer obj_cells obj_apoptosis obj_induced
17595766	HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness.	CGE-increased	subj_induces subj_Dgk subj_activation subj_MDA subj_MB-231 obj_induces obj_Dgk obj_activation obj_MDA-MB-231 obj_cells obj_required obj_cell
17595766	HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness.	IGE-unidentifiable	subj_induces subj_Dgk subj_activation subj_MDA subj_MB-231 obj_induces obj_Dgk obj_activation obj_MDA-MB-231 obj_cells obj_required obj_cell
17595766	HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness.	CCS-normalTOcancer	subj_induces subj_Dgk subj_activation subj_MDA subj_MB-231 obj_induces obj_Dgk obj_activation obj_MDA-MB-231 obj_cells obj_required obj_cell
17595766	HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness.	PT-causality	subj_induces subj_Dgk subj_activation subj_MDA subj_MB-231 obj_induces obj_Dgk obj_activation obj_MDA-MB-231 obj_cells obj_required obj_cell
17608728	Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.	CGE-increased	subj_inhibitor subj_PD153035 subj_induces subj_RAR-beta2 subj_isoforms subj_( subj_RAR obj_MDA obj_MB-453 obj_human obj_breast cancer obj_cells
17608728	Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.	IGE-	subj_inhibitor subj_PD153035 subj_induces subj_RAR-beta2 subj_isoforms subj_( subj_RAR obj_MDA obj_MB-453 obj_human obj_breast cancer obj_cells
17608728	Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.	CCS-unidentifiable	subj_inhibitor subj_PD153035 subj_induces subj_RAR-beta2 subj_isoforms subj_( subj_RAR obj_MDA obj_MB-453 obj_human obj_breast cancer obj_cells
17608728	Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.	PT-	subj_inhibitor subj_PD153035 subj_induces subj_RAR-beta2 subj_isoforms subj_( subj_RAR obj_MDA obj_MB-453 obj_human obj_breast cancer obj_cells
17616457	Long-term culture of MCF-7 cells in estrogen deprived medium (LTED) mimics aromatase inhibition in patients.	CGE-decreased	subj_LTED subj_) subj_mimics subj_aromatase subj_inhibition subj_patients obj_Long obj_term obj_culture obj_MCF-7 obj_cells obj_estrogen obj_deprived
17616457	Long-term culture of MCF-7 cells in estrogen deprived medium (LTED) mimics aromatase inhibition in patients.	IGE-unidentifiable	subj_LTED subj_) subj_mimics subj_aromatase subj_inhibition subj_patients obj_Long obj_term obj_culture obj_MCF-7 obj_cells obj_estrogen obj_deprived
17616457	Long-term culture of MCF-7 cells in estrogen deprived medium (LTED) mimics aromatase inhibition in patients.	CCS-normalTOcancer	subj_LTED subj_) subj_mimics subj_aromatase subj_inhibition subj_patients obj_Long obj_term obj_culture obj_MCF-7 obj_cells obj_estrogen obj_deprived
17616457	Long-term culture of MCF-7 cells in estrogen deprived medium (LTED) mimics aromatase inhibition in patients.	PT-observation	subj_LTED subj_) subj_mimics subj_aromatase subj_inhibition subj_patients obj_Long obj_term obj_culture obj_MCF-7 obj_cells obj_estrogen obj_deprived
17673518	Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.	CGE-increased	subj_growth subj_factor subj_( subj_HGF subj_) subj_overexpressed subj_contribute obj_overexpressed obj_contribute obj_growth obj_ovarian cancer obj_activating obj_autocrine obj_pathways
17673518	Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.	IGE-unchanged	subj_growth subj_factor subj_( subj_HGF subj_) subj_overexpressed subj_contribute obj_overexpressed obj_contribute obj_growth obj_ovarian cancer obj_activating obj_autocrine obj_pathways
17673518	Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.	CCS-normalTOcancer	subj_growth subj_factor subj_( subj_HGF subj_) subj_overexpressed subj_contribute obj_overexpressed obj_contribute obj_growth obj_ovarian cancer obj_activating obj_autocrine obj_pathways
17673518	Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.	PT-causality	subj_growth subj_factor subj_( subj_HGF subj_) subj_overexpressed subj_contribute obj_overexpressed obj_contribute obj_growth obj_ovarian cancer obj_activating obj_autocrine obj_pathways
17690890	Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.	CGE-increased	subj_Expression subj_overexpression subj_epidermal growth factor receptor subj_( subj_EGFR subj_) obj_colorectal obj_NSCLC obj_prostate obj_ovarian cancers
17690890	Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.	IGE-unchanged	subj_Expression subj_overexpression subj_epidermal growth factor receptor subj_( subj_EGFR subj_) obj_colorectal obj_NSCLC obj_prostate obj_ovarian cancers
17690890	Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.	CCS-normalTOcancer	subj_Expression subj_overexpression subj_epidermal growth factor receptor subj_( subj_EGFR subj_) obj_colorectal obj_NSCLC obj_prostate obj_ovarian cancers
17690890	Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.	PT-observation	subj_Expression subj_overexpression subj_epidermal growth factor receptor subj_( subj_EGFR subj_) obj_colorectal obj_NSCLC obj_prostate obj_ovarian cancers
17712489	hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.	CGE-decreased	subj_telomerase subj_activity subj_downregulating subj_hTERT mRNA subj_protein subj_expression subj_inhibition obj_alpha obj_induced obj_apoptosis obj_PC3 obj_cells
17712489	hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.	IGE-unidentifiable	subj_telomerase subj_activity subj_downregulating subj_hTERT mRNA subj_protein subj_expression subj_inhibition obj_alpha obj_induced obj_apoptosis obj_PC3 obj_cells
17712489	hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.	CCS-cancerTOnormal	subj_telomerase subj_activity subj_downregulating subj_hTERT mRNA subj_protein subj_expression subj_inhibition obj_alpha obj_induced obj_apoptosis obj_PC3 obj_cells
17712489	hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.	PT-causality	subj_telomerase subj_activity subj_downregulating subj_hTERT mRNA subj_protein subj_expression subj_inhibition obj_alpha obj_induced obj_apoptosis obj_PC3 obj_cells
17726528	Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.	CGE-decreased	subj_ABCB6 subj_expression subj_repressed subj_ABCB7 subj_expression obj_CEM obj_leukemia obj_MCF7 obj_breast cancer obj_cells obj_induced obj_ABCB6
17726528	Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.	IGE-	subj_ABCB6 subj_expression subj_repressed subj_ABCB7 subj_expression obj_CEM obj_leukemia obj_MCF7 obj_breast cancer obj_cells obj_induced obj_ABCB6
17726528	Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.	CCS-unidentifiable	subj_ABCB6 subj_expression subj_repressed subj_ABCB7 subj_expression obj_CEM obj_leukemia obj_MCF7 obj_breast cancer obj_cells obj_induced obj_ABCB6
17726528	Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.	PT-	subj_ABCB6 subj_expression subj_repressed subj_ABCB7 subj_expression obj_CEM obj_leukemia obj_MCF7 obj_breast cancer obj_cells obj_induced obj_ABCB6
17872978	In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.	CGE-increased	subj_findings subj_implicate subj_elevated subj_GC UNC-45 protein subj_expression subj_ovarian subj_carcinoma obj_UNC-45 obj_protein obj_expression obj_ovarian carcinoma obj_proliferation obj_metastasis
17872978	In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.	IGE-unidentifiable	subj_findings subj_implicate subj_elevated subj_GC UNC-45 protein subj_expression subj_ovarian subj_carcinoma obj_UNC-45 obj_protein obj_expression obj_ovarian carcinoma obj_proliferation obj_metastasis
17872978	In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.	CCS-normalTOcancer	subj_findings subj_implicate subj_elevated subj_GC UNC-45 protein subj_expression subj_ovarian subj_carcinoma obj_UNC-45 obj_protein obj_expression obj_ovarian carcinoma obj_proliferation obj_metastasis
17872978	In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.	PT-observation	subj_findings subj_implicate subj_elevated subj_GC UNC-45 protein subj_expression subj_ovarian subj_carcinoma obj_UNC-45 obj_protein obj_expression obj_ovarian carcinoma obj_proliferation obj_metastasis
17875724	We present here for the first time that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, including prostate cancer, interacts with PKCepsilon.	CGE-increased	subj_We subj_time subj_signal transducers and activators of transcription 3 subj_( subj_Stat3 subj_) obj_human obj_cancers obj_including obj_prostate cancer obj_interacts obj_PKCepsilon
17875724	We present here for the first time that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, including prostate cancer, interacts with PKCepsilon.	IGE-unchanged	subj_We subj_time subj_signal transducers and activators of transcription 3 subj_( subj_Stat3 subj_) obj_human obj_cancers obj_including obj_prostate cancer obj_interacts obj_PKCepsilon
17875724	We present here for the first time that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, including prostate cancer, interacts with PKCepsilon.	CCS-normalTOcancer	subj_We subj_time subj_signal transducers and activators of transcription 3 subj_( subj_Stat3 subj_) obj_human obj_cancers obj_including obj_prostate cancer obj_interacts obj_PKCepsilon
17875724	We present here for the first time that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, including prostate cancer, interacts with PKCepsilon.	PT-observation	subj_We subj_time subj_signal transducers and activators of transcription 3 subj_( subj_Stat3 subj_) obj_human obj_cancers obj_including obj_prostate cancer obj_interacts obj_PKCepsilon
17908958	Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.	CGE-increased	subj_Smad3 subj_overexpressed subj_advanced subj_human obj_cancer obj_progressive obj_growth obj_prostate cancer obj_cells obj_nude obj_mice
17908958	Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.	IGE-unchanged	subj_Smad3 subj_overexpressed subj_advanced subj_human obj_cancer obj_progressive obj_growth obj_prostate cancer obj_cells obj_nude obj_mice
17908958	Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.	CCS-normalTOcancer	subj_Smad3 subj_overexpressed subj_advanced subj_human obj_cancer obj_progressive obj_growth obj_prostate cancer obj_cells obj_nude obj_mice
17908958	Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.	PT-causality	subj_Smad3 subj_overexpressed subj_advanced subj_human obj_cancer obj_progressive obj_growth obj_prostate cancer obj_cells obj_nude obj_mice
17986353	These compounds decreased ERalpha in MCF-7 cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.	CGE-decreased	subj_compounds subj_decreased subj_ERalpha subj_MCF-7 subj_cells subj_mRNA obj_compounds obj_decreased obj_ERalpha obj_MCF-7 obj_cells obj_mRNA obj_protein
17986353	These compounds decreased ERalpha in MCF-7 cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.	IGE-	subj_compounds subj_decreased subj_ERalpha subj_MCF-7 subj_cells subj_mRNA obj_compounds obj_decreased obj_ERalpha obj_MCF-7 obj_cells obj_mRNA obj_protein
17986353	These compounds decreased ERalpha in MCF-7 cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.	CCS-unidentifiable	subj_compounds subj_decreased subj_ERalpha subj_MCF-7 subj_cells subj_mRNA obj_compounds obj_decreased obj_ERalpha obj_MCF-7 obj_cells obj_mRNA obj_protein
17986353	These compounds decreased ERalpha in MCF-7 cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.	PT-	subj_compounds subj_decreased subj_ERalpha subj_MCF-7 subj_cells subj_mRNA obj_compounds obj_decreased obj_ERalpha obj_MCF-7 obj_cells obj_mRNA obj_protein
18008330	Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.	CGE-increased	subj_Overexpression subj_IL-4 subj_increases subj_sensitivity subj_androgen obj_androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_response obj_androgen
18008330	Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.	IGE-unidentifiable	subj_Overexpression subj_IL-4 subj_increases subj_sensitivity subj_androgen obj_androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_response obj_androgen
18008330	Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.	CCS-normalTOcancer	subj_Overexpression subj_IL-4 subj_increases subj_sensitivity subj_androgen obj_androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_response obj_androgen
18008330	Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.	PT-causality	subj_Overexpression subj_IL-4 subj_increases subj_sensitivity subj_androgen obj_androgen obj_sensitive obj_LNCaP obj_prostate cancer obj_cells obj_response obj_androgen
18060053	Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.	CGE-increased	subj_ablation subj_pRb subj_activates subj_Cdk2 subj_antiestrogen subj_resistance subj_human obj_antiestrogen obj_resistance obj_human obj_breast cancer obj_cells obj_
18060053	Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.	IGE-	subj_ablation subj_pRb subj_activates subj_Cdk2 subj_antiestrogen subj_resistance subj_human obj_antiestrogen obj_resistance obj_human obj_breast cancer obj_cells obj_
18060053	Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.	CCS-unidentifiable	subj_ablation subj_pRb subj_activates subj_Cdk2 subj_antiestrogen subj_resistance subj_human obj_antiestrogen obj_resistance obj_human obj_breast cancer obj_cells obj_
18060053	Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.	PT-	subj_ablation subj_pRb subj_activates subj_Cdk2 subj_antiestrogen subj_resistance subj_human obj_antiestrogen obj_resistance obj_human obj_breast cancer obj_cells obj_
18066063	Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.	CGE-decreased	subj_tumors subj_mice subj_loss subj_PTEN subj_expression subj_BBC subj_subtype obj_human obj_sporadic obj_BRCA1-associated obj_hereditary breast cancers
18066063	Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.	IGE-unchanged	subj_tumors subj_mice subj_loss subj_PTEN subj_expression subj_BBC subj_subtype obj_human obj_sporadic obj_BRCA1-associated obj_hereditary breast cancers
18066063	Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.	CCS-normalTOcancer	subj_tumors subj_mice subj_loss subj_PTEN subj_expression subj_BBC subj_subtype obj_human obj_sporadic obj_BRCA1-associated obj_hereditary breast cancers
18066063	Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.	PT-observation	subj_tumors subj_mice subj_loss subj_PTEN subj_expression subj_BBC subj_subtype obj_human obj_sporadic obj_BRCA1-associated obj_hereditary breast cancers
18070364	Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.	CGE-increased	subj_Coordinate subj_regulation subj_TMEM97 subj_cholesterol biosynthesis genes subj_normal subj_ovarian subj_surface obj_: obj_implications obj_pathogenesis obj_ovarian cancer obj_
18070364	Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.	IGE-unchanged	subj_Coordinate subj_regulation subj_TMEM97 subj_cholesterol biosynthesis genes subj_normal subj_ovarian subj_surface obj_: obj_implications obj_pathogenesis obj_ovarian cancer obj_
18070364	Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.	CCS-normalTOcancer	subj_Coordinate subj_regulation subj_TMEM97 subj_cholesterol biosynthesis genes subj_normal subj_ovarian subj_surface obj_: obj_implications obj_pathogenesis obj_ovarian cancer obj_
18070364	Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.	PT-observation	subj_Coordinate subj_regulation subj_TMEM97 subj_cholesterol biosynthesis genes subj_normal subj_ovarian subj_surface obj_: obj_implications obj_pathogenesis obj_ovarian cancer obj_
18076023	The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.	CGE-decreased	subj_A5 subj_fibronectin subj_1 subj_neuropilin 1 subj_LNCaP-19 subj_compared subj_LNCaP obj_1 obj_LNCaP-19 obj_compared obj_LNCaP obj_expression obj_midkine obj_VEGF
18076023	The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.	IGE-unidentifiable	subj_A5 subj_fibronectin subj_1 subj_neuropilin 1 subj_LNCaP-19 subj_compared subj_LNCaP obj_1 obj_LNCaP-19 obj_compared obj_LNCaP obj_expression obj_midkine obj_VEGF
18076023	The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.	CCS-cancerTOnormal	subj_A5 subj_fibronectin subj_1 subj_neuropilin 1 subj_LNCaP-19 subj_compared subj_LNCaP obj_1 obj_LNCaP-19 obj_compared obj_LNCaP obj_expression obj_midkine obj_VEGF
18076023	The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.	PT-observation	subj_A5 subj_fibronectin subj_1 subj_neuropilin 1 subj_LNCaP-19 subj_compared subj_LNCaP obj_1 obj_LNCaP-19 obj_compared obj_LNCaP obj_expression obj_midkine obj_VEGF
18167127	Consistently, PI3-kinase inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type PC-3 cells.	CGE-decreased	subj_Consistently subj_PI3-kinase subj_inhibition subj_dominant subj_negative obj_invasion obj_wild obj_type obj_PC-3 obj_cells
18167127	Consistently, PI3-kinase inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type PC-3 cells.	IGE-unidentifiable	subj_Consistently subj_PI3-kinase subj_inhibition subj_dominant subj_negative obj_invasion obj_wild obj_type obj_PC-3 obj_cells
18167127	Consistently, PI3-kinase inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type PC-3 cells.	CCS-cancerTOnormal	subj_Consistently subj_PI3-kinase subj_inhibition subj_dominant subj_negative obj_invasion obj_wild obj_type obj_PC-3 obj_cells
18167127	Consistently, PI3-kinase inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type PC-3 cells.	PT-causality	subj_Consistently subj_PI3-kinase subj_inhibition subj_dominant subj_negative obj_invasion obj_wild obj_type obj_PC-3 obj_cells
18181175	Here, we show that overexpression of BIRC5 induces a high proliferation level in MCF-7 breast tumor cells.	CGE-increased	subj_Here subj_overexpression subj_BIRC5 subj_induces subj_proliferation subj_level obj_proliferation obj_level obj_MCF-7 obj_breast tumor obj_cells
18181175	Here, we show that overexpression of BIRC5 induces a high proliferation level in MCF-7 breast tumor cells.	IGE-unidentifiable	subj_Here subj_overexpression subj_BIRC5 subj_induces subj_proliferation subj_level obj_proliferation obj_level obj_MCF-7 obj_breast tumor obj_cells
18181175	Here, we show that overexpression of BIRC5 induces a high proliferation level in MCF-7 breast tumor cells.	CCS-normalTOcancer	subj_Here subj_overexpression subj_BIRC5 subj_induces subj_proliferation subj_level obj_proliferation obj_level obj_MCF-7 obj_breast tumor obj_cells
18181175	Here, we show that overexpression of BIRC5 induces a high proliferation level in MCF-7 breast tumor cells.	PT-causality	subj_Here subj_overexpression subj_BIRC5 subj_induces subj_proliferation subj_level obj_proliferation obj_level obj_MCF-7 obj_breast tumor obj_cells
18208621	Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1.	CGE-decreased	subj_mutations subj_epigenetic subj_loss subj_BRCA1 obj_37 obj_% obj_) obj_ovarian carcinomas obj_germline obj_somatic obj_BRCA1
18208621	Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1.	IGE-unchanged	subj_mutations subj_epigenetic subj_loss subj_BRCA1 obj_37 obj_% obj_) obj_ovarian carcinomas obj_germline obj_somatic obj_BRCA1
18208621	Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1.	CCS-normalTOcancer	subj_mutations subj_epigenetic subj_loss subj_BRCA1 obj_37 obj_% obj_) obj_ovarian carcinomas obj_germline obj_somatic obj_BRCA1
18208621	Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1.	PT-observation	subj_mutations subj_epigenetic subj_loss subj_BRCA1 obj_37 obj_% obj_) obj_ovarian carcinomas obj_germline obj_somatic obj_BRCA1
18270579	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.	CGE-increased	subj_response subj_Tamoxifen subj_Induction subj_ErbB-3 subj_expression subj_alpha6beta4 subj_integrin obj_tamoxifen obj_resistance obj_ERbeta1-negative obj_breast carcinomas obj_
18270579	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.	IGE-	subj_response subj_Tamoxifen subj_Induction subj_ErbB-3 subj_expression subj_alpha6beta4 subj_integrin obj_tamoxifen obj_resistance obj_ERbeta1-negative obj_breast carcinomas obj_
18270579	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.	CCS-unidentifiable	subj_response subj_Tamoxifen subj_Induction subj_ErbB-3 subj_expression subj_alpha6beta4 subj_integrin obj_tamoxifen obj_resistance obj_ERbeta1-negative obj_breast carcinomas obj_
18270579	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.	PT-	subj_response subj_Tamoxifen subj_Induction subj_ErbB-3 subj_expression subj_alpha6beta4 subj_integrin obj_tamoxifen obj_resistance obj_ERbeta1-negative obj_breast carcinomas obj_
18281549	Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.	CGE-decreased	subj_proteins subj_Bcl subj_XL subj_survivin subj_ obj_drug obj_efficacy obj_human obj_prostate cancer obj_regulates obj_antiapoptotic obj_proteins
18281549	Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.	IGE-	subj_proteins subj_Bcl subj_XL subj_survivin subj_ obj_drug obj_efficacy obj_human obj_prostate cancer obj_regulates obj_antiapoptotic obj_proteins
18281549	Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.	CCS-unidentifiable	subj_proteins subj_Bcl subj_XL subj_survivin subj_ obj_drug obj_efficacy obj_human obj_prostate cancer obj_regulates obj_antiapoptotic obj_proteins
18281549	Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.	PT-	subj_proteins subj_Bcl subj_XL subj_survivin subj_ obj_drug obj_efficacy obj_human obj_prostate cancer obj_regulates obj_antiapoptotic obj_proteins
18294401	The overexpression of HER II is also positively correlated with other markers of prognosis of breast cancer such as cathepsin expression.	CGE-increased	subj_overexpression subj_HER II subj_positively subj_correlated subj_markers obj_correlated obj_markers obj_prognosis obj_breast cancer obj_cathepsin obj_expression obj_
18294401	The overexpression of HER II is also positively correlated with other markers of prognosis of breast cancer such as cathepsin expression.	IGE-unchanged	subj_overexpression subj_HER II subj_positively subj_correlated subj_markers obj_correlated obj_markers obj_prognosis obj_breast cancer obj_cathepsin obj_expression obj_
18294401	The overexpression of HER II is also positively correlated with other markers of prognosis of breast cancer such as cathepsin expression.	CCS-normalTOcancer	subj_overexpression subj_HER II subj_positively subj_correlated subj_markers obj_correlated obj_markers obj_prognosis obj_breast cancer obj_cathepsin obj_expression obj_
18294401	The overexpression of HER II is also positively correlated with other markers of prognosis of breast cancer such as cathepsin expression.	PT-observation	subj_overexpression subj_HER II subj_positively subj_correlated subj_markers obj_correlated obj_markers obj_prognosis obj_breast cancer obj_cathepsin obj_expression obj_
18332867	Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.	CGE-decreased	subj_) subj_treatment subj_decreased subj_AR subj_prostate subj_specific subj_antigen obj_human obj_prostate obj_epithelial obj_PWR-1E obj_cells
18332867	Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.	IGE-	subj_) subj_treatment subj_decreased subj_AR subj_prostate subj_specific subj_antigen obj_human obj_prostate obj_epithelial obj_PWR-1E obj_cells
18332867	Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.	CCS-unidentifiable	subj_) subj_treatment subj_decreased subj_AR subj_prostate subj_specific subj_antigen obj_human obj_prostate obj_epithelial obj_PWR-1E obj_cells
18332867	Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.	PT-	subj_) subj_treatment subj_decreased subj_AR subj_prostate subj_specific subj_antigen obj_human obj_prostate obj_epithelial obj_PWR-1E obj_cells
18336887	The decrease in survivin gene expression by transfection of siRNA was accompanied by the inhibition of cell proliferation of PCa cells (31% and 25% decreased in LNCaP and PC-3 cells, P <0.01).	CGE-decreased	subj_decrease subj_survivin gene subj_expression subj_transfection subj_siRNA obj_25 obj_% obj_decreased obj_LNCaP obj_PC-3 obj_cells obj_P
18336887	The decrease in survivin gene expression by transfection of siRNA was accompanied by the inhibition of cell proliferation of PCa cells (31% and 25% decreased in LNCaP and PC-3 cells, P <0.01).	IGE-unidentifiable	subj_decrease subj_survivin gene subj_expression subj_transfection subj_siRNA obj_25 obj_% obj_decreased obj_LNCaP obj_PC-3 obj_cells obj_P
18336887	The decrease in survivin gene expression by transfection of siRNA was accompanied by the inhibition of cell proliferation of PCa cells (31% and 25% decreased in LNCaP and PC-3 cells, P <0.01).	CCS-cancerTOnormal	subj_decrease subj_survivin gene subj_expression subj_transfection subj_siRNA obj_25 obj_% obj_decreased obj_LNCaP obj_PC-3 obj_cells obj_P
18336887	The decrease in survivin gene expression by transfection of siRNA was accompanied by the inhibition of cell proliferation of PCa cells (31% and 25% decreased in LNCaP and PC-3 cells, P <0.01).	PT-observation	subj_decrease subj_survivin gene subj_expression subj_transfection subj_siRNA obj_25 obj_% obj_decreased obj_LNCaP obj_PC-3 obj_cells obj_P
18349265	Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.	CGE-increased	subj_PTH subj_IR subj_) subj_PTH subj_promotes subj_growth subj_invasiveness obj_promotes obj_growth obj_invasiveness obj_prostate cancer obj_cells obj_bone
18349265	Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.	IGE-unidentifiable	subj_PTH subj_IR subj_) subj_PTH subj_promotes subj_growth subj_invasiveness obj_promotes obj_growth obj_invasiveness obj_prostate cancer obj_cells obj_bone
18349265	Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.	CCS-normalTOcancer	subj_PTH subj_IR subj_) subj_PTH subj_promotes subj_growth subj_invasiveness obj_promotes obj_growth obj_invasiveness obj_prostate cancer obj_cells obj_bone
18349265	Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.	PT-causality	subj_PTH subj_IR subj_) subj_PTH subj_promotes subj_growth subj_invasiveness obj_promotes obj_growth obj_invasiveness obj_prostate cancer obj_cells obj_bone
18349819	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	CGE-decreased	subj_siRNA subj_mediated subj_knockdown subj_EDD subj_expression obj_platinum obj_resistant obj_A2780-cp70 obj_ovarian cancer obj_cells obj_siRNA obj_mediated
18349819	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	IGE-	subj_siRNA subj_mediated subj_knockdown subj_EDD subj_expression obj_platinum obj_resistant obj_A2780-cp70 obj_ovarian cancer obj_cells obj_siRNA obj_mediated
18349819	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	CCS-unidentifiable	subj_siRNA subj_mediated subj_knockdown subj_EDD subj_expression obj_platinum obj_resistant obj_A2780-cp70 obj_ovarian cancer obj_cells obj_siRNA obj_mediated
18349819	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	PT-	subj_siRNA subj_mediated subj_knockdown subj_EDD subj_expression obj_platinum obj_resistant obj_A2780-cp70 obj_ovarian cancer obj_cells obj_siRNA obj_mediated
18358509	We observed that re-expression of AR in the AR-negative cells PC3 decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and EGFR led to an interference with downstream signalling and internalization of activated EGFR.	CGE-increased	subj_signalling subj_internalization subj_activated subj_EGFR obj_AR obj_negative obj_cells obj_PC3 obj_decreases obj_anchorage obj_independent
18358509	We observed that re-expression of AR in the AR-negative cells PC3 decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and EGFR led to an interference with downstream signalling and internalization of activated EGFR.	IGE-	subj_signalling subj_internalization subj_activated subj_EGFR obj_AR obj_negative obj_cells obj_PC3 obj_decreases obj_anchorage obj_independent
18358509	We observed that re-expression of AR in the AR-negative cells PC3 decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and EGFR led to an interference with downstream signalling and internalization of activated EGFR.	CCS-unidentifiable	subj_signalling subj_internalization subj_activated subj_EGFR obj_AR obj_negative obj_cells obj_PC3 obj_decreases obj_anchorage obj_independent
18358509	We observed that re-expression of AR in the AR-negative cells PC3 decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and EGFR led to an interference with downstream signalling and internalization of activated EGFR.	PT-	subj_signalling subj_internalization subj_activated subj_EGFR obj_AR obj_negative obj_cells obj_PC3 obj_decreases obj_anchorage obj_independent
18373644	and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.	CGE-increased	subj_IGFBP5 subj_contributes subj_invasiveness subj_progression obj_cancers obj_roles obj_metastasis obj_breast cancer obj_investigated obj_To
18373644	and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.	IGE-	subj_IGFBP5 subj_contributes subj_invasiveness subj_progression obj_cancers obj_roles obj_metastasis obj_breast cancer obj_investigated obj_To
18373644	and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.	CCS-unidentifiable	subj_IGFBP5 subj_contributes subj_invasiveness subj_progression obj_cancers obj_roles obj_metastasis obj_breast cancer obj_investigated obj_To
18373644	and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.	PT-	subj_IGFBP5 subj_contributes subj_invasiveness subj_progression obj_cancers obj_roles obj_metastasis obj_breast cancer obj_investigated obj_To
18386461	Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.	CGE-increased	subj_ovarian subj_malignancies subj_Concentrations subj_follicle stimulating hormone subj_increased subj_ovarian subj_tumor obj_: obj_implications obj_management obj_ovarian cancer obj_
18386461	Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.	IGE-unchanged	subj_ovarian subj_malignancies subj_Concentrations subj_follicle stimulating hormone subj_increased subj_ovarian subj_tumor obj_: obj_implications obj_management obj_ovarian cancer obj_
18386461	Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.	CCS-normalTOcancer	subj_ovarian subj_malignancies subj_Concentrations subj_follicle stimulating hormone subj_increased subj_ovarian subj_tumor obj_: obj_implications obj_management obj_ovarian cancer obj_
18386461	Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.	PT-observation	subj_ovarian subj_malignancies subj_Concentrations subj_follicle stimulating hormone subj_increased subj_ovarian subj_tumor obj_: obj_implications obj_management obj_ovarian cancer obj_
18436522	Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.	CGE-increased	subj_survival subj_gene subj_transferred subj_vesicular stomatitis virus matrix protein subj_nude subj_mice subj_ obj_cisplatin obj_resistant obj_human obj_ovarian cancer obj_growth obj_prolonged obj_survival
18436522	Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.	IGE-unidentifiable	subj_survival subj_gene subj_transferred subj_vesicular stomatitis virus matrix protein subj_nude subj_mice subj_ obj_cisplatin obj_resistant obj_human obj_ovarian cancer obj_growth obj_prolonged obj_survival
18436522	Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.	CCS-cancerTOnormal	subj_survival subj_gene subj_transferred subj_vesicular stomatitis virus matrix protein subj_nude subj_mice subj_ obj_cisplatin obj_resistant obj_human obj_ovarian cancer obj_growth obj_prolonged obj_survival
18436522	Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.	PT-causality	subj_survival subj_gene subj_transferred subj_vesicular stomatitis virus matrix protein subj_nude subj_mice subj_ obj_cisplatin obj_resistant obj_human obj_ovarian cancer obj_growth obj_prolonged obj_survival
18490922	Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.	CGE-increased	subj_Overexpression subj_p45-sErbB3 subj_osteolytic subj_prostate subj_cancer obj_Overexpression obj_p45-sErbB3 obj_osteolytic obj_prostate cancer obj_cell obj_PC-3 obj_converted
18490922	Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.	IGE-	subj_Overexpression subj_p45-sErbB3 subj_osteolytic subj_prostate subj_cancer obj_Overexpression obj_p45-sErbB3 obj_osteolytic obj_prostate cancer obj_cell obj_PC-3 obj_converted
18490922	Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.	CCS-unidentifiable	subj_Overexpression subj_p45-sErbB3 subj_osteolytic subj_prostate subj_cancer obj_Overexpression obj_p45-sErbB3 obj_osteolytic obj_prostate cancer obj_cell obj_PC-3 obj_converted
18490922	Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.	PT-	subj_Overexpression subj_p45-sErbB3 subj_osteolytic subj_prostate subj_cancer obj_Overexpression obj_p45-sErbB3 obj_osteolytic obj_prostate cancer obj_cell obj_PC-3 obj_converted
18497984	A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.	CGE-increased	subj_OVCAR-3 subj_) subj_gain subj_TUBB3 subj_expression subj_induced subj_treatment obj_TUBB3 obj_protein obj_( obj_OVCAR-3 obj_) obj_gain obj_TUBB3
18497984	A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.	IGE-	subj_OVCAR-3 subj_) subj_gain subj_TUBB3 subj_expression subj_induced subj_treatment obj_TUBB3 obj_protein obj_( obj_OVCAR-3 obj_) obj_gain obj_TUBB3
18497984	A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.	CCS-unidentifiable	subj_OVCAR-3 subj_) subj_gain subj_TUBB3 subj_expression subj_induced subj_treatment obj_TUBB3 obj_protein obj_( obj_OVCAR-3 obj_) obj_gain obj_TUBB3
18497984	A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.	PT-	subj_OVCAR-3 subj_) subj_gain subj_TUBB3 subj_expression subj_induced subj_treatment obj_TUBB3 obj_protein obj_( obj_OVCAR-3 obj_) obj_gain obj_TUBB3
18519708	Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P < 0.001 for all).	CGE-decreased	subj_UGT2B17 subj_regulated subj_expression subj_SRD5A2 subj_( subj_P subj_< obj_Compared obj_primary obj_prostate tumors obj_castration obj_resistant obj_metastases
18519708	Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P < 0.001 for all).	IGE-unidentifiable	subj_UGT2B17 subj_regulated subj_expression subj_SRD5A2 subj_( subj_P subj_< obj_Compared obj_primary obj_prostate tumors obj_castration obj_resistant obj_metastases
18519708	Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P < 0.001 for all).	CCS-normalTOcancer	subj_UGT2B17 subj_regulated subj_expression subj_SRD5A2 subj_( subj_P subj_< obj_Compared obj_primary obj_prostate tumors obj_castration obj_resistant obj_metastases
18519708	Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P < 0.001 for all).	PT-observation	subj_UGT2B17 subj_regulated subj_expression subj_SRD5A2 subj_( subj_P subj_< obj_Compared obj_primary obj_prostate tumors obj_castration obj_resistant obj_metastases
18632752	Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.	CGE-decreased	subj_cancer subj_cells subj_reduced subj_ERK1/2 subj_activity subj_inhibited subj_cell obj_expression obj_MKP3 obj_MKP3-deficient obj_ovarian cancer obj_cells obj_reduced obj_ERK1/2
18632752	Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.	IGE-unidentifiable	subj_cancer subj_cells subj_reduced subj_ERK1/2 subj_activity subj_inhibited subj_cell obj_expression obj_MKP3 obj_MKP3-deficient obj_ovarian cancer obj_cells obj_reduced obj_ERK1/2
18632752	Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.	CCS-cancerTOnormal	subj_cancer subj_cells subj_reduced subj_ERK1/2 subj_activity subj_inhibited subj_cell obj_expression obj_MKP3 obj_MKP3-deficient obj_ovarian cancer obj_cells obj_reduced obj_ERK1/2
18632752	Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.	PT-observation	subj_cancer subj_cells subj_reduced subj_ERK1/2 subj_activity subj_inhibited subj_cell obj_expression obj_MKP3 obj_MKP3-deficient obj_ovarian cancer obj_cells obj_reduced obj_ERK1/2
18655371	A higher increase of the expression and maximal pixel intensity of ICAM-1, VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive breast carcinoma cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.	CGE-increased	subj_maximal subj_pixel subj_intensity subj_ICAM-1 subj_VCAM-1 subj_P subj_selectin obj_cells obj_cocultured obj_erbB2-positive obj_breast carcinoma obj_cells obj_compared obj_endothelial
18655371	A higher increase of the expression and maximal pixel intensity of ICAM-1, VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive breast carcinoma cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.	IGE-	subj_maximal subj_pixel subj_intensity subj_ICAM-1 subj_VCAM-1 subj_P subj_selectin obj_cells obj_cocultured obj_erbB2-positive obj_breast carcinoma obj_cells obj_compared obj_endothelial
18655371	A higher increase of the expression and maximal pixel intensity of ICAM-1, VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive breast carcinoma cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.	CCS-unidentifiable	subj_maximal subj_pixel subj_intensity subj_ICAM-1 subj_VCAM-1 subj_P subj_selectin obj_cells obj_cocultured obj_erbB2-positive obj_breast carcinoma obj_cells obj_compared obj_endothelial
18655371	A higher increase of the expression and maximal pixel intensity of ICAM-1, VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive breast carcinoma cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.	PT-	subj_maximal subj_pixel subj_intensity subj_ICAM-1 subj_VCAM-1 subj_P subj_selectin obj_cells obj_cocultured obj_erbB2-positive obj_breast carcinoma obj_cells obj_compared obj_endothelial
18702457	Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.	CGE-decreased	subj_activities subj_AdArs subj_inhibition subj_IKK/NFkappaB subj_signaling obj_) obj_breast obj_( obj_MDA-MB-468 obj_) obj_carcinoma obj_cells
18702457	Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.	IGE-unidentifiable	subj_activities subj_AdArs subj_inhibition subj_IKK/NFkappaB subj_signaling obj_) obj_breast obj_( obj_MDA-MB-468 obj_) obj_carcinoma obj_cells
18702457	Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.	CCS-cancerTOnormal	subj_activities subj_AdArs subj_inhibition subj_IKK/NFkappaB subj_signaling obj_) obj_breast obj_( obj_MDA-MB-468 obj_) obj_carcinoma obj_cells
18702457	Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.	PT-observation	subj_activities subj_AdArs subj_inhibition subj_IKK/NFkappaB subj_signaling obj_) obj_breast obj_( obj_MDA-MB-468 obj_) obj_carcinoma obj_cells
18713757	In addition, even a transient, siRNA-mediated p21 suppression in fibroblasts sufficiently stimulates MCF7 and MDA-MB-231 growth in vivo.	CGE-decreased	subj_transient subj_siRNA subj_mediated subj_p21 subj_suppression subj_fibroblasts subj_stimulates obj_fibroblasts obj_stimulates obj_MCF7 obj_MDA-MB-231 obj_growth obj_vivo
18713757	In addition, even a transient, siRNA-mediated p21 suppression in fibroblasts sufficiently stimulates MCF7 and MDA-MB-231 growth in vivo.	IGE-unidentifiable	subj_transient subj_siRNA subj_mediated subj_p21 subj_suppression subj_fibroblasts subj_stimulates obj_fibroblasts obj_stimulates obj_MCF7 obj_MDA-MB-231 obj_growth obj_vivo
18713757	In addition, even a transient, siRNA-mediated p21 suppression in fibroblasts sufficiently stimulates MCF7 and MDA-MB-231 growth in vivo.	CCS-normalTOcancer	subj_transient subj_siRNA subj_mediated subj_p21 subj_suppression subj_fibroblasts subj_stimulates obj_fibroblasts obj_stimulates obj_MCF7 obj_MDA-MB-231 obj_growth obj_vivo
18713757	In addition, even a transient, siRNA-mediated p21 suppression in fibroblasts sufficiently stimulates MCF7 and MDA-MB-231 growth in vivo.	PT-causality	subj_transient subj_siRNA subj_mediated subj_p21 subj_suppression subj_fibroblasts subj_stimulates obj_fibroblasts obj_stimulates obj_MCF7 obj_MDA-MB-231 obj_growth obj_vivo
18723500	The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin.	CGE-decreased	subj_drop subj_PCho subj_levels subj_FASN subj_inhibition subj_confirmed subj_SKOV-3 obj_inhibition obj_confirmed obj_SKOV-3 obj_ovarian cancer obj_cells obj_treated obj_Orlistat
18723500	The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin.	IGE-	subj_drop subj_PCho subj_levels subj_FASN subj_inhibition subj_confirmed subj_SKOV-3 obj_inhibition obj_confirmed obj_SKOV-3 obj_ovarian cancer obj_cells obj_treated obj_Orlistat
18723500	The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin.	CCS-unidentifiable	subj_drop subj_PCho subj_levels subj_FASN subj_inhibition subj_confirmed subj_SKOV-3 obj_inhibition obj_confirmed obj_SKOV-3 obj_ovarian cancer obj_cells obj_treated obj_Orlistat
18723500	The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin.	PT-	subj_drop subj_PCho subj_levels subj_FASN subj_inhibition subj_confirmed subj_SKOV-3 obj_inhibition obj_confirmed obj_SKOV-3 obj_ovarian cancer obj_cells obj_treated obj_Orlistat
18829495	Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of RhoA and inhibition of breast cancer cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.	CGE-increased	subj_EGFR subj_leading subj_activation subj_RhoA subj_inhibition subj_breast subj_cancer obj_activation obj_RhoA obj_inhibition obj_breast cancer obj_cell obj_invasion obj_irrespective
18829495	Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of RhoA and inhibition of breast cancer cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.	IGE-unidentifiable	subj_EGFR subj_leading subj_activation subj_RhoA subj_inhibition subj_breast subj_cancer obj_activation obj_RhoA obj_inhibition obj_breast cancer obj_cell obj_invasion obj_irrespective
18829495	Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of RhoA and inhibition of breast cancer cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.	CCS-cancerTOnormal	subj_EGFR subj_leading subj_activation subj_RhoA subj_inhibition subj_breast subj_cancer obj_activation obj_RhoA obj_inhibition obj_breast cancer obj_cell obj_invasion obj_irrespective
18829495	Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of RhoA and inhibition of breast cancer cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.	PT-observation	subj_EGFR subj_leading subj_activation subj_RhoA subj_inhibition subj_breast subj_cancer obj_activation obj_RhoA obj_inhibition obj_breast cancer obj_cell obj_invasion obj_irrespective
18840527	We showed, for the first time, that knockdown of PDI in MCF-7 human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates ERbeta protein, resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.	CGE-increased	subj_ERalpha subj_protein subj_regulates subj_ERbeta protein subj_drastic subj_increase subj_ERbeta obj_PDI obj_MCF-7 obj_human obj_breast cancer obj_cells obj_RNA obj_interference
18840527	We showed, for the first time, that knockdown of PDI in MCF-7 human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates ERbeta protein, resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.	IGE-	subj_ERalpha subj_protein subj_regulates subj_ERbeta protein subj_drastic subj_increase subj_ERbeta obj_PDI obj_MCF-7 obj_human obj_breast cancer obj_cells obj_RNA obj_interference
18840527	We showed, for the first time, that knockdown of PDI in MCF-7 human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates ERbeta protein, resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.	CCS-unidentifiable	subj_ERalpha subj_protein subj_regulates subj_ERbeta protein subj_drastic subj_increase subj_ERbeta obj_PDI obj_MCF-7 obj_human obj_breast cancer obj_cells obj_RNA obj_interference
18840527	We showed, for the first time, that knockdown of PDI in MCF-7 human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates ERbeta protein, resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.	PT-	subj_ERalpha subj_protein subj_regulates subj_ERbeta protein subj_drastic subj_increase subj_ERbeta obj_PDI obj_MCF-7 obj_human obj_breast cancer obj_cells obj_RNA obj_interference
18929692	Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone.	CGE-decreased	subj_/ subj_RANKL subj_axis subj_BMP subj_pathway subj_reduced subj_tumor obj_individual obj_pathway obj_osteolytic obj_prostate cancer obj_lesion obj_bone
18929692	Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone.	IGE-	subj_/ subj_RANKL subj_axis subj_BMP subj_pathway subj_reduced subj_tumor obj_individual obj_pathway obj_osteolytic obj_prostate cancer obj_lesion obj_bone
18929692	Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone.	CCS-unidentifiable	subj_/ subj_RANKL subj_axis subj_BMP subj_pathway subj_reduced subj_tumor obj_individual obj_pathway obj_osteolytic obj_prostate cancer obj_lesion obj_bone
18929692	Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone.	PT-	subj_/ subj_RANKL subj_axis subj_BMP subj_pathway subj_reduced subj_tumor obj_individual obj_pathway obj_osteolytic obj_prostate cancer obj_lesion obj_bone
18945339	HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients.	CGE-increased	subj_HER-2 subj_expression subj_observed subj_18.1 obj_18.1 obj_% obj_Tunisian obj_breast carcinoma obj_female obj_patients
18945339	HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients.	IGE-unchanged	subj_HER-2 subj_expression subj_observed subj_18.1 obj_18.1 obj_% obj_Tunisian obj_breast carcinoma obj_female obj_patients
18945339	HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients.	CCS-normalTOcancer	subj_HER-2 subj_expression subj_observed subj_18.1 obj_18.1 obj_% obj_Tunisian obj_breast carcinoma obj_female obj_patients
18945339	HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients.	PT-observation	subj_HER-2 subj_expression subj_observed subj_18.1 obj_18.1 obj_% obj_Tunisian obj_breast carcinoma obj_female obj_patients
19024511	[Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro].	CGE-increased	subj_Overexpression subj_human tumor metastasis-related gene TMSG-1 subj_suppresses subj_cell subj_proliferation obj_proliferation obj_invasion obj_highly obj_metastatic prostate cancer obj_cell obj_PC-3M-1E8 obj_vitro
19024511	[Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro].	IGE-unidentifiable	subj_Overexpression subj_human tumor metastasis-related gene TMSG-1 subj_suppresses subj_cell subj_proliferation obj_proliferation obj_invasion obj_highly obj_metastatic prostate cancer obj_cell obj_PC-3M-1E8 obj_vitro
19024511	[Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro].	CCS-cancerTOnormal	subj_Overexpression subj_human tumor metastasis-related gene TMSG-1 subj_suppresses subj_cell subj_proliferation obj_proliferation obj_invasion obj_highly obj_metastatic prostate cancer obj_cell obj_PC-3M-1E8 obj_vitro
19024511	[Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro].	PT-causality	subj_Overexpression subj_human tumor metastasis-related gene TMSG-1 subj_suppresses subj_cell subj_proliferation obj_proliferation obj_invasion obj_highly obj_metastatic prostate cancer obj_cell obj_PC-3M-1E8 obj_vitro
19041697	In addition, Cd enhanced DNA synthesis and pS2 mRNA levels in estrogen (10 pM estradiol) treated T47D cells.	CGE-increased	subj_enhanced subj_DNA subj_synthesis subj_pS2 mRNA subj_levels subj_estrogen subj_( obj_estradiol obj_) obj_treated obj_T47D obj_cells
19041697	In addition, Cd enhanced DNA synthesis and pS2 mRNA levels in estrogen (10 pM estradiol) treated T47D cells.	IGE-	subj_enhanced subj_DNA subj_synthesis subj_pS2 mRNA subj_levels subj_estrogen subj_( obj_estradiol obj_) obj_treated obj_T47D obj_cells
19041697	In addition, Cd enhanced DNA synthesis and pS2 mRNA levels in estrogen (10 pM estradiol) treated T47D cells.	CCS-unidentifiable	subj_enhanced subj_DNA subj_synthesis subj_pS2 mRNA subj_levels subj_estrogen subj_( obj_estradiol obj_) obj_treated obj_T47D obj_cells
19041697	In addition, Cd enhanced DNA synthesis and pS2 mRNA levels in estrogen (10 pM estradiol) treated T47D cells.	PT-	subj_enhanced subj_DNA subj_synthesis subj_pS2 mRNA subj_levels subj_estrogen subj_( obj_estradiol obj_) obj_treated obj_T47D obj_cells
19048115	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.	CGE-decreased	subj_Neurofibromin 1 subj_( subj_NF1 subj_) obj_defects obj_common obj_human obj_ovarian serous carcinomas obj_occur obj_TP53 obj_mutations
19048115	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.	IGE-unchanged	subj_Neurofibromin 1 subj_( subj_NF1 subj_) obj_defects obj_common obj_human obj_ovarian serous carcinomas obj_occur obj_TP53 obj_mutations
19048115	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.	CCS-normalTOcancer	subj_Neurofibromin 1 subj_( subj_NF1 subj_) obj_defects obj_common obj_human obj_ovarian serous carcinomas obj_occur obj_TP53 obj_mutations
19048115	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.	PT-observation	subj_Neurofibromin 1 subj_( subj_NF1 subj_) obj_defects obj_common obj_human obj_ovarian serous carcinomas obj_occur obj_TP53 obj_mutations
19087284	Our findings show, for the first time, that DC is a natural tumor promoter by elevating Flk-1 and decreasing ceramide-mediated apoptosis of breast cancer progenitor cells.	CGE-increased	subj_tumor subj_promoter subj_elevating subj_Flk-1 subj_decreasing subj_ceramide subj_mediated obj_ceramide obj_mediated obj_apoptosis obj_breast cancer obj_progenitor obj_cells
19087284	Our findings show, for the first time, that DC is a natural tumor promoter by elevating Flk-1 and decreasing ceramide-mediated apoptosis of breast cancer progenitor cells.	IGE-unidentifiable	subj_tumor subj_promoter subj_elevating subj_Flk-1 subj_decreasing subj_ceramide subj_mediated obj_ceramide obj_mediated obj_apoptosis obj_breast cancer obj_progenitor obj_cells
19087284	Our findings show, for the first time, that DC is a natural tumor promoter by elevating Flk-1 and decreasing ceramide-mediated apoptosis of breast cancer progenitor cells.	CCS-normalTOcancer	subj_tumor subj_promoter subj_elevating subj_Flk-1 subj_decreasing subj_ceramide subj_mediated obj_ceramide obj_mediated obj_apoptosis obj_breast cancer obj_progenitor obj_cells
19087284	Our findings show, for the first time, that DC is a natural tumor promoter by elevating Flk-1 and decreasing ceramide-mediated apoptosis of breast cancer progenitor cells.	PT-causality	subj_tumor subj_promoter subj_elevating subj_Flk-1 subj_decreasing subj_ceramide subj_mediated obj_ceramide obj_mediated obj_apoptosis obj_breast cancer obj_progenitor obj_cells
19097929	Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer.	CGE-increased	subj_KLF6-SV1 subj_expression subj_poor subj_prognosis obj_prognosis obj_prostate obj_lung obj_ovarian cancer
19097929	Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer.	IGE-unchanged	subj_KLF6-SV1 subj_expression subj_poor subj_prognosis obj_prognosis obj_prostate obj_lung obj_ovarian cancer
19097929	Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer.	CCS-normalTOcancer	subj_KLF6-SV1 subj_expression subj_poor subj_prognosis obj_prognosis obj_prostate obj_lung obj_ovarian cancer
19097929	Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer.	PT-observation	subj_KLF6-SV1 subj_expression subj_poor subj_prognosis obj_prognosis obj_prostate obj_lung obj_ovarian cancer
19115233	We further demonstrate that Pfn1 downregulation results in a hyper-motile phenotype of MDA-MB-231 cells in an Ena/VASP-dependent mechanism.	CGE-decreased	subj_We subj_demonstrate subj_Pfn1 subj_downregulation subj_hyper subj_motile obj_hyper obj_motile obj_phenotype obj_MDA-MB-231 obj_cells obj_Ena obj_/
19115233	We further demonstrate that Pfn1 downregulation results in a hyper-motile phenotype of MDA-MB-231 cells in an Ena/VASP-dependent mechanism.	IGE-unidentifiable	subj_We subj_demonstrate subj_Pfn1 subj_downregulation subj_hyper subj_motile obj_hyper obj_motile obj_phenotype obj_MDA-MB-231 obj_cells obj_Ena obj_/
19115233	We further demonstrate that Pfn1 downregulation results in a hyper-motile phenotype of MDA-MB-231 cells in an Ena/VASP-dependent mechanism.	CCS-normalTOcancer	subj_We subj_demonstrate subj_Pfn1 subj_downregulation subj_hyper subj_motile obj_hyper obj_motile obj_phenotype obj_MDA-MB-231 obj_cells obj_Ena obj_/
19115233	We further demonstrate that Pfn1 downregulation results in a hyper-motile phenotype of MDA-MB-231 cells in an Ena/VASP-dependent mechanism.	PT-causality	subj_We subj_demonstrate subj_Pfn1 subj_downregulation subj_hyper subj_motile obj_hyper obj_motile obj_phenotype obj_MDA-MB-231 obj_cells obj_Ena obj_/
19181441	We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.	CGE-increased	subj_FSH subj_receptor subj_( subj_FSHR subj_) subj_increased subj_ovarian obj_OEIs obj_) obj_benign obj_ovarian epithelial tumors obj_( obj_OETs obj_)
19181441	We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.	IGE-	subj_FSH subj_receptor subj_( subj_FSHR subj_) subj_increased subj_ovarian obj_OEIs obj_) obj_benign obj_ovarian epithelial tumors obj_( obj_OETs obj_)
19181441	We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.	CCS-unidentifiable	subj_FSH subj_receptor subj_( subj_FSHR subj_) subj_increased subj_ovarian obj_OEIs obj_) obj_benign obj_ovarian epithelial tumors obj_( obj_OETs obj_)
19181441	We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.	PT-	subj_FSH subj_receptor subj_( subj_FSHR subj_) subj_increased subj_ovarian obj_OEIs obj_) obj_benign obj_ovarian epithelial tumors obj_( obj_OETs obj_)
19212833	PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.	CGE-decreased	subj_PDLIM4 mRNA subj_protein subj_expression subj_levels obj_DU145 obj_CWR22 obj_PC3 obj_prostate cancer obj_cells
19212833	PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.	IGE-unchanged	subj_PDLIM4 mRNA subj_protein subj_expression subj_levels obj_DU145 obj_CWR22 obj_PC3 obj_prostate cancer obj_cells
19212833	PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.	CCS-normalTOcancer	subj_PDLIM4 mRNA subj_protein subj_expression subj_levels obj_DU145 obj_CWR22 obj_PC3 obj_prostate cancer obj_cells
19212833	PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.	PT-observation	subj_PDLIM4 mRNA subj_protein subj_expression subj_levels obj_DU145 obj_CWR22 obj_PC3 obj_prostate cancer obj_cells
19415690	Exogenous uMtCK in LNCaP cells surprisingly contributed to overproduction of ROS, activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.	CGE-increased	subj_surprisingly subj_contributed subj_overproduction subj_ROS subj_activation subj_Akt subj_signaling obj_uMtCK obj_LNCaP obj_cells obj_surprisingly obj_contributed
19415690	Exogenous uMtCK in LNCaP cells surprisingly contributed to overproduction of ROS, activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.	IGE-unidentifiable	subj_surprisingly subj_contributed subj_overproduction subj_ROS subj_activation subj_Akt subj_signaling obj_uMtCK obj_LNCaP obj_cells obj_surprisingly obj_contributed
19415690	Exogenous uMtCK in LNCaP cells surprisingly contributed to overproduction of ROS, activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.	CCS-normalTOcancer	subj_surprisingly subj_contributed subj_overproduction subj_ROS subj_activation subj_Akt subj_signaling obj_uMtCK obj_LNCaP obj_cells obj_surprisingly obj_contributed
19415690	Exogenous uMtCK in LNCaP cells surprisingly contributed to overproduction of ROS, activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.	PT-observation	subj_surprisingly subj_contributed subj_overproduction subj_ROS subj_activation subj_Akt subj_signaling obj_uMtCK obj_LNCaP obj_cells obj_surprisingly obj_contributed
19419758	OBJECTIVE: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.	CGE-decreased	subj_We subj_TCEAL7 subj_( subj_transcription elongation factor A (SII)-like 7 subj_) subj_epigenetically subj_regulated obj_epigenetically obj_regulated obj_majority obj_epithelial ovarian cancers
19419758	OBJECTIVE: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.	IGE-unchanged	subj_We subj_TCEAL7 subj_( subj_transcription elongation factor A (SII)-like 7 subj_) subj_epigenetically subj_regulated obj_epigenetically obj_regulated obj_majority obj_epithelial ovarian cancers
19419758	OBJECTIVE: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.	CCS-normalTOcancer	subj_We subj_TCEAL7 subj_( subj_transcription elongation factor A (SII)-like 7 subj_) subj_epigenetically subj_regulated obj_epigenetically obj_regulated obj_majority obj_epithelial ovarian cancers
19419758	OBJECTIVE: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.	PT-observation	subj_We subj_TCEAL7 subj_( subj_transcription elongation factor A (SII)-like 7 subj_) subj_epigenetically subj_regulated obj_epigenetically obj_regulated obj_majority obj_epithelial ovarian cancers
19423340	The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3.	CGE-increased	subj_adriamycin subj_paclitaxel subj_overexpressing subj_class III beta-tubulin subj_A2780TC1 subj_A2780TC3 obj_cell obj_lines obj_include obj_ovarian cancer obj_cell obj_lines obj_resistant
19423340	The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3.	IGE-unidentifiable	subj_adriamycin subj_paclitaxel subj_overexpressing subj_class III beta-tubulin subj_A2780TC1 subj_A2780TC3 obj_cell obj_lines obj_include obj_ovarian cancer obj_cell obj_lines obj_resistant
19423340	The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3.	CCS-normalTOcancer	subj_adriamycin subj_paclitaxel subj_overexpressing subj_class III beta-tubulin subj_A2780TC1 subj_A2780TC3 obj_cell obj_lines obj_include obj_ovarian cancer obj_cell obj_lines obj_resistant
19423340	The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3.	PT-observation	subj_adriamycin subj_paclitaxel subj_overexpressing subj_class III beta-tubulin subj_A2780TC1 subj_A2780TC3 obj_cell obj_lines obj_include obj_ovarian cancer obj_cell obj_lines obj_resistant
19432961	Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.	CGE-decreased	subj_expression subj_miR-342 subj_therapeutically subj_challenging subj_triple obj_challenging obj_triple obj_negative obj_breast tumours obj_increased obj_miR-342 obj_expression
19432961	Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.	IGE-unidentifiable	subj_expression subj_miR-342 subj_therapeutically subj_challenging subj_triple obj_challenging obj_triple obj_negative obj_breast tumours obj_increased obj_miR-342 obj_expression
19432961	Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.	CCS-normalTOcancer	subj_expression subj_miR-342 subj_therapeutically subj_challenging subj_triple obj_challenging obj_triple obj_negative obj_breast tumours obj_increased obj_miR-342 obj_expression
19432961	Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.	PT-observation	subj_expression subj_miR-342 subj_therapeutically subj_challenging subj_triple obj_challenging obj_triple obj_negative obj_breast tumours obj_increased obj_miR-342 obj_expression
19438741	Furthermore, MRP1 expression correlated with topoisomerase IIalpha expression both at mRNA and protein level (P < 0.001 and P = 0.023, respectively).
CONCLUSION: In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness.	CGE-increased	subj_ovarian subj_cancer subj_overexpression subj_MRP1 subj_adverse subj_marker subj_patient obj_summary obj_patients obj_primary obj_ovarian cancer obj_overexpression obj_MRP1 obj_adverse
19438741	Furthermore, MRP1 expression correlated with topoisomerase IIalpha expression both at mRNA and protein level (P < 0.001 and P = 0.023, respectively).
CONCLUSION: In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness.	IGE-unidentifiable	subj_ovarian subj_cancer subj_overexpression subj_MRP1 subj_adverse subj_marker subj_patient obj_summary obj_patients obj_primary obj_ovarian cancer obj_overexpression obj_MRP1 obj_adverse
19438741	Furthermore, MRP1 expression correlated with topoisomerase IIalpha expression both at mRNA and protein level (P < 0.001 and P = 0.023, respectively).
CONCLUSION: In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness.	CCS-normalTOcancer	subj_ovarian subj_cancer subj_overexpression subj_MRP1 subj_adverse subj_marker subj_patient obj_summary obj_patients obj_primary obj_ovarian cancer obj_overexpression obj_MRP1 obj_adverse
19438741	Furthermore, MRP1 expression correlated with topoisomerase IIalpha expression both at mRNA and protein level (P < 0.001 and P = 0.023, respectively).
CONCLUSION: In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness.	PT-observation	subj_ovarian subj_cancer subj_overexpression subj_MRP1 subj_adverse subj_marker subj_patient obj_summary obj_patients obj_primary obj_ovarian cancer obj_overexpression obj_MRP1 obj_adverse
19483721	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.	CGE-increased	subj_PKIB subj_prostate subj_cancer subj_promotes obj_PKIB obj_prostate cancer obj_promotes obj_aggressiveness obj_linking
19483721	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.	IGE-unidentifiable	subj_PKIB subj_prostate subj_cancer subj_promotes obj_PKIB obj_prostate cancer obj_promotes obj_aggressiveness obj_linking
19483721	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.	CCS-normalTOcancer	subj_PKIB subj_prostate subj_cancer subj_promotes obj_PKIB obj_prostate cancer obj_promotes obj_aggressiveness obj_linking
19483721	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.	PT-causality	subj_PKIB subj_prostate subj_cancer subj_promotes obj_PKIB obj_prostate cancer obj_promotes obj_aggressiveness obj_linking
19486012	ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.	CGE-decreased	subj_advanced subj_stage subj_samples subj_ZEB2 subj_knockdown subj_ovarian subj_adenocarcinoma obj_samples obj_ZEB2 obj_knockdown obj_ovarian adenocarcinoma obj_SKOV3 obj_cells obj_increase
19486012	ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.	IGE-	subj_advanced subj_stage subj_samples subj_ZEB2 subj_knockdown subj_ovarian subj_adenocarcinoma obj_samples obj_ZEB2 obj_knockdown obj_ovarian adenocarcinoma obj_SKOV3 obj_cells obj_increase
19486012	ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.	CCS-unidentifiable	subj_advanced subj_stage subj_samples subj_ZEB2 subj_knockdown subj_ovarian subj_adenocarcinoma obj_samples obj_ZEB2 obj_knockdown obj_ovarian adenocarcinoma obj_SKOV3 obj_cells obj_increase
19486012	ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.	PT-	subj_advanced subj_stage subj_samples subj_ZEB2 subj_knockdown subj_ovarian subj_adenocarcinoma obj_samples obj_ZEB2 obj_knockdown obj_ovarian adenocarcinoma obj_SKOV3 obj_cells obj_increase
19584279	Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.	CGE-increased	subj_relapsed subj_castration subj_coincident subj_AR subj_reactivation obj_ERG obj_expression obj_restored obj_VCaP obj_xenografts obj_relapsed obj_castration
19584279	Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.	IGE-unidentifiable	subj_relapsed subj_castration subj_coincident subj_AR subj_reactivation obj_ERG obj_expression obj_restored obj_VCaP obj_xenografts obj_relapsed obj_castration
19584279	Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.	CCS-normalTOcancer	subj_relapsed subj_castration subj_coincident subj_AR subj_reactivation obj_ERG obj_expression obj_restored obj_VCaP obj_xenografts obj_relapsed obj_castration
19584279	Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.	PT-observation	subj_relapsed subj_castration subj_coincident subj_AR subj_reactivation obj_ERG obj_expression obj_restored obj_VCaP obj_xenografts obj_relapsed obj_castration
19633975	These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.	CGE-decreased	subj_ability subj_PC-3 subj_reducing subj_MMP-2 subj_MMP-9 subj_expressions subj_suppressing obj_inhibit obj_metastatic obj_ability obj_PC-3 obj_reducing obj_MMP-2 obj_MMP-9
19633975	These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.	IGE-unidentifiable	subj_ability subj_PC-3 subj_reducing subj_MMP-2 subj_MMP-9 subj_expressions subj_suppressing obj_inhibit obj_metastatic obj_ability obj_PC-3 obj_reducing obj_MMP-2 obj_MMP-9
19633975	These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.	CCS-cancerTOnormal	subj_ability subj_PC-3 subj_reducing subj_MMP-2 subj_MMP-9 subj_expressions subj_suppressing obj_inhibit obj_metastatic obj_ability obj_PC-3 obj_reducing obj_MMP-2 obj_MMP-9
19633975	These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.	PT-causality	subj_ability subj_PC-3 subj_reducing subj_MMP-2 subj_MMP-9 subj_expressions subj_suppressing obj_inhibit obj_metastatic obj_ability obj_PC-3 obj_reducing obj_MMP-2 obj_MMP-9
19638582	Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.	CGE-increased	subj_growth subj_indirectly subj_activating subj_Hh subj_signaling subj_surrounding subj_stroma obj_including obj_colon obj_pancreatic obj_ovarian cancer obj_promote obj_tumor obj_growth
19638582	Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.	IGE-unidentifiable	subj_growth subj_indirectly subj_activating subj_Hh subj_signaling subj_surrounding subj_stroma obj_including obj_colon obj_pancreatic obj_ovarian cancer obj_promote obj_tumor obj_growth
19638582	Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.	CCS-normalTOcancer	subj_growth subj_indirectly subj_activating subj_Hh subj_signaling subj_surrounding subj_stroma obj_including obj_colon obj_pancreatic obj_ovarian cancer obj_promote obj_tumor obj_growth
19638582	Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.	PT-causality	subj_growth subj_indirectly subj_activating subj_Hh subj_signaling subj_surrounding subj_stroma obj_including obj_colon obj_pancreatic obj_ovarian cancer obj_promote obj_tumor obj_growth
19649288	GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts.	CGE-decreased	subj_inhibition subj_6-bromoindirubin-3'-oxime subj_suppressed subj_hTERT subj_expression subj_telomerase subj_activity obj_growth obj_hTERT obj_expression obj_ovarian cancer obj_xenografts
19649288	GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts.	IGE-unidentifiable	subj_inhibition subj_6-bromoindirubin-3'-oxime subj_suppressed subj_hTERT subj_expression subj_telomerase subj_activity obj_growth obj_hTERT obj_expression obj_ovarian cancer obj_xenografts
19649288	GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts.	CCS-cancerTOnormal	subj_inhibition subj_6-bromoindirubin-3'-oxime subj_suppressed subj_hTERT subj_expression subj_telomerase subj_activity obj_growth obj_hTERT obj_expression obj_ovarian cancer obj_xenografts
19649288	GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts.	PT-observation	subj_inhibition subj_6-bromoindirubin-3'-oxime subj_suppressed subj_hTERT subj_expression subj_telomerase subj_activity obj_growth obj_hTERT obj_expression obj_ovarian cancer obj_xenografts
19706771	These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen.	CGE-increased	subj_result subj_increased subj_accumulation subj_AR subj_enhanced subj_growth subj_prostate obj_AR obj_enhanced obj_growth obj_prostate cancer obj_cells obj_levels obj_androgen
19706771	These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen.	IGE-unidentifiable	subj_result subj_increased subj_accumulation subj_AR subj_enhanced subj_growth subj_prostate obj_AR obj_enhanced obj_growth obj_prostate cancer obj_cells obj_levels obj_androgen
19706771	These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen.	CCS-normalTOcancer	subj_result subj_increased subj_accumulation subj_AR subj_enhanced subj_growth subj_prostate obj_AR obj_enhanced obj_growth obj_prostate cancer obj_cells obj_levels obj_androgen
19706771	These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen.	PT-causality	subj_result subj_increased subj_accumulation subj_AR subj_enhanced subj_growth subj_prostate obj_AR obj_enhanced obj_growth obj_prostate cancer obj_cells obj_levels obj_androgen
1978301	Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.	CGE-increased	subj_levels subj_adrenocorticotropic hormone subj_( subj_ACTH)-induced subj_increments obj_GT obj_albumin obj_measured obj_prostatic cancer obj_patients obj_6 obj_months
1978301	Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.	IGE-	subj_levels subj_adrenocorticotropic hormone subj_( subj_ACTH)-induced subj_increments obj_GT obj_albumin obj_measured obj_prostatic cancer obj_patients obj_6 obj_months
1978301	Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.	CCS-unidentifiable	subj_levels subj_adrenocorticotropic hormone subj_( subj_ACTH)-induced subj_increments obj_GT obj_albumin obj_measured obj_prostatic cancer obj_patients obj_6 obj_months
1978301	Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.	PT-	subj_levels subj_adrenocorticotropic hormone subj_( subj_ACTH)-induced subj_increments obj_GT obj_albumin obj_measured obj_prostatic cancer obj_patients obj_6 obj_months
19789311	These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.	CGE-decreased	subj_data subj_blocking subj_TSPO subj_function subj_tumor subj_cells obj_cancer obj_evidence obj_benzodiazepines obj_prostate cancer obj_therapeutics
19789311	These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.	IGE-unidentifiable	subj_data subj_blocking subj_TSPO subj_function subj_tumor subj_cells obj_cancer obj_evidence obj_benzodiazepines obj_prostate cancer obj_therapeutics
19789311	These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.	CCS-cancerTOnormal	subj_data subj_blocking subj_TSPO subj_function subj_tumor subj_cells obj_cancer obj_evidence obj_benzodiazepines obj_prostate cancer obj_therapeutics
19789311	These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.	PT-causality	subj_data subj_blocking subj_TSPO subj_function subj_tumor subj_cells obj_cancer obj_evidence obj_benzodiazepines obj_prostate cancer obj_therapeutics
1985102	Furthermore, in four breast cancer cell lines, the extent of induction of TGF-beta correlated with intracellular levels of Gestodene binding site.	CGE-increased	subj_lines subj_extent subj_induction subj_TGF-beta subj_correlated subj_intracellular subj_levels obj_Furthermore obj_breast cancer obj_cell obj_lines obj_extent
1985102	Furthermore, in four breast cancer cell lines, the extent of induction of TGF-beta correlated with intracellular levels of Gestodene binding site.	IGE-	subj_lines subj_extent subj_induction subj_TGF-beta subj_correlated subj_intracellular subj_levels obj_Furthermore obj_breast cancer obj_cell obj_lines obj_extent
1985102	Furthermore, in four breast cancer cell lines, the extent of induction of TGF-beta correlated with intracellular levels of Gestodene binding site.	CCS-unidentifiable	subj_lines subj_extent subj_induction subj_TGF-beta subj_correlated subj_intracellular subj_levels obj_Furthermore obj_breast cancer obj_cell obj_lines obj_extent
1985102	Furthermore, in four breast cancer cell lines, the extent of induction of TGF-beta correlated with intracellular levels of Gestodene binding site.	PT-	subj_lines subj_extent subj_induction subj_TGF-beta subj_correlated subj_intracellular subj_levels obj_Furthermore obj_breast cancer obj_cell obj_lines obj_extent
19876919	Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.	CGE-increased	subj_dependent subj_manner subj_increased subj_p38 subj_activation obj_Pak1 obj_overexpression obj_enhanced obj_ovarian cancer obj_cell obj_migration obj_invasion
19876919	Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.	IGE-unidentifiable	subj_dependent subj_manner subj_increased subj_p38 subj_activation obj_Pak1 obj_overexpression obj_enhanced obj_ovarian cancer obj_cell obj_migration obj_invasion
19876919	Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.	CCS-normalTOcancer	subj_dependent subj_manner subj_increased subj_p38 subj_activation obj_Pak1 obj_overexpression obj_enhanced obj_ovarian cancer obj_cell obj_migration obj_invasion
19876919	Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.	PT-observation	subj_dependent subj_manner subj_increased subj_p38 subj_activation obj_Pak1 obj_overexpression obj_enhanced obj_ovarian cancer obj_cell obj_migration obj_invasion
19879420	Recently, it was shown that CLU is silenced by promoter methylation in the murine TRAMP-C2 cell line, as well as in the human prostate cancer cell line LNCaP. Consistently, CLU expression was found to be significantly reduced in untreated and hormone-refractory human prostate carcinomas.	CGE-decreased	subj_cell subj_LNCaP. subj_Consistently subj_CLU subj_expression subj_reduced subj_untreated obj_hormone obj_refractory obj_human obj_prostate carcinomas
19879420	Recently, it was shown that CLU is silenced by promoter methylation in the murine TRAMP-C2 cell line, as well as in the human prostate cancer cell line LNCaP. Consistently, CLU expression was found to be significantly reduced in untreated and hormone-refractory human prostate carcinomas.	IGE-unidentifiable	subj_cell subj_LNCaP. subj_Consistently subj_CLU subj_expression subj_reduced subj_untreated obj_hormone obj_refractory obj_human obj_prostate carcinomas
19879420	Recently, it was shown that CLU is silenced by promoter methylation in the murine TRAMP-C2 cell line, as well as in the human prostate cancer cell line LNCaP. Consistently, CLU expression was found to be significantly reduced in untreated and hormone-refractory human prostate carcinomas.	CCS-normalTOcancer	subj_cell subj_LNCaP. subj_Consistently subj_CLU subj_expression subj_reduced subj_untreated obj_hormone obj_refractory obj_human obj_prostate carcinomas
19879420	Recently, it was shown that CLU is silenced by promoter methylation in the murine TRAMP-C2 cell line, as well as in the human prostate cancer cell line LNCaP. Consistently, CLU expression was found to be significantly reduced in untreated and hormone-refractory human prostate carcinomas.	PT-observation	subj_cell subj_LNCaP. subj_Consistently subj_CLU subj_expression subj_reduced subj_untreated obj_hormone obj_refractory obj_human obj_prostate carcinomas
19935792	Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.	CGE-increased	subj_cell subj_lines subj_induced subj_CCBE1 subj_expression subj_indicating subj_epigenetic obj_demethylation obj_/ obj_deacetylation obj_ovarian cancer obj_cell obj_lines obj_induced
19935792	Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.	IGE-	subj_cell subj_lines subj_induced subj_CCBE1 subj_expression subj_indicating subj_epigenetic obj_demethylation obj_/ obj_deacetylation obj_ovarian cancer obj_cell obj_lines obj_induced
19935792	Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.	CCS-unidentifiable	subj_cell subj_lines subj_induced subj_CCBE1 subj_expression subj_indicating subj_epigenetic obj_demethylation obj_/ obj_deacetylation obj_ovarian cancer obj_cell obj_lines obj_induced
19935792	Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.	PT-	subj_cell subj_lines subj_induced subj_CCBE1 subj_expression subj_indicating subj_epigenetic obj_demethylation obj_/ obj_deacetylation obj_ovarian cancer obj_cell obj_lines obj_induced
19995430	We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.	CGE-increased	subj_cancers subj_inducing subj_overexpression subj_CUL4A subj_TFDP1 subj_cell subj_cycle obj_tumor obj_progression obj_basal obj_breast cancers obj_inducing obj_overexpression obj_CUL4A
19995430	We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.	IGE-unchanged	subj_cancers subj_inducing subj_overexpression subj_CUL4A subj_TFDP1 subj_cell subj_cycle obj_tumor obj_progression obj_basal obj_breast cancers obj_inducing obj_overexpression obj_CUL4A
19995430	We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.	CCS-normalTOcancer	subj_cancers subj_inducing subj_overexpression subj_CUL4A subj_TFDP1 subj_cell subj_cycle obj_tumor obj_progression obj_basal obj_breast cancers obj_inducing obj_overexpression obj_CUL4A
19995430	We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.	PT-causality	subj_cancers subj_inducing subj_overexpression subj_CUL4A subj_TFDP1 subj_cell subj_cycle obj_tumor obj_progression obj_basal obj_breast cancers obj_inducing obj_overexpression obj_CUL4A
20036116	The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice.	CGE-increased	subj_HER2 subj_overexpressing subj_human subj_SKOV-3 obj_overexpressing obj_human obj_SKOV-3 obj_ovarian tumour obj_cell obj_vitro obj_experiments
20036116	The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice.	IGE-unidentifiable	subj_HER2 subj_overexpressing subj_human subj_SKOV-3 obj_overexpressing obj_human obj_SKOV-3 obj_ovarian tumour obj_cell obj_vitro obj_experiments
20036116	The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice.	CCS-normalTOcancer	subj_HER2 subj_overexpressing subj_human subj_SKOV-3 obj_overexpressing obj_human obj_SKOV-3 obj_ovarian tumour obj_cell obj_vitro obj_experiments
20036116	The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice.	PT-observation	subj_HER2 subj_overexpressing subj_human subj_SKOV-3 obj_overexpressing obj_human obj_SKOV-3 obj_ovarian tumour obj_cell obj_vitro obj_experiments
20075391	We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt.	CGE-increased	subj_carcinomas subj_exhibit subj_hyperactivation subj_Akt obj_DR26 obj_mice obj_develop obj_ovarian carcinomas obj_exhibit obj_hyperactivation obj_Akt
20075391	We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt.	IGE-unchanged	subj_carcinomas subj_exhibit subj_hyperactivation subj_Akt obj_DR26 obj_mice obj_develop obj_ovarian carcinomas obj_exhibit obj_hyperactivation obj_Akt
20075391	We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt.	CCS-normalTOcancer	subj_carcinomas subj_exhibit subj_hyperactivation subj_Akt obj_DR26 obj_mice obj_develop obj_ovarian carcinomas obj_exhibit obj_hyperactivation obj_Akt
20075391	We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt.	PT-observation	subj_carcinomas subj_exhibit subj_hyperactivation subj_Akt obj_DR26 obj_mice obj_develop obj_ovarian carcinomas obj_exhibit obj_hyperactivation obj_Akt
20217214	Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.	CGE-decreased	subj_findings subj_regulation subj_ICAM-1 subj_mammary subj_epithelial subj_cells obj_expression obj_psoriasin obj_grade obj_DCIS obj_tumors obj_induction obj_MUC1
20217214	Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.	IGE-	subj_findings subj_regulation subj_ICAM-1 subj_mammary subj_epithelial subj_cells obj_expression obj_psoriasin obj_grade obj_DCIS obj_tumors obj_induction obj_MUC1
20217214	Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.	CCS-unidentifiable	subj_findings subj_regulation subj_ICAM-1 subj_mammary subj_epithelial subj_cells obj_expression obj_psoriasin obj_grade obj_DCIS obj_tumors obj_induction obj_MUC1
20217214	Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.	PT-	subj_findings subj_regulation subj_ICAM-1 subj_mammary subj_epithelial subj_cells obj_expression obj_psoriasin obj_grade obj_DCIS obj_tumors obj_induction obj_MUC1
20302909	Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells.	CGE-decreased	subj_miR-21 subj_targets subj_PTEN subj_PDCD4 subj_reduced subj_ERalpha46-transfected subj_E(2)-treated obj_reduced obj_ERalpha46-transfected obj_E(2)-treated obj_MCF-7 obj_cells
20302909	Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells.	IGE-	subj_miR-21 subj_targets subj_PTEN subj_PDCD4 subj_reduced subj_ERalpha46-transfected subj_E(2)-treated obj_reduced obj_ERalpha46-transfected obj_E(2)-treated obj_MCF-7 obj_cells
20302909	Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells.	CCS-unidentifiable	subj_miR-21 subj_targets subj_PTEN subj_PDCD4 subj_reduced subj_ERalpha46-transfected subj_E(2)-treated obj_reduced obj_ERalpha46-transfected obj_E(2)-treated obj_MCF-7 obj_cells
20302909	Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells.	PT-	subj_miR-21 subj_targets subj_PTEN subj_PDCD4 subj_reduced subj_ERalpha46-transfected subj_E(2)-treated obj_reduced obj_ERalpha46-transfected obj_E(2)-treated obj_MCF-7 obj_cells
20305816	Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-2'-deoxycytidine treatment.	CGE-increased	subj_cells subj_tissues subj_endogenous subj_BORIS transcripts subj_induced subj_MCF-7 subj_cells obj_BORIS obj_transcripts obj_induced obj_MCF-7 obj_cells obj_5-aza-2'-deoxycytidine obj_treatment
20305816	Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-2'-deoxycytidine treatment.	IGE-	subj_cells subj_tissues subj_endogenous subj_BORIS transcripts subj_induced subj_MCF-7 subj_cells obj_BORIS obj_transcripts obj_induced obj_MCF-7 obj_cells obj_5-aza-2'-deoxycytidine obj_treatment
20305816	Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-2'-deoxycytidine treatment.	CCS-unidentifiable	subj_cells subj_tissues subj_endogenous subj_BORIS transcripts subj_induced subj_MCF-7 subj_cells obj_BORIS obj_transcripts obj_induced obj_MCF-7 obj_cells obj_5-aza-2'-deoxycytidine obj_treatment
20305816	Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-2'-deoxycytidine treatment.	PT-	subj_cells subj_tissues subj_endogenous subj_BORIS transcripts subj_induced subj_MCF-7 subj_cells obj_BORIS obj_transcripts obj_induced obj_MCF-7 obj_cells obj_5-aza-2'-deoxycytidine obj_treatment
20309881	This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer.	CGE-decreased	subj_promotes subj_Twist subj_expression subj_E-cadherin subj_downregulation subj_induces subj_EMT obj_downregulation obj_induces obj_EMT obj_ovarian cancer
20309881	This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer.	IGE-	subj_promotes subj_Twist subj_expression subj_E-cadherin subj_downregulation subj_induces subj_EMT obj_downregulation obj_induces obj_EMT obj_ovarian cancer
20309881	This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer.	CCS-unidentifiable	subj_promotes subj_Twist subj_expression subj_E-cadherin subj_downregulation subj_induces subj_EMT obj_downregulation obj_induces obj_EMT obj_ovarian cancer
20309881	This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer.	PT-	subj_promotes subj_Twist subj_expression subj_E-cadherin subj_downregulation subj_induces subj_EMT obj_downregulation obj_induces obj_EMT obj_ovarian cancer
20336778	In this study, while demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.	CGE-decreased	subj_demonstrating subj_suppressed subj_levels subj_Tm1 subj_prostate subj_cancer subj_cell obj_suppressed obj_levels obj_Tm1 obj_prostate cancer obj_cell obj_lines obj_LNCaP
20336778	In this study, while demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.	IGE-unchanged	subj_demonstrating subj_suppressed subj_levels subj_Tm1 subj_prostate subj_cancer subj_cell obj_suppressed obj_levels obj_Tm1 obj_prostate cancer obj_cell obj_lines obj_LNCaP
20336778	In this study, while demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.	CCS-normalTOcancer	subj_demonstrating subj_suppressed subj_levels subj_Tm1 subj_prostate subj_cancer subj_cell obj_suppressed obj_levels obj_Tm1 obj_prostate cancer obj_cell obj_lines obj_LNCaP
20336778	In this study, while demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.	PT-observation	subj_demonstrating subj_suppressed subj_levels subj_Tm1 subj_prostate subj_cancer subj_cell obj_suppressed obj_levels obj_Tm1 obj_prostate cancer obj_cell obj_lines obj_LNCaP
20388850	Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.	CGE-increased	subj_implicate subj_overexpressed subj_GRB7 subj_GRB7v subj_grade subj_tumors subj_exert obj_regulating obj_signaling obj_pathways obj_ovarian cancer obj_cells
20388850	Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.	IGE-unidentifiable	subj_implicate subj_overexpressed subj_GRB7 subj_GRB7v subj_grade subj_tumors subj_exert obj_regulating obj_signaling obj_pathways obj_ovarian cancer obj_cells
20388850	Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.	CCS-normalTOcancer	subj_implicate subj_overexpressed subj_GRB7 subj_GRB7v subj_grade subj_tumors subj_exert obj_regulating obj_signaling obj_pathways obj_ovarian cancer obj_cells
20388850	Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.	PT-observation	subj_implicate subj_overexpressed subj_GRB7 subj_GRB7v subj_grade subj_tumors subj_exert obj_regulating obj_signaling obj_pathways obj_ovarian cancer obj_cells
20390342	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.	CGE-increased	subj_CTEN (C-terminal tensin-like) subj_oncogene subj_overexpressed subj_invasive obj_) obj_oncogene obj_overexpressed obj_invasive breast carcinoma obj_poor obj_prognosis obj_
20390342	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.	IGE-unchanged	subj_CTEN (C-terminal tensin-like) subj_oncogene subj_overexpressed subj_invasive obj_) obj_oncogene obj_overexpressed obj_invasive breast carcinoma obj_poor obj_prognosis obj_
20390342	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.	CCS-normalTOcancer	subj_CTEN (C-terminal tensin-like) subj_oncogene subj_overexpressed subj_invasive obj_) obj_oncogene obj_overexpressed obj_invasive breast carcinoma obj_poor obj_prognosis obj_
20390342	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.	PT-observation	subj_CTEN (C-terminal tensin-like) subj_oncogene subj_overexpressed subj_invasive obj_) obj_oncogene obj_overexpressed obj_invasive breast carcinoma obj_poor obj_prognosis obj_
20495363	Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression.	CGE-decreased	subj_patients subj_lack subj_stromal subj_Cav-1 subj_expression obj_promising obj_therapeutic obj_strategy obj_breast cancer obj_patients obj_lack obj_stromal
20495363	Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression.	IGE-	subj_patients subj_lack subj_stromal subj_Cav-1 subj_expression obj_promising obj_therapeutic obj_strategy obj_breast cancer obj_patients obj_lack obj_stromal
20495363	Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression.	CCS-unidentifiable	subj_patients subj_lack subj_stromal subj_Cav-1 subj_expression obj_promising obj_therapeutic obj_strategy obj_breast cancer obj_patients obj_lack obj_stromal
20495363	Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression.	PT-	subj_patients subj_lack subj_stromal subj_Cav-1 subj_expression obj_promising obj_therapeutic obj_strategy obj_breast cancer obj_patients obj_lack obj_stromal
20499410	After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human prostate cancer, owing in part to methylation in the regulatory region of this gene in prostate cancer cells.	CGE-decreased	subj_) subj_identified subj_expression subj_GLIPR1 subj_regulated subj_human subj_prostate obj_regulatory obj_region obj_gene obj_prostate cancer obj_cells
20499410	After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human prostate cancer, owing in part to methylation in the regulatory region of this gene in prostate cancer cells.	IGE-unchanged	subj_) subj_identified subj_expression subj_GLIPR1 subj_regulated subj_human subj_prostate obj_regulatory obj_region obj_gene obj_prostate cancer obj_cells
20499410	After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human prostate cancer, owing in part to methylation in the regulatory region of this gene in prostate cancer cells.	CCS-normalTOcancer	subj_) subj_identified subj_expression subj_GLIPR1 subj_regulated subj_human subj_prostate obj_regulatory obj_region obj_gene obj_prostate cancer obj_cells
20499410	After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human prostate cancer, owing in part to methylation in the regulatory region of this gene in prostate cancer cells.	PT-observation	subj_) subj_identified subj_expression subj_GLIPR1 subj_regulated subj_human subj_prostate obj_regulatory obj_region obj_gene obj_prostate cancer obj_cells
20504320	In aggregate, these studies support the notion that TGF-beta plays an important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-beta signaling results in a therapeutic effect independently of the tissue-tropism of the metastatic cells.	CGE-decreased	subj_breast subj_cancer subj_inhibiting subj_TGF-beta subj_signaling subj_therapeutic subj_independently obj_lung obj_metastases obj_basal obj_breast cancer obj_inhibiting obj_TGF obj_beta
20504320	In aggregate, these studies support the notion that TGF-beta plays an important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-beta signaling results in a therapeutic effect independently of the tissue-tropism of the metastatic cells.	IGE-unidentifiable	subj_breast subj_cancer subj_inhibiting subj_TGF-beta subj_signaling subj_therapeutic subj_independently obj_lung obj_metastases obj_basal obj_breast cancer obj_inhibiting obj_TGF obj_beta
20504320	In aggregate, these studies support the notion that TGF-beta plays an important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-beta signaling results in a therapeutic effect independently of the tissue-tropism of the metastatic cells.	CCS-cancerTOnormal	subj_breast subj_cancer subj_inhibiting subj_TGF-beta subj_signaling subj_therapeutic subj_independently obj_lung obj_metastases obj_basal obj_breast cancer obj_inhibiting obj_TGF obj_beta
20504320	In aggregate, these studies support the notion that TGF-beta plays an important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-beta signaling results in a therapeutic effect independently of the tissue-tropism of the metastatic cells.	PT-causality	subj_breast subj_cancer subj_inhibiting subj_TGF-beta subj_signaling subj_therapeutic subj_independently obj_lung obj_metastases obj_basal obj_breast cancer obj_inhibiting obj_TGF obj_beta
20505730	Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours.	CGE-decreased	subj_Consistently subj_loss subj_CD95 subj_mouse subj_models subj_ovarian obj_CD95 obj_mouse obj_models obj_ovarian cancer obj_liver obj_cancer obj_reduces
20505730	Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours.	IGE-unidentifiable	subj_Consistently subj_loss subj_CD95 subj_mouse subj_models subj_ovarian obj_CD95 obj_mouse obj_models obj_ovarian cancer obj_liver obj_cancer obj_reduces
20505730	Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours.	CCS-cancerTOnormal	subj_Consistently subj_loss subj_CD95 subj_mouse subj_models subj_ovarian obj_CD95 obj_mouse obj_models obj_ovarian cancer obj_liver obj_cancer obj_reduces
20505730	Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours.	PT-causality	subj_Consistently subj_loss subj_CD95 subj_mouse subj_models subj_ovarian obj_CD95 obj_mouse obj_models obj_ovarian cancer obj_liver obj_cancer obj_reduces
20525379	AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.	CGE-decreased	subj_AGR2 subj_knockdown subj_induced subj_cell obj_induced obj_cell obj_death obj_ZR-75-1 obj_T47 obj_D obj_cells
20525379	AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.	IGE-unidentifiable	subj_AGR2 subj_knockdown subj_induced subj_cell obj_induced obj_cell obj_death obj_ZR-75-1 obj_T47 obj_D obj_cells
20525379	AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.	CCS-cancerTOnormal	subj_AGR2 subj_knockdown subj_induced subj_cell obj_induced obj_cell obj_death obj_ZR-75-1 obj_T47 obj_D obj_cells
20525379	AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.	PT-causality	subj_AGR2 subj_knockdown subj_induced subj_cell obj_induced obj_cell obj_death obj_ZR-75-1 obj_T47 obj_D obj_cells
20535861	The synergistic action of unopposed oestrogen and leptin, compounded by increasing insulin, cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and breast cancer.	CGE-increased	subj_leptin subj_compounded subj_increasing subj_insulin subj_cortisol subj_xeno subj_oestrogen obj_enlargement obj_prostate obj_cancer obj_breast cancer
20535861	The synergistic action of unopposed oestrogen and leptin, compounded by increasing insulin, cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and breast cancer.	IGE-unidentifiable	subj_leptin subj_compounded subj_increasing subj_insulin subj_cortisol subj_xeno subj_oestrogen obj_enlargement obj_prostate obj_cancer obj_breast cancer
20535861	The synergistic action of unopposed oestrogen and leptin, compounded by increasing insulin, cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and breast cancer.	CCS-normalTOcancer	subj_leptin subj_compounded subj_increasing subj_insulin subj_cortisol subj_xeno subj_oestrogen obj_enlargement obj_prostate obj_cancer obj_breast cancer
20535861	The synergistic action of unopposed oestrogen and leptin, compounded by increasing insulin, cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and breast cancer.	PT-causality	subj_leptin subj_compounded subj_increasing subj_insulin subj_cortisol subj_xeno subj_oestrogen obj_enlargement obj_prostate obj_cancer obj_breast cancer
20536410	The findings of the present study suggest that COX-2 overexpression in lobular and ductal breast cancers, which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.	CGE-increased	subj_findings subj_study subj_COX-2 subj_overexpression subj_lobular subj_ductal obj_COX-2 obj_overexpression obj_lobular obj_ductal breast cancers obj_correlates obj_traditional obj_clinico
20536410	The findings of the present study suggest that COX-2 overexpression in lobular and ductal breast cancers, which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.	IGE-unchanged	subj_findings subj_study subj_COX-2 subj_overexpression subj_lobular subj_ductal obj_COX-2 obj_overexpression obj_lobular obj_ductal breast cancers obj_correlates obj_traditional obj_clinico
20536410	The findings of the present study suggest that COX-2 overexpression in lobular and ductal breast cancers, which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.	CCS-normalTOcancer	subj_findings subj_study subj_COX-2 subj_overexpression subj_lobular subj_ductal obj_COX-2 obj_overexpression obj_lobular obj_ductal breast cancers obj_correlates obj_traditional obj_clinico
20536410	The findings of the present study suggest that COX-2 overexpression in lobular and ductal breast cancers, which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.	PT-observation	subj_findings subj_study subj_COX-2 subj_overexpression subj_lobular subj_ductal obj_COX-2 obj_overexpression obj_lobular obj_ductal breast cancers obj_correlates obj_traditional obj_clinico
20622894	The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest.	CGE-increased	subj_knockdown subj_led subj_upregulation subj_p21 subj_and/or subj_decrease subj_survivin obj_proliferation obj_human obj_HER2-positive obj_breast cancer obj_lines obj_requires obj_HSF1
20622894	The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest.	IGE-unidentifiable	subj_knockdown subj_led subj_upregulation subj_p21 subj_and/or subj_decrease subj_survivin obj_proliferation obj_human obj_HER2-positive obj_breast cancer obj_lines obj_requires obj_HSF1
20622894	The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest.	CCS-cancerTOnormal	subj_knockdown subj_led subj_upregulation subj_p21 subj_and/or subj_decrease subj_survivin obj_proliferation obj_human obj_HER2-positive obj_breast cancer obj_lines obj_requires obj_HSF1
20622894	The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest.	PT-causality	subj_knockdown subj_led subj_upregulation subj_p21 subj_and/or subj_decrease subj_survivin obj_proliferation obj_human obj_HER2-positive obj_breast cancer obj_lines obj_requires obj_HSF1
20630060	In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in MDA-MB-231 human breast cancer cells.	CGE-increased	subj_antagonist subj_induced subj_activation subj_caspase-3 subj_MDA subj_MB-231 subj_human obj_MDA obj_MB-231 obj_human obj_breast cancer obj_cells
20630060	In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in MDA-MB-231 human breast cancer cells.	IGE-	subj_antagonist subj_induced subj_activation subj_caspase-3 subj_MDA subj_MB-231 subj_human obj_MDA obj_MB-231 obj_human obj_breast cancer obj_cells
20630060	In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in MDA-MB-231 human breast cancer cells.	CCS-unidentifiable	subj_antagonist subj_induced subj_activation subj_caspase-3 subj_MDA subj_MB-231 subj_human obj_MDA obj_MB-231 obj_human obj_breast cancer obj_cells
20630060	In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in MDA-MB-231 human breast cancer cells.	PT-	subj_antagonist subj_induced subj_activation subj_caspase-3 subj_MDA subj_MB-231 subj_human obj_MDA obj_MB-231 obj_human obj_breast cancer obj_cells
20635137	GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.	CGE-increased	subj_GRB7 protein subj_expression subj_independent subj_adverse obj_prognostic obj_factor obj_human obj_breast cancer
20635137	GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.	IGE-unchanged	subj_GRB7 protein subj_expression subj_independent subj_adverse obj_prognostic obj_factor obj_human obj_breast cancer
20635137	GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.	CCS-normalTOcancer	subj_GRB7 protein subj_expression subj_independent subj_adverse obj_prognostic obj_factor obj_human obj_breast cancer
20635137	GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.	PT-observation	subj_GRB7 protein subj_expression subj_independent subj_adverse obj_prognostic obj_factor obj_human obj_breast cancer
20657552	Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.	CGE-increased	subj_expression subj_CD146 subj_cell subj_adhesion subj_molecule obj_melanoma obj_prostate obj_cancer obj_ovarian cancer
20657552	Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.	IGE-unidentifiable	subj_expression subj_CD146 subj_cell subj_adhesion subj_molecule obj_melanoma obj_prostate obj_cancer obj_ovarian cancer
20657552	Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.	CCS-normalTOcancer	subj_expression subj_CD146 subj_cell subj_adhesion subj_molecule obj_melanoma obj_prostate obj_cancer obj_ovarian cancer
20657552	Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.	PT-observation	subj_expression subj_CD146 subj_cell subj_adhesion subj_molecule obj_melanoma obj_prostate obj_cancer obj_ovarian cancer
20711231	Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.	CGE-decreased	subj_formation subj_downregulation subj_Erk subj_Akt subj_signaling subj_vivo obj_Finally obj_ErbB2-amplified obj_breast cancer obj_cells obj_expressing obj_specific
20711231	Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.	IGE-unidentifiable	subj_formation subj_downregulation subj_Erk subj_Akt subj_signaling subj_vivo obj_Finally obj_ErbB2-amplified obj_breast cancer obj_cells obj_expressing obj_specific
20711231	Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.	CCS-cancerTOnormal	subj_formation subj_downregulation subj_Erk subj_Akt subj_signaling subj_vivo obj_Finally obj_ErbB2-amplified obj_breast cancer obj_cells obj_expressing obj_specific
20711231	Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.	PT-observation	subj_formation subj_downregulation subj_Erk subj_Akt subj_signaling subj_vivo obj_Finally obj_ErbB2-amplified obj_breast cancer obj_cells obj_expressing obj_specific
20718682	Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.	CGE-increased	subj_Preoperatively subj_elevated subj_thyroglobulin subj_( subj_Tg subj_) obj_oncologist obj_surgical obj_management obj_malignant ovarian teratoma
20718682	Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.	IGE-	subj_Preoperatively subj_elevated subj_thyroglobulin subj_( subj_Tg subj_) obj_oncologist obj_surgical obj_management obj_malignant ovarian teratoma
20718682	Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.	CCS-unidentifiable	subj_Preoperatively subj_elevated subj_thyroglobulin subj_( subj_Tg subj_) obj_oncologist obj_surgical obj_management obj_malignant ovarian teratoma
20718682	Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.	PT-	subj_Preoperatively subj_elevated subj_thyroglobulin subj_( subj_Tg subj_) obj_oncologist obj_surgical obj_management obj_malignant ovarian teratoma
20736065	Selective inhibition of human 3-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.	CGE-decreased	subj_inhibition subj_human 3-hydroxysteroid dehydrogenase type 1 subj_potential subj_treatment subj_breast obj_1 obj_potential obj_treatment obj_breast cancer obj_
20736065	Selective inhibition of human 3-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.	IGE-unidentifiable	subj_inhibition subj_human 3-hydroxysteroid dehydrogenase type 1 subj_potential subj_treatment subj_breast obj_1 obj_potential obj_treatment obj_breast cancer obj_
20736065	Selective inhibition of human 3-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.	CCS-cancerTOnormal	subj_inhibition subj_human 3-hydroxysteroid dehydrogenase type 1 subj_potential subj_treatment subj_breast obj_1 obj_potential obj_treatment obj_breast cancer obj_
20736065	Selective inhibition of human 3-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.	PT-causality	subj_inhibition subj_human 3-hydroxysteroid dehydrogenase type 1 subj_potential subj_treatment subj_breast obj_1 obj_potential obj_treatment obj_breast cancer obj_
20853062	Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).	CGE-decreased	subj_estrogen subj_receptor subj_( subj_ER subj_) subj_progesterone subj_receptor obj_( obj_TN obj_) obj_breast cancers obj_lack obj_estrogen obj_receptor
20853062	Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).	IGE-unidentifiable	subj_estrogen subj_receptor subj_( subj_ER subj_) subj_progesterone subj_receptor obj_( obj_TN obj_) obj_breast cancers obj_lack obj_estrogen obj_receptor
20853062	Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).	CCS-normalTOcancer	subj_estrogen subj_receptor subj_( subj_ER subj_) subj_progesterone subj_receptor obj_( obj_TN obj_) obj_breast cancers obj_lack obj_estrogen obj_receptor
20853062	Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).	PT-observation	subj_estrogen subj_receptor subj_( subj_ER subj_) subj_progesterone subj_receptor obj_( obj_TN obj_) obj_breast cancers obj_lack obj_estrogen obj_receptor
20873592	Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05).	CGE-decreased	subj_let-7 subj_decreased subj_expressions subj_miR-96 subj_miR-182 subj_miR-183 subj_statistically obj_Compared obj_BPH obj_PCa obj_patients obj_decreased
20873592	Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05).	IGE-unidentifiable	subj_let-7 subj_decreased subj_expressions subj_miR-96 subj_miR-182 subj_miR-183 subj_statistically obj_Compared obj_BPH obj_PCa obj_patients obj_decreased
20873592	Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05).	CCS-normalTOcancer	subj_let-7 subj_decreased subj_expressions subj_miR-96 subj_miR-182 subj_miR-183 subj_statistically obj_Compared obj_BPH obj_PCa obj_patients obj_decreased
20873592	Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05).	PT-observation	subj_let-7 subj_decreased subj_expressions subj_miR-96 subj_miR-182 subj_miR-183 subj_statistically obj_Compared obj_BPH obj_PCa obj_patients obj_decreased
20878528	In the parental HEY cell line, additional treatment with the PPAR ligands led to an increased protein expression of DR5 and a further decline of XIAP expression.	CGE-increased	subj_increased subj_protein subj_expression subj_DR5 subj_decline subj_XIAP subj_expression obj_In obj_parental obj_HEY obj_cell obj_additional obj_treatment
20878528	In the parental HEY cell line, additional treatment with the PPAR ligands led to an increased protein expression of DR5 and a further decline of XIAP expression.	IGE-	subj_increased subj_protein subj_expression subj_DR5 subj_decline subj_XIAP subj_expression obj_In obj_parental obj_HEY obj_cell obj_additional obj_treatment
20878528	In the parental HEY cell line, additional treatment with the PPAR ligands led to an increased protein expression of DR5 and a further decline of XIAP expression.	CCS-unidentifiable	subj_increased subj_protein subj_expression subj_DR5 subj_decline subj_XIAP subj_expression obj_In obj_parental obj_HEY obj_cell obj_additional obj_treatment
20878528	In the parental HEY cell line, additional treatment with the PPAR ligands led to an increased protein expression of DR5 and a further decline of XIAP expression.	PT-	subj_increased subj_protein subj_expression subj_DR5 subj_decline subj_XIAP subj_expression obj_In obj_parental obj_HEY obj_cell obj_additional obj_treatment
21070441	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	CGE-increased	subj_breast subj_cancer subj_overexpressing subj_Her-2/neu subj_radiation subj_concurrent subj_Lapatinib obj_response obj_brain obj_metastases obj_breast cancer obj_overexpressing obj_Her-2/neu obj_radiation
21070441	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	IGE-unidentifiable	subj_breast subj_cancer subj_overexpressing subj_Her-2/neu subj_radiation subj_concurrent subj_Lapatinib obj_response obj_brain obj_metastases obj_breast cancer obj_overexpressing obj_Her-2/neu obj_radiation
21070441	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	CCS-normalTOcancer	subj_breast subj_cancer subj_overexpressing subj_Her-2/neu subj_radiation subj_concurrent subj_Lapatinib obj_response obj_brain obj_metastases obj_breast cancer obj_overexpressing obj_Her-2/neu obj_radiation
21070441	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	PT-observation	subj_breast subj_cancer subj_overexpressing subj_Her-2/neu subj_radiation subj_concurrent subj_Lapatinib obj_response obj_brain obj_metastases obj_breast cancer obj_overexpressing obj_Her-2/neu obj_radiation
21099103	show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease.	CGE-decreased	subj_Sharma subj_RB1 subj_loss subj_late subj_event obj_late obj_event obj_human obj_prostate cancer obj_coincident obj_emergence obj_castrate
21099103	show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease.	IGE-unidentifiable	subj_Sharma subj_RB1 subj_loss subj_late subj_event obj_late obj_event obj_human obj_prostate cancer obj_coincident obj_emergence obj_castrate
21099103	show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease.	CCS-normalTOcancer	subj_Sharma subj_RB1 subj_loss subj_late subj_event obj_late obj_event obj_human obj_prostate cancer obj_coincident obj_emergence obj_castrate
21099103	show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease.	PT-observation	subj_Sharma subj_RB1 subj_loss subj_late subj_event obj_late obj_event obj_human obj_prostate cancer obj_coincident obj_emergence obj_castrate
21119365	In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011).	CGE-increased	subj_addition subj_Ang-2 subj_levels subj_patients subj_ovarian obj_< obj_0.0005 obj_) obj_borderline ovarian tumors obj_( obj_P obj_=
21119365	In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011).	IGE-unidentifiable	subj_addition subj_Ang-2 subj_levels subj_patients subj_ovarian obj_< obj_0.0005 obj_) obj_borderline ovarian tumors obj_( obj_P obj_=
21119365	In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011).	CCS-normalTOcancer	subj_addition subj_Ang-2 subj_levels subj_patients subj_ovarian obj_< obj_0.0005 obj_) obj_borderline ovarian tumors obj_( obj_P obj_=
21119365	In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011).	PT-observation	subj_addition subj_Ang-2 subj_levels subj_patients subj_ovarian obj_< obj_0.0005 obj_) obj_borderline ovarian tumors obj_( obj_P obj_=
21125667	Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome.	CGE-increased	subj_Up subj_regulated subj_expression subj_AR subj_GRP78 subj_expression subj_untreated obj_GRP78 obj_expression obj_untreated obj_prostate cancer obj_predicts obj_favourable obj_outcome
21125667	Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome.	IGE-unidentifiable	subj_Up subj_regulated subj_expression subj_AR subj_GRP78 subj_expression subj_untreated obj_GRP78 obj_expression obj_untreated obj_prostate cancer obj_predicts obj_favourable obj_outcome
21125667	Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome.	CCS-normalTOcancer	subj_Up subj_regulated subj_expression subj_AR subj_GRP78 subj_expression subj_untreated obj_GRP78 obj_expression obj_untreated obj_prostate cancer obj_predicts obj_favourable obj_outcome
21125667	Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome.	PT-observation	subj_Up subj_regulated subj_expression subj_AR subj_GRP78 subj_expression subj_untreated obj_GRP78 obj_expression obj_untreated obj_prostate cancer obj_predicts obj_favourable obj_outcome
21176537	down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human breast cancer cell line in nude mice.	CGE-decreased	subj_BCSG1-siRNA subj_regulates subj_expression subj_BCSG1 subj_inhibits subj_effectively subj_growth obj_growth obj_transplaned obj_human obj_breast cancer obj_cell obj_nude obj_mice
21176537	down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human breast cancer cell line in nude mice.	IGE-unidentifiable	subj_BCSG1-siRNA subj_regulates subj_expression subj_BCSG1 subj_inhibits subj_effectively subj_growth obj_growth obj_transplaned obj_human obj_breast cancer obj_cell obj_nude obj_mice
21176537	down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human breast cancer cell line in nude mice.	CCS-cancerTOnormal	subj_BCSG1-siRNA subj_regulates subj_expression subj_BCSG1 subj_inhibits subj_effectively subj_growth obj_growth obj_transplaned obj_human obj_breast cancer obj_cell obj_nude obj_mice
21176537	down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human breast cancer cell line in nude mice.	PT-observation	subj_BCSG1-siRNA subj_regulates subj_expression subj_BCSG1 subj_inhibits subj_effectively subj_growth obj_growth obj_transplaned obj_human obj_breast cancer obj_cell obj_nude obj_mice
21247495	BACKGROUND: Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients.	CGE-increased	subj_: subj_Osteopontin subj_( subj_OPN subj_) obj_blood obj_primary obj_tumors obj_breast cancer obj_patients
21247495	BACKGROUND: Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients.	IGE-unchanged	subj_: subj_Osteopontin subj_( subj_OPN subj_) obj_blood obj_primary obj_tumors obj_breast cancer obj_patients
21247495	BACKGROUND: Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients.	CCS-normalTOcancer	subj_: subj_Osteopontin subj_( subj_OPN subj_) obj_blood obj_primary obj_tumors obj_breast cancer obj_patients
21247495	BACKGROUND: Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients.	PT-observation	subj_: subj_Osteopontin subj_( subj_OPN subj_) obj_blood obj_primary obj_tumors obj_breast cancer obj_patients
21263452	Increased levels of plasma haemoxygenase-1 in prostate cancer.	CGE-increased	subj_levels subj_plasma haemoxygenase-1 subj_prostate subj_cancer subj_ obj_levels obj_plasma obj_haemoxygenase-1 obj_prostate cancer obj_
21263452	Increased levels of plasma haemoxygenase-1 in prostate cancer.	IGE-unchanged	subj_levels subj_plasma haemoxygenase-1 subj_prostate subj_cancer subj_ obj_levels obj_plasma obj_haemoxygenase-1 obj_prostate cancer obj_
21263452	Increased levels of plasma haemoxygenase-1 in prostate cancer.	CCS-normalTOcancer	subj_levels subj_plasma haemoxygenase-1 subj_prostate subj_cancer subj_ obj_levels obj_plasma obj_haemoxygenase-1 obj_prostate cancer obj_
21263452	Increased levels of plasma haemoxygenase-1 in prostate cancer.	PT-observation	subj_levels subj_plasma haemoxygenase-1 subj_prostate subj_cancer subj_ obj_levels obj_plasma obj_haemoxygenase-1 obj_prostate cancer obj_
21320357	EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.	CGE-increased	subj_EPCR subj_expression subj_regulated subj_mRNA obj_levels obj_invasive obj_prostate obj_DU-145 obj_PC-3 obj_cells obj_comparison
21320357	EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.	IGE-unchanged	subj_EPCR subj_expression subj_regulated subj_mRNA obj_levels obj_invasive obj_prostate obj_DU-145 obj_PC-3 obj_cells obj_comparison
21320357	EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.	CCS-normalTOcancer	subj_EPCR subj_expression subj_regulated subj_mRNA obj_levels obj_invasive obj_prostate obj_DU-145 obj_PC-3 obj_cells obj_comparison
21320357	EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.	PT-observation	subj_EPCR subj_expression subj_regulated subj_mRNA obj_levels obj_invasive obj_prostate obj_DU-145 obj_PC-3 obj_cells obj_comparison
21323863	Targeting and down-regulation of ErbB2, a member of EGF receptor family, is regarded as one of the key aspect for cancer treatment because it is often overexpressed in breast and ovarian cancer cells.	CGE-increased	subj_Targeting subj_regulation subj_ErbB2 subj_EGF subj_receptor subj_family obj_treatment obj_overexpressed obj_breast obj_ovarian cancer obj_cells
21323863	Targeting and down-regulation of ErbB2, a member of EGF receptor family, is regarded as one of the key aspect for cancer treatment because it is often overexpressed in breast and ovarian cancer cells.	IGE-unchanged	subj_Targeting subj_regulation subj_ErbB2 subj_EGF subj_receptor subj_family obj_treatment obj_overexpressed obj_breast obj_ovarian cancer obj_cells
21323863	Targeting and down-regulation of ErbB2, a member of EGF receptor family, is regarded as one of the key aspect for cancer treatment because it is often overexpressed in breast and ovarian cancer cells.	CCS-normalTOcancer	subj_Targeting subj_regulation subj_ErbB2 subj_EGF subj_receptor subj_family obj_treatment obj_overexpressed obj_breast obj_ovarian cancer obj_cells
21323863	Targeting and down-regulation of ErbB2, a member of EGF receptor family, is regarded as one of the key aspect for cancer treatment because it is often overexpressed in breast and ovarian cancer cells.	PT-observation	subj_Targeting subj_regulation subj_ErbB2 subj_EGF subj_receptor subj_family obj_treatment obj_overexpressed obj_breast obj_ovarian cancer obj_cells
21340838	Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2).	CGE-increased	subj_Amplification subj_overexpression subj_c-erbB-2 oncogene subj_( subj_HER-2 subj_neu obj_20 obj_30 obj_% obj_ovarian cancers obj_characterizes obj_patients obj_poor
21340838	Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2).	IGE-unchanged	subj_Amplification subj_overexpression subj_c-erbB-2 oncogene subj_( subj_HER-2 subj_neu obj_20 obj_30 obj_% obj_ovarian cancers obj_characterizes obj_patients obj_poor
21340838	Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2).	CCS-normalTOcancer	subj_Amplification subj_overexpression subj_c-erbB-2 oncogene subj_( subj_HER-2 subj_neu obj_20 obj_30 obj_% obj_ovarian cancers obj_characterizes obj_patients obj_poor
21340838	Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2).	PT-observation	subj_Amplification subj_overexpression subj_c-erbB-2 oncogene subj_( subj_HER-2 subj_neu obj_20 obj_30 obj_% obj_ovarian cancers obj_characterizes obj_patients obj_poor
21400218	Its stimulation on breast cancer cell lines induces 1 integrin and promotes tumor invasiveness.	CGE-increased	subj_cell subj_lines subj_induces subj_1 integrin subj_promotes subj_tumor subj_invasiveness obj_stimulation obj_breast cancer obj_cell obj_lines obj_induces
21400218	Its stimulation on breast cancer cell lines induces 1 integrin and promotes tumor invasiveness.	IGE-unidentifiable	subj_cell subj_lines subj_induces subj_1 integrin subj_promotes subj_tumor subj_invasiveness obj_stimulation obj_breast cancer obj_cell obj_lines obj_induces
21400218	Its stimulation on breast cancer cell lines induces 1 integrin and promotes tumor invasiveness.	CCS-normalTOcancer	subj_cell subj_lines subj_induces subj_1 integrin subj_promotes subj_tumor subj_invasiveness obj_stimulation obj_breast cancer obj_cell obj_lines obj_induces
21400218	Its stimulation on breast cancer cell lines induces 1 integrin and promotes tumor invasiveness.	PT-observation	subj_cell subj_lines subj_induces subj_1 integrin subj_promotes subj_tumor subj_invasiveness obj_stimulation obj_breast cancer obj_cell obj_lines obj_induces
21415100	In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.	CGE-decreased	subj_entry subj_reduced subj_expression subj_Orai1 subj_mRNA subj_protein subj_levels obj_apoptosis obj_resistant obj_properties obj_DU145 obj_cells obj_decreased obj_function
21415100	In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.	IGE-unidentifiable	subj_entry subj_reduced subj_expression subj_Orai1 subj_mRNA subj_protein subj_levels obj_apoptosis obj_resistant obj_properties obj_DU145 obj_cells obj_decreased obj_function
21415100	In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.	CCS-normalTOcancer	subj_entry subj_reduced subj_expression subj_Orai1 subj_mRNA subj_protein subj_levels obj_apoptosis obj_resistant obj_properties obj_DU145 obj_cells obj_decreased obj_function
21415100	In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.	PT-observation	subj_entry subj_reduced subj_expression subj_Orai1 subj_mRNA subj_protein subj_levels obj_apoptosis obj_resistant obj_properties obj_DU145 obj_cells obj_decreased obj_function
21436696	Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma.	CGE-decreased	subj_protein subj_expression subj_TSLC1 gene subj_conferring subj_aggressive subj_behavior obj_conferring obj_aggressive obj_behavior obj_ovarian carcinoma
21436696	Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma.	IGE-unidentifiable	subj_protein subj_expression subj_TSLC1 gene subj_conferring subj_aggressive subj_behavior obj_conferring obj_aggressive obj_behavior obj_ovarian carcinoma
21436696	Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma.	CCS-normalTOcancer	subj_protein subj_expression subj_TSLC1 gene subj_conferring subj_aggressive subj_behavior obj_conferring obj_aggressive obj_behavior obj_ovarian carcinoma
21436696	Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma.	PT-causality	subj_protein subj_expression subj_TSLC1 gene subj_conferring subj_aggressive subj_behavior obj_conferring obj_aggressive obj_behavior obj_ovarian carcinoma
21479359	Our findings demonstrate the efficacy of LA in upregulating E-cadherin, - and -catenin in LNCaP cells.	CGE-increased	subj_E subj_cadherin subj_- subj_-catenin subj_LNCaP subj_cells obj_cadherin obj_- obj_-catenin obj_LNCaP obj_cells
21479359	Our findings demonstrate the efficacy of LA in upregulating E-cadherin, - and -catenin in LNCaP cells.	IGE-	subj_E subj_cadherin subj_- subj_-catenin subj_LNCaP subj_cells obj_cadherin obj_- obj_-catenin obj_LNCaP obj_cells
21479359	Our findings demonstrate the efficacy of LA in upregulating E-cadherin, - and -catenin in LNCaP cells.	CCS-unidentifiable	subj_E subj_cadherin subj_- subj_-catenin subj_LNCaP subj_cells obj_cadherin obj_- obj_-catenin obj_LNCaP obj_cells
21479359	Our findings demonstrate the efficacy of LA in upregulating E-cadherin, - and -catenin in LNCaP cells.	PT-	subj_E subj_cadherin subj_- subj_-catenin subj_LNCaP subj_cells obj_cadherin obj_- obj_-catenin obj_LNCaP obj_cells
21539834	Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers.	CGE-increased	subj_Cyclin E subj_overexpressed subj_breast subj_lung obj_skin obj_gastrointestinal obj_cervical obj_ovarian cancers
21539834	Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers.	IGE-unchanged	subj_Cyclin E subj_overexpressed subj_breast subj_lung obj_skin obj_gastrointestinal obj_cervical obj_ovarian cancers
21539834	Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers.	CCS-normalTOcancer	subj_Cyclin E subj_overexpressed subj_breast subj_lung obj_skin obj_gastrointestinal obj_cervical obj_ovarian cancers
21539834	Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers.	PT-observation	subj_Cyclin E subj_overexpressed subj_breast subj_lung obj_skin obj_gastrointestinal obj_cervical obj_ovarian cancers
21607411	In 60% of breast cancers, the pp60(c-src) level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.	CGE-increased	subj_% subj_breast subj_cancers subj_pp60(c-src) subj_level subj_increased subj_reaction obj_60 obj_% obj_breast cancers obj_pp60(c obj_src obj_)
21607411	In 60% of breast cancers, the pp60(c-src) level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.	IGE-unidentifiable	subj_% subj_breast subj_cancers subj_pp60(c-src) subj_level subj_increased subj_reaction obj_60 obj_% obj_breast cancers obj_pp60(c obj_src obj_)
21607411	In 60% of breast cancers, the pp60(c-src) level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.	CCS-normalTOcancer	subj_% subj_breast subj_cancers subj_pp60(c-src) subj_level subj_increased subj_reaction obj_60 obj_% obj_breast cancers obj_pp60(c obj_src obj_)
21607411	In 60% of breast cancers, the pp60(c-src) level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.	PT-observation	subj_% subj_breast subj_cancers subj_pp60(c-src) subj_level subj_increased subj_reaction obj_60 obj_% obj_breast cancers obj_pp60(c obj_src obj_)
21643005	Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells.	CGE-increased	subj_stimulate subj_promoter subj_activity subj_FASN subj_MCF-7 subj_cells obj_promoter obj_activity obj_FASN obj_MCF-7 obj_cells
21643005	Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells.	IGE-	subj_stimulate subj_promoter subj_activity subj_FASN subj_MCF-7 subj_cells obj_promoter obj_activity obj_FASN obj_MCF-7 obj_cells
21643005	Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells.	CCS-unidentifiable	subj_stimulate subj_promoter subj_activity subj_FASN subj_MCF-7 subj_cells obj_promoter obj_activity obj_FASN obj_MCF-7 obj_cells
21643005	Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells.	PT-	subj_stimulate subj_promoter subj_activity subj_FASN subj_MCF-7 subj_cells obj_promoter obj_activity obj_FASN obj_MCF-7 obj_cells
21695196	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.	CGE-increased	subj_specific subj_elevated subj_expression subj_hyaluronidase-1 subj_( subj_HYAL-1 subj_) obj_( obj_HYAL-1 obj_) obj_epithelial ovarian cancer obj_
21695196	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.	IGE-unchanged	subj_specific subj_elevated subj_expression subj_hyaluronidase-1 subj_( subj_HYAL-1 subj_) obj_( obj_HYAL-1 obj_) obj_epithelial ovarian cancer obj_
21695196	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.	CCS-normalTOcancer	subj_specific subj_elevated subj_expression subj_hyaluronidase-1 subj_( subj_HYAL-1 subj_) obj_( obj_HYAL-1 obj_) obj_epithelial ovarian cancer obj_
21695196	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.	PT-observation	subj_specific subj_elevated subj_expression subj_hyaluronidase-1 subj_( subj_HYAL-1 subj_) obj_( obj_HYAL-1 obj_) obj_epithelial ovarian cancer obj_
21740819	This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells.	CGE-decreased	subj_VEGF subj_A subj_decrease subj_VEGF-A subj_expression subj_inhibit subj_cell obj_cell obj_migration obj_SKOV3 obj_ovarian cancer obj_cells
21740819	This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells.	IGE-unidentifiable	subj_VEGF subj_A subj_decrease subj_VEGF-A subj_expression subj_inhibit subj_cell obj_cell obj_migration obj_SKOV3 obj_ovarian cancer obj_cells
21740819	This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells.	CCS-cancerTOnormal	subj_VEGF subj_A subj_decrease subj_VEGF-A subj_expression subj_inhibit subj_cell obj_cell obj_migration obj_SKOV3 obj_ovarian cancer obj_cells
21740819	This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells.	PT-observation	subj_VEGF subj_A subj_decrease subj_VEGF-A subj_expression subj_inhibit subj_cell obj_cell obj_migration obj_SKOV3 obj_ovarian cancer obj_cells
21789713	Combined inhibition of the PKA and NF-B signaling pathways via inhibition of PKA and Akt induced significant apoptosis and dramatically reduced clonogenic potential, outperforming docetaxel, the standard of care treatment for CR CaP. Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p=0.002).	CGE-increased	subj_neoplasia subj_CaP subj_determined subj_RLN2 subj_upregulated subj_CaP subj_BPH obj_( obj_BPH obj_) obj_prostatic intraepithelial neoplasia obj_CaP obj_determined obj_RLN2
21789713	Combined inhibition of the PKA and NF-B signaling pathways via inhibition of PKA and Akt induced significant apoptosis and dramatically reduced clonogenic potential, outperforming docetaxel, the standard of care treatment for CR CaP. Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p=0.002).	IGE-unidentifiable	subj_neoplasia subj_CaP subj_determined subj_RLN2 subj_upregulated subj_CaP subj_BPH obj_( obj_BPH obj_) obj_prostatic intraepithelial neoplasia obj_CaP obj_determined obj_RLN2
21789713	Combined inhibition of the PKA and NF-B signaling pathways via inhibition of PKA and Akt induced significant apoptosis and dramatically reduced clonogenic potential, outperforming docetaxel, the standard of care treatment for CR CaP. Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p=0.002).	CCS-normalTOcancer	subj_neoplasia subj_CaP subj_determined subj_RLN2 subj_upregulated subj_CaP subj_BPH obj_( obj_BPH obj_) obj_prostatic intraepithelial neoplasia obj_CaP obj_determined obj_RLN2
21789713	Combined inhibition of the PKA and NF-B signaling pathways via inhibition of PKA and Akt induced significant apoptosis and dramatically reduced clonogenic potential, outperforming docetaxel, the standard of care treatment for CR CaP. Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p=0.002).	PT-observation	subj_neoplasia subj_CaP subj_determined subj_RLN2 subj_upregulated subj_CaP subj_BPH obj_( obj_BPH obj_) obj_prostatic intraepithelial neoplasia obj_CaP obj_determined obj_RLN2
21789787	The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.	CGE-increased	subj_The subj_increased subj_NTN1 subj_observed subj_cancerous subj_tissues obj_represent obj_candidate obj_biomarker obj_ovarian cancer
21789787	The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.	IGE-unchanged	subj_The subj_increased subj_NTN1 subj_observed subj_cancerous subj_tissues obj_represent obj_candidate obj_biomarker obj_ovarian cancer
21789787	The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.	CCS-normalTOcancer	subj_The subj_increased subj_NTN1 subj_observed subj_cancerous subj_tissues obj_represent obj_candidate obj_biomarker obj_ovarian cancer
21789787	The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.	PT-observation	subj_The subj_increased subj_NTN1 subj_observed subj_cancerous subj_tissues obj_represent obj_candidate obj_biomarker obj_ovarian cancer
21791629	About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression.	CGE-increased	subj_TMPRSS2-ERG subj_fusions subj_concurrent subj_ERG subj_overexpression obj_50 obj_% obj_prostate cancers obj_TMPRSS2-ERG obj_fusions obj_concurrent
21791629	About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression.	IGE-unchanged	subj_TMPRSS2-ERG subj_fusions subj_concurrent subj_ERG subj_overexpression obj_50 obj_% obj_prostate cancers obj_TMPRSS2-ERG obj_fusions obj_concurrent
21791629	About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression.	CCS-normalTOcancer	subj_TMPRSS2-ERG subj_fusions subj_concurrent subj_ERG subj_overexpression obj_50 obj_% obj_prostate cancers obj_TMPRSS2-ERG obj_fusions obj_concurrent
21791629	About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression.	PT-observation	subj_TMPRSS2-ERG subj_fusions subj_concurrent subj_ERG subj_overexpression obj_50 obj_% obj_prostate cancers obj_TMPRSS2-ERG obj_fusions obj_concurrent
21809344	Runx2 expression in C4-2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression.	CGE-increased	subj_synergized subj_AR subj_promote subj_PIP subj_expression subj_knockdown subj_T47D obj_PIP obj_expression obj_knockdown obj_T47D obj_BCa obj_cells obj_abrogated
21809344	Runx2 expression in C4-2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression.	IGE-	subj_synergized subj_AR subj_promote subj_PIP subj_expression subj_knockdown subj_T47D obj_PIP obj_expression obj_knockdown obj_T47D obj_BCa obj_cells obj_abrogated
21809344	Runx2 expression in C4-2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression.	CCS-unidentifiable	subj_synergized subj_AR subj_promote subj_PIP subj_expression subj_knockdown subj_T47D obj_PIP obj_expression obj_knockdown obj_T47D obj_BCa obj_cells obj_abrogated
21809344	Runx2 expression in C4-2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression.	PT-	subj_synergized subj_AR subj_promote subj_PIP subj_expression subj_knockdown subj_T47D obj_PIP obj_expression obj_knockdown obj_T47D obj_BCa obj_cells obj_abrogated
21855113	Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.	CGE-increased	subj_Scavenger receptor class A, member 3 subj_( subj_SCARA3 subj_) obj_PPC obj_) obj_compared obj_breast carcinoma obj_effusions obj_global obj_gene
21855113	Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.	IGE-	subj_Scavenger receptor class A, member 3 subj_( subj_SCARA3 subj_) obj_PPC obj_) obj_compared obj_breast carcinoma obj_effusions obj_global obj_gene
21855113	Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.	CCS-unidentifiable	subj_Scavenger receptor class A, member 3 subj_( subj_SCARA3 subj_) obj_PPC obj_) obj_compared obj_breast carcinoma obj_effusions obj_global obj_gene
21855113	Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.	PT-	subj_Scavenger receptor class A, member 3 subj_( subj_SCARA3 subj_) obj_PPC obj_) obj_compared obj_breast carcinoma obj_effusions obj_global obj_gene
21861338	R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.	CGE-increased	subj_equol subj_regulated subj_activation subj_estrogen receptor-alpha obj_motility obj_invasion obj_PC3 obj_DU145 obj_cells obj_strong obj_observed
21861338	R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.	IGE-unidentifiable	subj_equol subj_regulated subj_activation subj_estrogen receptor-alpha obj_motility obj_invasion obj_PC3 obj_DU145 obj_cells obj_strong obj_observed
21861338	R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.	CCS-cancerTOnormal	subj_equol subj_regulated subj_activation subj_estrogen receptor-alpha obj_motility obj_invasion obj_PC3 obj_DU145 obj_cells obj_strong obj_observed
21861338	R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.	PT-causality	subj_equol subj_regulated subj_activation subj_estrogen receptor-alpha obj_motility obj_invasion obj_PC3 obj_DU145 obj_cells obj_strong obj_observed
21923922	Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked EGF-stimulated p38 signaling.	CGE-increased	subj_p38 subj_MAPK subj_recapitulated subj_Brk subj_overexpression subj_HC11 subj_murine obj_MEC obj_Brk obj_knock obj_breast cancer obj_cells obj_blocked obj_EGF
21923922	Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked EGF-stimulated p38 signaling.	IGE-	subj_p38 subj_MAPK subj_recapitulated subj_Brk subj_overexpression subj_HC11 subj_murine obj_MEC obj_Brk obj_knock obj_breast cancer obj_cells obj_blocked obj_EGF
21923922	Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked EGF-stimulated p38 signaling.	CCS-unidentifiable	subj_p38 subj_MAPK subj_recapitulated subj_Brk subj_overexpression subj_HC11 subj_murine obj_MEC obj_Brk obj_knock obj_breast cancer obj_cells obj_blocked obj_EGF
21923922	Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked EGF-stimulated p38 signaling.	PT-	subj_p38 subj_MAPK subj_recapitulated subj_Brk subj_overexpression subj_HC11 subj_murine obj_MEC obj_Brk obj_knock obj_breast cancer obj_cells obj_blocked obj_EGF
21957230	Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.	CGE-increased	subj_p130cas subj_expression subj_poor subj_clinical obj_clinical obj_outcome obj_human obj_ovarian carcinoma obj_p130cas obj_gene obj_silencing
21957230	Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.	IGE-unchanged	subj_p130cas subj_expression subj_poor subj_clinical obj_clinical obj_outcome obj_human obj_ovarian carcinoma obj_p130cas obj_gene obj_silencing
21957230	Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.	CCS-normalTOcancer	subj_p130cas subj_expression subj_poor subj_clinical obj_clinical obj_outcome obj_human obj_ovarian carcinoma obj_p130cas obj_gene obj_silencing
21957230	Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.	PT-causality	subj_p130cas subj_expression subj_poor subj_clinical obj_clinical obj_outcome obj_human obj_ovarian carcinoma obj_p130cas obj_gene obj_silencing
21983172	We also observed a reduction of UBR1 protein levels in geldanamycin-treated mouse embryonic fibroblasts and human breast cancer cells, suggesting that UBR1 is an Hsp90 client.	CGE-decreased	subj_We subj_observed subj_reduction subj_UBR1 protein subj_levels subj_geldanamycin subj_treated obj_embryonic obj_fibroblasts obj_human obj_breast cancer obj_cells obj_suggesting obj_UBR1
21983172	We also observed a reduction of UBR1 protein levels in geldanamycin-treated mouse embryonic fibroblasts and human breast cancer cells, suggesting that UBR1 is an Hsp90 client.	IGE-unidentifiable	subj_We subj_observed subj_reduction subj_UBR1 protein subj_levels subj_geldanamycin subj_treated obj_embryonic obj_fibroblasts obj_human obj_breast cancer obj_cells obj_suggesting obj_UBR1
21983172	We also observed a reduction of UBR1 protein levels in geldanamycin-treated mouse embryonic fibroblasts and human breast cancer cells, suggesting that UBR1 is an Hsp90 client.	CCS-normalTOcancer	subj_We subj_observed subj_reduction subj_UBR1 protein subj_levels subj_geldanamycin subj_treated obj_embryonic obj_fibroblasts obj_human obj_breast cancer obj_cells obj_suggesting obj_UBR1
21983172	We also observed a reduction of UBR1 protein levels in geldanamycin-treated mouse embryonic fibroblasts and human breast cancer cells, suggesting that UBR1 is an Hsp90 client.	PT-observation	subj_We subj_observed subj_reduction subj_UBR1 protein subj_levels subj_geldanamycin subj_treated obj_embryonic obj_fibroblasts obj_human obj_breast cancer obj_cells obj_suggesting obj_UBR1
22001143	Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.	CGE-decreased	subj_cancer subj_effective subj_data subj_androgen receptor subj_expression subj_decreases subj_exposure obj_Anti obj_androgen obj_ovarian cancer obj_effective obj_data obj_androgen
22001143	Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.	IGE-	subj_cancer subj_effective subj_data subj_androgen receptor subj_expression subj_decreases subj_exposure obj_Anti obj_androgen obj_ovarian cancer obj_effective obj_data obj_androgen
22001143	Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.	CCS-unidentifiable	subj_cancer subj_effective subj_data subj_androgen receptor subj_expression subj_decreases subj_exposure obj_Anti obj_androgen obj_ovarian cancer obj_effective obj_data obj_androgen
22001143	Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.	PT-	subj_cancer subj_effective subj_data subj_androgen receptor subj_expression subj_decreases subj_exposure obj_Anti obj_androgen obj_ovarian cancer obj_effective obj_data obj_androgen
22027746	Expression level of vascular marker and HIF-1 in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner.	CGE-increased	subj_level subj_vascular subj_marker subj_HIF-1 subj_OVCAR-3 subj_increased subj_response obj_vascular obj_marker obj_HIF-1 obj_OVCAR-3 obj_increased obj_response obj_hCG
22027746	Expression level of vascular marker and HIF-1 in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner.	IGE-	subj_level subj_vascular subj_marker subj_HIF-1 subj_OVCAR-3 subj_increased subj_response obj_vascular obj_marker obj_HIF-1 obj_OVCAR-3 obj_increased obj_response obj_hCG
22027746	Expression level of vascular marker and HIF-1 in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner.	CCS-unidentifiable	subj_level subj_vascular subj_marker subj_HIF-1 subj_OVCAR-3 subj_increased subj_response obj_vascular obj_marker obj_HIF-1 obj_OVCAR-3 obj_increased obj_response obj_hCG
22027746	Expression level of vascular marker and HIF-1 in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner.	PT-	subj_level subj_vascular subj_marker subj_HIF-1 subj_OVCAR-3 subj_increased subj_response obj_vascular obj_marker obj_HIF-1 obj_OVCAR-3 obj_increased obj_response obj_hCG
22037875	Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy.	CGE-decreased	subj_study subj_combined subj_inhibition subj_Cyclin D1 subj_D3 subj_suitable subj_strategy obj_D3 obj_suitable obj_strategy obj_breast cancer obj_prevention obj_therapy
22037875	Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy.	IGE-	subj_study subj_combined subj_inhibition subj_Cyclin D1 subj_D3 subj_suitable subj_strategy obj_D3 obj_suitable obj_strategy obj_breast cancer obj_prevention obj_therapy
22037875	Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy.	CCS-unidentifiable	subj_study subj_combined subj_inhibition subj_Cyclin D1 subj_D3 subj_suitable subj_strategy obj_D3 obj_suitable obj_strategy obj_breast cancer obj_prevention obj_therapy
22037875	Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy.	PT-	subj_study subj_combined subj_inhibition subj_Cyclin D1 subj_D3 subj_suitable subj_strategy obj_D3 obj_suitable obj_strategy obj_breast cancer obj_prevention obj_therapy
22043900	We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.	CGE-increased	subj_PC3 subj_cells subj_expression subj_FAS subj_DR3 subj_increased subj_SW620 obj_DR3 obj_) obj_increased obj_PC3 obj_cells obj_expression obj_FAS
22043900	We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.	IGE-	subj_PC3 subj_cells subj_expression subj_FAS subj_DR3 subj_increased subj_SW620 obj_DR3 obj_) obj_increased obj_PC3 obj_cells obj_expression obj_FAS
22043900	We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.	CCS-unidentifiable	subj_PC3 subj_cells subj_expression subj_FAS subj_DR3 subj_increased subj_SW620 obj_DR3 obj_) obj_increased obj_PC3 obj_cells obj_expression obj_FAS
22043900	We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.	PT-	subj_PC3 subj_cells subj_expression subj_FAS subj_DR3 subj_increased subj_SW620 obj_DR3 obj_) obj_increased obj_PC3 obj_cells obj_expression obj_FAS
22116304	Our results indicated that hypoxia and L-mimosine modulated Btg2 and Ndrg1 at the transcriptional level, which is dependent on HIF-1. L-Mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.	CGE-increased	subj_Mimosine subj_enhanced subj_expression subj_Btg2 subj_Ndrg1 subj_attenuated subj_cell obj_proliferation obj_PC-3 obj_LNCaP obj_prostate carcinoma obj_cells
22116304	Our results indicated that hypoxia and L-mimosine modulated Btg2 and Ndrg1 at the transcriptional level, which is dependent on HIF-1. L-Mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.	IGE-unidentifiable	subj_Mimosine subj_enhanced subj_expression subj_Btg2 subj_Ndrg1 subj_attenuated subj_cell obj_proliferation obj_PC-3 obj_LNCaP obj_prostate carcinoma obj_cells
22116304	Our results indicated that hypoxia and L-mimosine modulated Btg2 and Ndrg1 at the transcriptional level, which is dependent on HIF-1. L-Mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.	CCS-cancerTOnormal	subj_Mimosine subj_enhanced subj_expression subj_Btg2 subj_Ndrg1 subj_attenuated subj_cell obj_proliferation obj_PC-3 obj_LNCaP obj_prostate carcinoma obj_cells
22116304	Our results indicated that hypoxia and L-mimosine modulated Btg2 and Ndrg1 at the transcriptional level, which is dependent on HIF-1. L-Mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.	PT-causality	subj_Mimosine subj_enhanced subj_expression subj_Btg2 subj_Ndrg1 subj_attenuated subj_cell obj_proliferation obj_PC-3 obj_LNCaP obj_prostate carcinoma obj_cells
22142513	The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.	CGE-decreased	subj_expression subj_programmed cell death 6 subj_( subj_PDCD6 subj_) obj_cancer obj_cell obj_lines obj_ovarian cancer obj_tissues obj_compared obj_normal
22142513	The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.	IGE-unchanged	subj_expression subj_programmed cell death 6 subj_( subj_PDCD6 subj_) obj_cancer obj_cell obj_lines obj_ovarian cancer obj_tissues obj_compared obj_normal
22142513	The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.	CCS-normalTOcancer	subj_expression subj_programmed cell death 6 subj_( subj_PDCD6 subj_) obj_cancer obj_cell obj_lines obj_ovarian cancer obj_tissues obj_compared obj_normal
22142513	The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.	PT-observation	subj_expression subj_programmed cell death 6 subj_( subj_PDCD6 subj_) obj_cancer obj_cell obj_lines obj_ovarian cancer obj_tissues obj_compared obj_normal
22179838	Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays.	CGE-decreased	subj_Experimentally subj_reducing subj_expression subj_SCRIB subj_short subj_hairpin subj_RNAs obj_reduces obj_growth obj_human obj_breast cancer obj_cells obj_xenograft obj_assays
22179838	Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays.	IGE-unidentifiable	subj_Experimentally subj_reducing subj_expression subj_SCRIB subj_short subj_hairpin subj_RNAs obj_reduces obj_growth obj_human obj_breast cancer obj_cells obj_xenograft obj_assays
22179838	Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays.	CCS-cancerTOnormal	subj_Experimentally subj_reducing subj_expression subj_SCRIB subj_short subj_hairpin subj_RNAs obj_reduces obj_growth obj_human obj_breast cancer obj_cells obj_xenograft obj_assays
22179838	Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays.	PT-causality	subj_Experimentally subj_reducing subj_expression subj_SCRIB subj_short subj_hairpin subj_RNAs obj_reduces obj_growth obj_human obj_breast cancer obj_cells obj_xenograft obj_assays
22199300	Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.	CGE-increased	subj_cancer subj_cells subj_transfected subj_EP4-siRNA subj_treatments subj_EP4 subj_antagonist obj_Prostate cancer obj_cells obj_transfected obj_EP4-siRNA
22199300	Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.	IGE-	subj_cancer subj_cells subj_transfected subj_EP4-siRNA subj_treatments subj_EP4 subj_antagonist obj_Prostate cancer obj_cells obj_transfected obj_EP4-siRNA
22199300	Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.	CCS-unidentifiable	subj_cancer subj_cells subj_transfected subj_EP4-siRNA subj_treatments subj_EP4 subj_antagonist obj_Prostate cancer obj_cells obj_transfected obj_EP4-siRNA
22199300	Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.	PT-	subj_cancer subj_cells subj_transfected subj_EP4-siRNA subj_treatments subj_EP4 subj_antagonist obj_Prostate cancer obj_cells obj_transfected obj_EP4-siRNA
22228571	RT-PCR and Western blot showed that the expressions of only c-Met and STAT3 decreased obviously in colon and breast cancer cells exposed to LS-7.	CGE-decreased	subj_blot subj_expressions subj_Met subj_STAT3 subj_decreased subj_colon subj_breast obj_STAT3 obj_decreased obj_colon obj_breast cancer obj_cells obj_exposed obj_LS-7
22228571	RT-PCR and Western blot showed that the expressions of only c-Met and STAT3 decreased obviously in colon and breast cancer cells exposed to LS-7.	IGE-	subj_blot subj_expressions subj_Met subj_STAT3 subj_decreased subj_colon subj_breast obj_STAT3 obj_decreased obj_colon obj_breast cancer obj_cells obj_exposed obj_LS-7
22228571	RT-PCR and Western blot showed that the expressions of only c-Met and STAT3 decreased obviously in colon and breast cancer cells exposed to LS-7.	CCS-unidentifiable	subj_blot subj_expressions subj_Met subj_STAT3 subj_decreased subj_colon subj_breast obj_STAT3 obj_decreased obj_colon obj_breast cancer obj_cells obj_exposed obj_LS-7
22228571	RT-PCR and Western blot showed that the expressions of only c-Met and STAT3 decreased obviously in colon and breast cancer cells exposed to LS-7.	PT-	subj_blot subj_expressions subj_Met subj_STAT3 subj_decreased subj_colon subj_breast obj_STAT3 obj_decreased obj_colon obj_breast cancer obj_cells obj_exposed obj_LS-7
22310293	miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL).	CGE-increased	subj_miR-9 subj_overexpressed subj_cancer subj_forms obj_tumours obj_hepatocellular obj_carcinomas obj_breast cancer obj_Hodgkin obj_lymphoma obj_(
22310293	miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL).	IGE-unchanged	subj_miR-9 subj_overexpressed subj_cancer subj_forms obj_tumours obj_hepatocellular obj_carcinomas obj_breast cancer obj_Hodgkin obj_lymphoma obj_(
22310293	miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL).	CCS-normalTOcancer	subj_miR-9 subj_overexpressed subj_cancer subj_forms obj_tumours obj_hepatocellular obj_carcinomas obj_breast cancer obj_Hodgkin obj_lymphoma obj_(
22310293	miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL).	PT-observation	subj_miR-9 subj_overexpressed subj_cancer subj_forms obj_tumours obj_hepatocellular obj_carcinomas obj_breast cancer obj_Hodgkin obj_lymphoma obj_(
22312289	Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.	CGE-decreased	subj_p16 subj_p21 subj_decrease subj_p27 subj_protein subj_expression subj_level obj_D1 obj_cyclin obj_E obj_ovarian cancer obj_cells obj_decrease obj_mRNA
22312289	Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.	IGE-	subj_p16 subj_p21 subj_decrease subj_p27 subj_protein subj_expression subj_level obj_D1 obj_cyclin obj_E obj_ovarian cancer obj_cells obj_decrease obj_mRNA
22312289	Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.	CCS-unidentifiable	subj_p16 subj_p21 subj_decrease subj_p27 subj_protein subj_expression subj_level obj_D1 obj_cyclin obj_E obj_ovarian cancer obj_cells obj_decrease obj_mRNA
22312289	Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.	PT-	subj_p16 subj_p21 subj_decrease subj_p27 subj_protein subj_expression subj_level obj_D1 obj_cyclin obj_E obj_ovarian cancer obj_cells obj_decrease obj_mRNA
22364742	Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven breast cancer, where IL6 loss significantly impairs tumorigenesis.	CGE-decreased	subj_ErbB2-driven subj_breast subj_cancer subj_IL6 subj_loss subj_impairs subj_tumorigenesis obj_mouse obj_model obj_ErbB2-driven obj_breast cancer obj_IL6 obj_loss obj_impairs
22364742	Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven breast cancer, where IL6 loss significantly impairs tumorigenesis.	IGE-unidentifiable	subj_ErbB2-driven subj_breast subj_cancer subj_IL6 subj_loss subj_impairs subj_tumorigenesis obj_mouse obj_model obj_ErbB2-driven obj_breast cancer obj_IL6 obj_loss obj_impairs
22364742	Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven breast cancer, where IL6 loss significantly impairs tumorigenesis.	CCS-cancerTOnormal	subj_ErbB2-driven subj_breast subj_cancer subj_IL6 subj_loss subj_impairs subj_tumorigenesis obj_mouse obj_model obj_ErbB2-driven obj_breast cancer obj_IL6 obj_loss obj_impairs
22364742	Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven breast cancer, where IL6 loss significantly impairs tumorigenesis.	PT-causality	subj_ErbB2-driven subj_breast subj_cancer subj_IL6 subj_loss subj_impairs subj_tumorigenesis obj_mouse obj_model obj_ErbB2-driven obj_breast cancer obj_IL6 obj_loss obj_impairs
2440556	Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.	CGE-increased	subj_therapeutic subj_implications subj_Increase subj_urokinase-type plasminogen activator gene subj_expression subj_human subj_lung obj_expression obj_human obj_lung obj_breast carcinomas obj_
2440556	Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.	IGE-unchanged	subj_therapeutic subj_implications subj_Increase subj_urokinase-type plasminogen activator gene subj_expression subj_human subj_lung obj_expression obj_human obj_lung obj_breast carcinomas obj_
2440556	Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.	CCS-normalTOcancer	subj_therapeutic subj_implications subj_Increase subj_urokinase-type plasminogen activator gene subj_expression subj_human subj_lung obj_expression obj_human obj_lung obj_breast carcinomas obj_
2440556	Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.	PT-observation	subj_therapeutic subj_implications subj_Increase subj_urokinase-type plasminogen activator gene subj_expression subj_human subj_lung obj_expression obj_human obj_lung obj_breast carcinomas obj_
2516715	In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells.	CGE-increased	subj_TAA subj_CEA subj_BCA-225 subj_HLA-DR subj_expression subj_T47D subj_MCF-7 obj_DR obj_expression obj_T47D obj_MCF-7 obj_cells
2516715	In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells.	IGE-	subj_TAA subj_CEA subj_BCA-225 subj_HLA-DR subj_expression subj_T47D subj_MCF-7 obj_DR obj_expression obj_T47D obj_MCF-7 obj_cells
2516715	In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells.	CCS-unidentifiable	subj_TAA subj_CEA subj_BCA-225 subj_HLA-DR subj_expression subj_T47D subj_MCF-7 obj_DR obj_expression obj_T47D obj_MCF-7 obj_cells
2516715	In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells.	PT-	subj_TAA subj_CEA subj_BCA-225 subj_HLA-DR subj_expression subj_T47D subj_MCF-7 obj_DR obj_expression obj_T47D obj_MCF-7 obj_cells
2521857	We now show that the MDA468 breast cancer cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and TGF-alpha mRNA.	CGE-increased	subj_accumulation subj_EGF subj_receptor subj_TGF-alpha mRNA obj_We obj_MDA468 obj_breast cancer obj_cells obj_express obj_mRNA
2521857	We now show that the MDA468 breast cancer cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and TGF-alpha mRNA.	IGE-unchanged	subj_accumulation subj_EGF subj_receptor subj_TGF-alpha mRNA obj_We obj_MDA468 obj_breast cancer obj_cells obj_express obj_mRNA
2521857	We now show that the MDA468 breast cancer cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and TGF-alpha mRNA.	CCS-normalTOcancer	subj_accumulation subj_EGF subj_receptor subj_TGF-alpha mRNA obj_We obj_MDA468 obj_breast cancer obj_cells obj_express obj_mRNA
2521857	We now show that the MDA468 breast cancer cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and TGF-alpha mRNA.	PT-observation	subj_accumulation subj_EGF subj_receptor subj_TGF-alpha mRNA obj_We obj_MDA468 obj_breast cancer obj_cells obj_express obj_mRNA
3298786	Enhanced Ha-ras expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in breast carcinomas ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.	CGE-increased	subj_Ha-ras subj_expression subj_documented subj_66 obj_normal obj_counterparts obj_levels obj_breast carcinomas obj_ranging obj_10.1 obj_50.4
3298786	Enhanced Ha-ras expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in breast carcinomas ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.	IGE-unchanged	subj_Ha-ras subj_expression subj_documented subj_66 obj_normal obj_counterparts obj_levels obj_breast carcinomas obj_ranging obj_10.1 obj_50.4
3298786	Enhanced Ha-ras expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in breast carcinomas ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.	CCS-normalTOcancer	subj_Ha-ras subj_expression subj_documented subj_66 obj_normal obj_counterparts obj_levels obj_breast carcinomas obj_ranging obj_10.1 obj_50.4
3298786	Enhanced Ha-ras expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in breast carcinomas ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.	PT-observation	subj_Ha-ras subj_expression subj_documented subj_66 obj_normal obj_counterparts obj_levels obj_breast carcinomas obj_ranging obj_10.1 obj_50.4
3465487	Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.	CGE-increased	subj_ovarian subj_tumor subj_marker subj_CA-125 subj_serum subj_healthy subj_subject obj_increases obj_concentration obj_ovarian tumor obj_marker obj_CA-125 obj_serum
3465487	Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.	IGE-unchanged	subj_ovarian subj_tumor subj_marker subj_CA-125 subj_serum subj_healthy subj_subject obj_increases obj_concentration obj_ovarian tumor obj_marker obj_CA-125 obj_serum
3465487	Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.	CCS-normalTOcancer	subj_ovarian subj_tumor subj_marker subj_CA-125 subj_serum subj_healthy subj_subject obj_increases obj_concentration obj_ovarian tumor obj_marker obj_CA-125 obj_serum
3465487	Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.	PT-observation	subj_ovarian subj_tumor subj_marker subj_CA-125 subj_serum subj_healthy subj_subject obj_increases obj_concentration obj_ovarian tumor obj_marker obj_CA-125 obj_serum
3524819	Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.	CGE-decreased	subj_clinicopathological subj_data subj_loss subj_H-ras-1 allele subj_breast subj_carcinoma subj_DNAs obj_H obj_ras-1 obj_allele obj_breast carcinoma obj_DNAs obj_linked obj_histological
3524819	Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.	IGE-unchanged	subj_clinicopathological subj_data subj_loss subj_H-ras-1 allele subj_breast subj_carcinoma subj_DNAs obj_H obj_ras-1 obj_allele obj_breast carcinoma obj_DNAs obj_linked obj_histological
3524819	Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.	CCS-normalTOcancer	subj_clinicopathological subj_data subj_loss subj_H-ras-1 allele subj_breast subj_carcinoma subj_DNAs obj_H obj_ras-1 obj_allele obj_breast carcinoma obj_DNAs obj_linked obj_histological
3524819	Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.	PT-observation	subj_clinicopathological subj_data subj_loss subj_H-ras-1 allele subj_breast subj_carcinoma subj_DNAs obj_H obj_ras-1 obj_allele obj_breast carcinoma obj_DNAs obj_linked obj_histological
7438115	These findings support the assumption that induction of PGR by estrogen in human breast cancer is mediated by a mechanism involving nuclear receptors.	CGE-increased	subj_support subj_assumption subj_induction subj_PGR subj_estrogen subj_human subj_breast obj_PGR obj_estrogen obj_human obj_breast cancer obj_mediated obj_mechanism obj_involving
7438115	These findings support the assumption that induction of PGR by estrogen in human breast cancer is mediated by a mechanism involving nuclear receptors.	IGE-	subj_support subj_assumption subj_induction subj_PGR subj_estrogen subj_human subj_breast obj_PGR obj_estrogen obj_human obj_breast cancer obj_mediated obj_mechanism obj_involving
7438115	These findings support the assumption that induction of PGR by estrogen in human breast cancer is mediated by a mechanism involving nuclear receptors.	CCS-unidentifiable	subj_support subj_assumption subj_induction subj_PGR subj_estrogen subj_human subj_breast obj_PGR obj_estrogen obj_human obj_breast cancer obj_mediated obj_mechanism obj_involving
7438115	These findings support the assumption that induction of PGR by estrogen in human breast cancer is mediated by a mechanism involving nuclear receptors.	PT-	subj_support subj_assumption subj_induction subj_PGR subj_estrogen subj_human subj_breast obj_PGR obj_estrogen obj_human obj_breast cancer obj_mediated obj_mechanism obj_involving
7511267	Accumulation of p53 protein in the absence of detectable mutant p53 was recognized more often in prostate cancer than in any other tumor examined.	CGE-increased	subj_Accumulation subj_p53 protein subj_absence subj_detectable subj_mutant obj_mutant obj_p53 obj_recognized obj_prostate cancer obj_tumor obj_examined
7511267	Accumulation of p53 protein in the absence of detectable mutant p53 was recognized more often in prostate cancer than in any other tumor examined.	IGE-	subj_Accumulation subj_p53 protein subj_absence subj_detectable subj_mutant obj_mutant obj_p53 obj_recognized obj_prostate cancer obj_tumor obj_examined
7511267	Accumulation of p53 protein in the absence of detectable mutant p53 was recognized more often in prostate cancer than in any other tumor examined.	CCS-unidentifiable	subj_Accumulation subj_p53 protein subj_absence subj_detectable subj_mutant obj_mutant obj_p53 obj_recognized obj_prostate cancer obj_tumor obj_examined
7511267	Accumulation of p53 protein in the absence of detectable mutant p53 was recognized more often in prostate cancer than in any other tumor examined.	PT-	subj_Accumulation subj_p53 protein subj_absence subj_detectable subj_mutant obj_mutant obj_p53 obj_recognized obj_prostate cancer obj_tumor obj_examined
7525636	stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells.	CGE-decreased	subj_demonstrated subj_5-fold subj_decrease subj_IGFBP-2 mRNA subj_( subj_P subj_< obj_< obj_0.01 obj_) obj_BPH obj_compared obj_normal obj_cells
7525636	stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells.	IGE-unchanged	subj_demonstrated subj_5-fold subj_decrease subj_IGFBP-2 mRNA subj_( subj_P subj_< obj_< obj_0.01 obj_) obj_BPH obj_compared obj_normal obj_cells
7525636	stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells.	CCS-normalTOcancer	subj_demonstrated subj_5-fold subj_decrease subj_IGFBP-2 mRNA subj_( subj_P subj_< obj_< obj_0.01 obj_) obj_BPH obj_compared obj_normal obj_cells
7525636	stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells.	PT-observation	subj_demonstrated subj_5-fold subj_decrease subj_IGFBP-2 mRNA subj_( subj_P subj_< obj_< obj_0.01 obj_) obj_BPH obj_compared obj_normal obj_cells
7686495	In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.	CGE-increased	subj_1 subj_stimulate subj_induction subj_fibronectin subj_plasminogen subj_activator subj_inhibitor-1 obj_In obj_PC-3 obj_PC-3U obj_cells obj_TGF
7686495	In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.	IGE-	subj_1 subj_stimulate subj_induction subj_fibronectin subj_plasminogen subj_activator subj_inhibitor-1 obj_In obj_PC-3 obj_PC-3U obj_cells obj_TGF
7686495	In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.	CCS-unidentifiable	subj_1 subj_stimulate subj_induction subj_fibronectin subj_plasminogen subj_activator subj_inhibitor-1 obj_In obj_PC-3 obj_PC-3U obj_cells obj_TGF
7686495	In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.	PT-	subj_1 subj_stimulate subj_induction subj_fibronectin subj_plasminogen subj_activator subj_inhibitor-1 obj_In obj_PC-3 obj_PC-3U obj_cells obj_TGF
7696178	OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1.	CGE-increased	subj_beta subj_1 subj_induced subj_CIP1 subj_expression subj_response subj_TGF obj_OVCA420 obj_cell obj_dramatically obj_growth
7696178	OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1.	IGE-unidentifiable	subj_beta subj_1 subj_induced subj_CIP1 subj_expression subj_response subj_TGF obj_OVCA420 obj_cell obj_dramatically obj_growth
7696178	OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1.	CCS-cancerTOnormal	subj_beta subj_1 subj_induced subj_CIP1 subj_expression subj_response subj_TGF obj_OVCA420 obj_cell obj_dramatically obj_growth
7696178	OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1.	PT-observation	subj_beta subj_1 subj_induced subj_CIP1 subj_expression subj_response subj_TGF obj_OVCA420 obj_cell obj_dramatically obj_growth
7763262	Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.	CGE-decreased	subj_Blocking subj_IL-1 alpha subj_activity subj_HOC-7 subj_cells obj_IL-1 obj_alpha obj_treated obj_HOC-7 obj_cells
7763262	Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.	IGE-	subj_Blocking subj_IL-1 alpha subj_activity subj_HOC-7 subj_cells obj_IL-1 obj_alpha obj_treated obj_HOC-7 obj_cells
7763262	Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.	CCS-unidentifiable	subj_Blocking subj_IL-1 alpha subj_activity subj_HOC-7 subj_cells obj_IL-1 obj_alpha obj_treated obj_HOC-7 obj_cells
7763262	Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.	PT-	subj_Blocking subj_IL-1 alpha subj_activity subj_HOC-7 subj_cells obj_IL-1 obj_alpha obj_treated obj_HOC-7 obj_cells
7840509	The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.	CGE-increased	subj_growth subj_factor subj_( subj_EGF subj_) subj_testosterone subj_direct obj_obesity obj_favor obj_development obj_breast cancer obj_demonstrated obj_experimentally obj_:
7840509	The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.	IGE-unidentifiable	subj_growth subj_factor subj_( subj_EGF subj_) subj_testosterone subj_direct obj_obesity obj_favor obj_development obj_breast cancer obj_demonstrated obj_experimentally obj_:
7840509	The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.	CCS-normalTOcancer	subj_growth subj_factor subj_( subj_EGF subj_) subj_testosterone subj_direct obj_obesity obj_favor obj_development obj_breast cancer obj_demonstrated obj_experimentally obj_:
7840509	The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.	PT-causality	subj_growth subj_factor subj_( subj_EGF subj_) subj_testosterone subj_direct obj_obesity obj_favor obj_development obj_breast cancer obj_demonstrated obj_experimentally obj_:
7913408	Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.	CGE-increased	subj_drug subj_resistant subj_overexpression subj_P-glycoprotein subj_markedly subj_resistant subj_cryptophycin obj_Ovarian carcinoma obj_breast obj_carcinoma obj_cells
7913408	Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.	IGE-	subj_drug subj_resistant subj_overexpression subj_P-glycoprotein subj_markedly subj_resistant subj_cryptophycin obj_Ovarian carcinoma obj_breast obj_carcinoma obj_cells
7913408	Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.	CCS-unidentifiable	subj_drug subj_resistant subj_overexpression subj_P-glycoprotein subj_markedly subj_resistant subj_cryptophycin obj_Ovarian carcinoma obj_breast obj_carcinoma obj_cells
7913408	Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.	PT-	subj_drug subj_resistant subj_overexpression subj_P-glycoprotein subj_markedly subj_resistant subj_cryptophycin obj_Ovarian carcinoma obj_breast obj_carcinoma obj_cells
7917361	We conclude that c-erbB-2 protein overexpression assessed by IHC is a superior prognostic indicator in operable breast cancer compared to c-erbB-2 gene amplification analysed by the dot-blot technique.	CGE-increased	subj_conclude subj_c-erbB-2 protein subj_overexpression subj_assessed subj_IHC obj_prognostic obj_indicator obj_operable obj_breast cancer obj_compared obj_erbB-2 obj_gene
7917361	We conclude that c-erbB-2 protein overexpression assessed by IHC is a superior prognostic indicator in operable breast cancer compared to c-erbB-2 gene amplification analysed by the dot-blot technique.	IGE-unidentifiable	subj_conclude subj_c-erbB-2 protein subj_overexpression subj_assessed subj_IHC obj_prognostic obj_indicator obj_operable obj_breast cancer obj_compared obj_erbB-2 obj_gene
7917361	We conclude that c-erbB-2 protein overexpression assessed by IHC is a superior prognostic indicator in operable breast cancer compared to c-erbB-2 gene amplification analysed by the dot-blot technique.	CCS-normalTOcancer	subj_conclude subj_c-erbB-2 protein subj_overexpression subj_assessed subj_IHC obj_prognostic obj_indicator obj_operable obj_breast cancer obj_compared obj_erbB-2 obj_gene
7917361	We conclude that c-erbB-2 protein overexpression assessed by IHC is a superior prognostic indicator in operable breast cancer compared to c-erbB-2 gene amplification analysed by the dot-blot technique.	PT-observation	subj_conclude subj_c-erbB-2 protein subj_overexpression subj_assessed subj_IHC obj_prognostic obj_indicator obj_operable obj_breast cancer obj_compared obj_erbB-2 obj_gene
7947821	Cell-surface expression of galectin-3 was reduced following treatment of viable T47D human breast carcinoma cells with gelatinase A.	CGE-decreased	subj_Cell subj_surface subj_expression subj_galectin-3 subj_reduced subj_treatment subj_viable obj_viable obj_T47D obj_human obj_breast carcinoma obj_cells obj_gelatinase
7947821	Cell-surface expression of galectin-3 was reduced following treatment of viable T47D human breast carcinoma cells with gelatinase A.	IGE-	subj_Cell subj_surface subj_expression subj_galectin-3 subj_reduced subj_treatment subj_viable obj_viable obj_T47D obj_human obj_breast carcinoma obj_cells obj_gelatinase
7947821	Cell-surface expression of galectin-3 was reduced following treatment of viable T47D human breast carcinoma cells with gelatinase A.	CCS-unidentifiable	subj_Cell subj_surface subj_expression subj_galectin-3 subj_reduced subj_treatment subj_viable obj_viable obj_T47D obj_human obj_breast carcinoma obj_cells obj_gelatinase
7947821	Cell-surface expression of galectin-3 was reduced following treatment of viable T47D human breast carcinoma cells with gelatinase A.	PT-	subj_Cell subj_surface subj_expression subj_galectin-3 subj_reduced subj_treatment subj_viable obj_viable obj_T47D obj_human obj_breast carcinoma obj_cells obj_gelatinase
7949208	The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.	CGE-decreased	subj_inhibition subj_aromatase subj_activity subj_imidazole subj_derivatives obj_patients obj_hormone obj_dependent obj_breast cancer obj_appears obj_favorable obj_alternative
7949208	The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.	IGE-unidentifiable	subj_inhibition subj_aromatase subj_activity subj_imidazole subj_derivatives obj_patients obj_hormone obj_dependent obj_breast cancer obj_appears obj_favorable obj_alternative
7949208	The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.	CCS-cancerTOnormal	subj_inhibition subj_aromatase subj_activity subj_imidazole subj_derivatives obj_patients obj_hormone obj_dependent obj_breast cancer obj_appears obj_favorable obj_alternative
7949208	The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.	PT-causality	subj_inhibition subj_aromatase subj_activity subj_imidazole subj_derivatives obj_patients obj_hormone obj_dependent obj_breast cancer obj_appears obj_favorable obj_alternative
8080727	A strong association has been observed between reduced expression of the nm23 gene and acquisition of metastatic behaviour in some tumour cells, including breast cancer and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.	CGE-decreased	subj_observed subj_reduced subj_expression subj_nm23 gene subj_acquisition subj_metastatic subj_behaviour obj_tumour obj_cells obj_including obj_breast cancer obj_melanoma obj_neuroblastoma obj_colon
8080727	A strong association has been observed between reduced expression of the nm23 gene and acquisition of metastatic behaviour in some tumour cells, including breast cancer and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.	IGE-unidentifiable	subj_observed subj_reduced subj_expression subj_nm23 gene subj_acquisition subj_metastatic subj_behaviour obj_tumour obj_cells obj_including obj_breast cancer obj_melanoma obj_neuroblastoma obj_colon
8080727	A strong association has been observed between reduced expression of the nm23 gene and acquisition of metastatic behaviour in some tumour cells, including breast cancer and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.	CCS-normalTOcancer	subj_observed subj_reduced subj_expression subj_nm23 gene subj_acquisition subj_metastatic subj_behaviour obj_tumour obj_cells obj_including obj_breast cancer obj_melanoma obj_neuroblastoma obj_colon
8080727	A strong association has been observed between reduced expression of the nm23 gene and acquisition of metastatic behaviour in some tumour cells, including breast cancer and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.	PT-observation	subj_observed subj_reduced subj_expression subj_nm23 gene subj_acquisition subj_metastatic subj_behaviour obj_tumour obj_cells obj_including obj_breast cancer obj_melanoma obj_neuroblastoma obj_colon
8244317	These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.	CGE-increased	subj_These subj_p53 subj_accumulation subj_occurs subj_frequently obj_role obj_subsets obj_patients obj_ovarian carcinoma
8244317	These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.	IGE-unchanged	subj_These subj_p53 subj_accumulation subj_occurs subj_frequently obj_role obj_subsets obj_patients obj_ovarian carcinoma
8244317	These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.	CCS-normalTOcancer	subj_These subj_p53 subj_accumulation subj_occurs subj_frequently obj_role obj_subsets obj_patients obj_ovarian carcinoma
8244317	These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.	PT-observation	subj_These subj_p53 subj_accumulation subj_occurs subj_frequently obj_role obj_subsets obj_patients obj_ovarian carcinoma
8431895	The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.	CGE-increased	subj_7 subj_) subj_overexpression subj_c-erbB-2 subj_( subj_HER-2/neu subj_) obj_50 obj_% obj_advanced obj_ovarian cancers
8431895	The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.	IGE-unchanged	subj_7 subj_) subj_overexpression subj_c-erbB-2 subj_( subj_HER-2/neu subj_) obj_50 obj_% obj_advanced obj_ovarian cancers
8431895	The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.	CCS-normalTOcancer	subj_7 subj_) subj_overexpression subj_c-erbB-2 subj_( subj_HER-2/neu subj_) obj_50 obj_% obj_advanced obj_ovarian cancers
8431895	The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.	PT-observation	subj_7 subj_) subj_overexpression subj_c-erbB-2 subj_( subj_HER-2/neu subj_) obj_50 obj_% obj_advanced obj_ovarian cancers
8600090	This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.	CGE-decreased	subj_decrease subj_UTP subj_CTP subj_pools subj_promoted subj_fivefold obj_[ obj_3H]BrdUrd obj_DNA obj_BG-1 obj_cells
8600090	This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.	IGE-	subj_decrease subj_UTP subj_CTP subj_pools subj_promoted subj_fivefold obj_[ obj_3H]BrdUrd obj_DNA obj_BG-1 obj_cells
8600090	This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.	CCS-unidentifiable	subj_decrease subj_UTP subj_CTP subj_pools subj_promoted subj_fivefold obj_[ obj_3H]BrdUrd obj_DNA obj_BG-1 obj_cells
8600090	This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.	PT-	subj_decrease subj_UTP subj_CTP subj_pools subj_promoted subj_fivefold obj_[ obj_3H]BrdUrd obj_DNA obj_BG-1 obj_cells
8612685	PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of PKC-alpha and -epsilon in DU-145 cells.	CGE-decreased	subj_treatment subj_caused subj_downregulation subj_PKC-alpha and -epsilon subj_DU-145 subj_cells obj_PKC obj_alpha obj_-epsilon obj_DU-145 obj_cells
8612685	PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of PKC-alpha and -epsilon in DU-145 cells.	IGE-	subj_treatment subj_caused subj_downregulation subj_PKC-alpha and -epsilon subj_DU-145 subj_cells obj_PKC obj_alpha obj_-epsilon obj_DU-145 obj_cells
8612685	PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of PKC-alpha and -epsilon in DU-145 cells.	CCS-unidentifiable	subj_treatment subj_caused subj_downregulation subj_PKC-alpha and -epsilon subj_DU-145 subj_cells obj_PKC obj_alpha obj_-epsilon obj_DU-145 obj_cells
8612685	PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of PKC-alpha and -epsilon in DU-145 cells.	PT-	subj_treatment subj_caused subj_downregulation subj_PKC-alpha and -epsilon subj_DU-145 subj_cells obj_PKC obj_alpha obj_-epsilon obj_DU-145 obj_cells
8672936	The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.	CGE-increased	subj_accumulation subj_p53 protein subj_analysed subj_immunohistochemically subj_ovarian obj_protein obj_analysed obj_immunohistochemically obj_ovarian cancer obj_correlated obj_clinical obj_data
8672936	The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.	IGE-unchanged	subj_accumulation subj_p53 protein subj_analysed subj_immunohistochemically subj_ovarian obj_protein obj_analysed obj_immunohistochemically obj_ovarian cancer obj_correlated obj_clinical obj_data
8672936	The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.	CCS-normalTOcancer	subj_accumulation subj_p53 protein subj_analysed subj_immunohistochemically subj_ovarian obj_protein obj_analysed obj_immunohistochemically obj_ovarian cancer obj_correlated obj_clinical obj_data
8672936	The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.	PT-observation	subj_accumulation subj_p53 protein subj_analysed subj_immunohistochemically subj_ovarian obj_protein obj_analysed obj_immunohistochemically obj_ovarian cancer obj_correlated obj_clinical obj_data
8780381	In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.	CGE-decreased	subj_prostate subj_adenocarcinoma subj_glands subj_beta 1C variant subj_dramatically subj_regulated subj_27 obj_In obj_adjacent obj_prostate adenocarcinoma obj_glands obj_beta obj_1C
8780381	In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.	IGE-unidentifiable	subj_prostate subj_adenocarcinoma subj_glands subj_beta 1C variant subj_dramatically subj_regulated subj_27 obj_In obj_adjacent obj_prostate adenocarcinoma obj_glands obj_beta obj_1C
8780381	In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.	CCS-normalTOcancer	subj_prostate subj_adenocarcinoma subj_glands subj_beta 1C variant subj_dramatically subj_regulated subj_27 obj_In obj_adjacent obj_prostate adenocarcinoma obj_glands obj_beta obj_1C
8780381	In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.	PT-observation	subj_prostate subj_adenocarcinoma subj_glands subj_beta 1C variant subj_dramatically subj_regulated subj_27 obj_In obj_adjacent obj_prostate adenocarcinoma obj_glands obj_beta obj_1C
8838861	The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).	CGE-decreased	subj_observed subj_relationship subj_regulation subj_Bcl-2 subj_induction subj_apoptosis subj_causal obj_overexpression obj_Bcl-2 obj_protection obj_MCF-7 obj_cells obj_cytotoxic obj_morphological
8838861	The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).	IGE-unidentifiable	subj_observed subj_relationship subj_regulation subj_Bcl-2 subj_induction subj_apoptosis subj_causal obj_overexpression obj_Bcl-2 obj_protection obj_MCF-7 obj_cells obj_cytotoxic obj_morphological
8838861	The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).	CCS-cancerTOnormal	subj_observed subj_relationship subj_regulation subj_Bcl-2 subj_induction subj_apoptosis subj_causal obj_overexpression obj_Bcl-2 obj_protection obj_MCF-7 obj_cells obj_cytotoxic obj_morphological
8838861	The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).	PT-observation	subj_observed subj_relationship subj_regulation subj_Bcl-2 subj_induction subj_apoptosis subj_causal obj_overexpression obj_Bcl-2 obj_protection obj_MCF-7 obj_cells obj_cytotoxic obj_morphological
8978405	Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.	CGE-decreased	subj_R1881 subj_completely subj_blocked subj_gamma-glutamyl transpeptidase subj_activity subj_ obj_oxidative obj_stress obj_produced obj_LNCaP obj_cells obj_1 obj_nM
8978405	Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.	IGE-	subj_R1881 subj_completely subj_blocked subj_gamma-glutamyl transpeptidase subj_activity subj_ obj_oxidative obj_stress obj_produced obj_LNCaP obj_cells obj_1 obj_nM
8978405	Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.	CCS-unidentifiable	subj_R1881 subj_completely subj_blocked subj_gamma-glutamyl transpeptidase subj_activity subj_ obj_oxidative obj_stress obj_produced obj_LNCaP obj_cells obj_1 obj_nM
8978405	Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.	PT-	subj_R1881 subj_completely subj_blocked subj_gamma-glutamyl transpeptidase subj_activity subj_ obj_oxidative obj_stress obj_produced obj_LNCaP obj_cells obj_1 obj_nM
9010319	M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.	IGE-	subj_suppressed subj_progesterone subj_receptor subj_TGFalpha mRNA subj_induction subj_restored subj_TGFbeta obj_control obj_levels obj_T3-treated obj_MCF-7 obj_cells
9010319	M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.	CGE-increased	subj_suppressed subj_progesterone subj_receptor subj_TGFalpha mRNA subj_induction subj_restored subj_TGFbeta obj_control obj_levels obj_T3-treated obj_MCF-7 obj_cells
9010319	M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.	CCS-unidentifiable	subj_suppressed subj_progesterone subj_receptor subj_TGFalpha mRNA subj_induction subj_restored subj_TGFbeta obj_control obj_levels obj_T3-treated obj_MCF-7 obj_cells
9010319	M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.	PT-	subj_suppressed subj_progesterone subj_receptor subj_TGFalpha mRNA subj_induction subj_restored subj_TGFbeta obj_control obj_levels obj_T3-treated obj_MCF-7 obj_cells
9042197	Loss of c-kit expression has been reported in 80-90% of breast cancer specimens, suggesting a possible role in the development of tumors.	CGE-decreased	subj_Loss subj_c-kit subj_expression subj_reported subj_80 obj_80 obj_90 obj_% obj_breast cancer obj_specimens obj_suggesting obj_role
9042197	Loss of c-kit expression has been reported in 80-90% of breast cancer specimens, suggesting a possible role in the development of tumors.	IGE-unchanged	subj_Loss subj_c-kit subj_expression subj_reported subj_80 obj_80 obj_90 obj_% obj_breast cancer obj_specimens obj_suggesting obj_role
9042197	Loss of c-kit expression has been reported in 80-90% of breast cancer specimens, suggesting a possible role in the development of tumors.	CCS-normalTOcancer	subj_Loss subj_c-kit subj_expression subj_reported subj_80 obj_80 obj_90 obj_% obj_breast cancer obj_specimens obj_suggesting obj_role
9042197	Loss of c-kit expression has been reported in 80-90% of breast cancer specimens, suggesting a possible role in the development of tumors.	PT-observation	subj_Loss subj_c-kit subj_expression subj_reported subj_80 obj_80 obj_90 obj_% obj_breast cancer obj_specimens obj_suggesting obj_role
9092801	In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h. Progestin-induced increases in PRG1 mRNA were inhibited by the progestin antagonist RU 486 and occurred via the progesterone receptor.	CGE-increased	subj_T-47D subj_cells subj_PRG1 mRNA subj_rapidly subj_transiently subj_induced obj_T-47D obj_cells obj_PRG1 obj_mRNA
9092801	In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h. Progestin-induced increases in PRG1 mRNA were inhibited by the progestin antagonist RU 486 and occurred via the progesterone receptor.	IGE-	subj_T-47D subj_cells subj_PRG1 mRNA subj_rapidly subj_transiently subj_induced obj_T-47D obj_cells obj_PRG1 obj_mRNA
9092801	In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h. Progestin-induced increases in PRG1 mRNA were inhibited by the progestin antagonist RU 486 and occurred via the progesterone receptor.	CCS-unidentifiable	subj_T-47D subj_cells subj_PRG1 mRNA subj_rapidly subj_transiently subj_induced obj_T-47D obj_cells obj_PRG1 obj_mRNA
9092801	In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h. Progestin-induced increases in PRG1 mRNA were inhibited by the progestin antagonist RU 486 and occurred via the progesterone receptor.	PT-	subj_T-47D subj_cells subj_PRG1 mRNA subj_rapidly subj_transiently subj_induced obj_T-47D obj_cells obj_PRG1 obj_mRNA
9114434	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2)	CGE-increased	subj_levels subj_mRNA subj_activity subj_gamma-glutamyl transpeptidase subj_( subj_gamma subj_GT obj_studies obj_sublines obj_human obj_ovarian carcinoma obj_cell obj_A2780 obj_exhibited
9114434	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2)	IGE-unidentifiable	subj_levels subj_mRNA subj_activity subj_gamma-glutamyl transpeptidase subj_( subj_gamma subj_GT obj_studies obj_sublines obj_human obj_ovarian carcinoma obj_cell obj_A2780 obj_exhibited
9114434	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2)	CCS-normalTOcancer	subj_levels subj_mRNA subj_activity subj_gamma-glutamyl transpeptidase subj_( subj_gamma subj_GT obj_studies obj_sublines obj_human obj_ovarian carcinoma obj_cell obj_A2780 obj_exhibited
9114434	Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2)	PT-observation	subj_levels subj_mRNA subj_activity subj_gamma-glutamyl transpeptidase subj_( subj_gamma subj_GT obj_studies obj_sublines obj_human obj_ovarian carcinoma obj_cell obj_A2780 obj_exhibited
9116750	In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH).	CGE-increased	subj_tissues subj_localized subj_accumulations subj_TGF-beta1 subj_prostate subj_cancer subj_benign obj_beta1 obj_prostate obj_cancer obj_benign prostatic hyperplasia obj_( obj_BPH obj_)
9116750	In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH).	IGE-unchanged	subj_tissues subj_localized subj_accumulations subj_TGF-beta1 subj_prostate subj_cancer subj_benign obj_beta1 obj_prostate obj_cancer obj_benign prostatic hyperplasia obj_( obj_BPH obj_)
9116750	In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH).	CCS-normalTOcancer	subj_tissues subj_localized subj_accumulations subj_TGF-beta1 subj_prostate subj_cancer subj_benign obj_beta1 obj_prostate obj_cancer obj_benign prostatic hyperplasia obj_( obj_BPH obj_)
9116750	In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH).	PT-observation	subj_tissues subj_localized subj_accumulations subj_TGF-beta1 subj_prostate subj_cancer subj_benign obj_beta1 obj_prostate obj_cancer obj_benign prostatic hyperplasia obj_( obj_BPH obj_)
91252	Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.	CGE-decreased	subj_( subj_) subj_decrease subj_albumin subj_alpha subj_2- subj_beta obj_) obj_18 obj_patients obj_prostatic cancer obj_prior obj_cryoprostatectomy obj_disclosed
91252	Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.	IGE-	subj_( subj_) subj_decrease subj_albumin subj_alpha subj_2- subj_beta obj_) obj_18 obj_patients obj_prostatic cancer obj_prior obj_cryoprostatectomy obj_disclosed
91252	Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.	CCS-unidentifiable	subj_( subj_) subj_decrease subj_albumin subj_alpha subj_2- subj_beta obj_) obj_18 obj_patients obj_prostatic cancer obj_prior obj_cryoprostatectomy obj_disclosed
91252	Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.	PT-	subj_( subj_) subj_decrease subj_albumin subj_alpha subj_2- subj_beta obj_) obj_18 obj_patients obj_prostatic cancer obj_prior obj_cryoprostatectomy obj_disclosed
9458352	Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis.	CGE-decreased	subj_cell subj_cycle subj_regulating subj_c-myc gene subj_inducing subj_p53-dependent subj_apoptosis obj_ovarian obj_NIH obj_: obj_OVCAR-3 obj_tumor obj_cells obj_inducing
9458352	Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis.	IGE-unidentifiable	subj_cell subj_cycle subj_regulating subj_c-myc gene subj_inducing subj_p53-dependent subj_apoptosis obj_ovarian obj_NIH obj_: obj_OVCAR-3 obj_tumor obj_cells obj_inducing
9458352	Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis.	CCS-cancerTOnormal	subj_cell subj_cycle subj_regulating subj_c-myc gene subj_inducing subj_p53-dependent subj_apoptosis obj_ovarian obj_NIH obj_: obj_OVCAR-3 obj_tumor obj_cells obj_inducing
9458352	Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis.	PT-causality	subj_cell subj_cycle subj_regulating subj_c-myc gene subj_inducing subj_p53-dependent subj_apoptosis obj_ovarian obj_NIH obj_: obj_OVCAR-3 obj_tumor obj_cells obj_inducing
9582091	Our results suggest novel mechanisms by which MnSOD overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for prostate cancer.	CGE-increased	subj_Our subj_mechanisms subj_MnSOD subj_overexpression subj_modulate subj_malignant obj_applications obj_developing obj_therapies obj_prostate cancer
9582091	Our results suggest novel mechanisms by which MnSOD overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for prostate cancer.	IGE-	subj_Our subj_mechanisms subj_MnSOD subj_overexpression subj_modulate subj_malignant obj_applications obj_developing obj_therapies obj_prostate cancer
9582091	Our results suggest novel mechanisms by which MnSOD overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for prostate cancer.	CCS-unidentifiable	subj_Our subj_mechanisms subj_MnSOD subj_overexpression subj_modulate subj_malignant obj_applications obj_developing obj_therapies obj_prostate cancer
9582091	Our results suggest novel mechanisms by which MnSOD overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for prostate cancer.	PT-	subj_Our subj_mechanisms subj_MnSOD subj_overexpression subj_modulate subj_malignant obj_applications obj_developing obj_therapies obj_prostate cancer
9586898	A decrease in PSA level is associated with both survival and response in soft tissue lesions and should be incorporated into the response criteria and reporting of trials of cytotoxic agents in prostate cancer.	CGE-decreased	subj_decrease subj_PSA subj_level subj_survival subj_response obj_trials obj_cytotoxic obj_agents obj_prostate cancer
9586898	A decrease in PSA level is associated with both survival and response in soft tissue lesions and should be incorporated into the response criteria and reporting of trials of cytotoxic agents in prostate cancer.	IGE-	subj_decrease subj_PSA subj_level subj_survival subj_response obj_trials obj_cytotoxic obj_agents obj_prostate cancer
9586898	A decrease in PSA level is associated with both survival and response in soft tissue lesions and should be incorporated into the response criteria and reporting of trials of cytotoxic agents in prostate cancer.	CCS-unidentifiable	subj_decrease subj_PSA subj_level subj_survival subj_response obj_trials obj_cytotoxic obj_agents obj_prostate cancer
9586898	A decrease in PSA level is associated with both survival and response in soft tissue lesions and should be incorporated into the response criteria and reporting of trials of cytotoxic agents in prostate cancer.	PT-	subj_decrease subj_PSA subj_level subj_survival subj_response obj_trials obj_cytotoxic obj_agents obj_prostate cancer
9590136	Our findings suggest that LH/hCG influences the chemosensitivity of ovarian cancer cells through an apoptosis-inhibitory signal possibly via up-regulation of IGF-1 expression.	CGE-increased	subj_inhibitory subj_signal subj_regulation subj_IGF-1 subj_expression obj_hCG obj_influences obj_chemosensitivity obj_ovarian cancer obj_cells obj_apoptosis obj_inhibitory
9590136	Our findings suggest that LH/hCG influences the chemosensitivity of ovarian cancer cells through an apoptosis-inhibitory signal possibly via up-regulation of IGF-1 expression.	IGE-unidentifiable	subj_inhibitory subj_signal subj_regulation subj_IGF-1 subj_expression obj_hCG obj_influences obj_chemosensitivity obj_ovarian cancer obj_cells obj_apoptosis obj_inhibitory
9590136	Our findings suggest that LH/hCG influences the chemosensitivity of ovarian cancer cells through an apoptosis-inhibitory signal possibly via up-regulation of IGF-1 expression.	CCS-normalTOcancer	subj_inhibitory subj_signal subj_regulation subj_IGF-1 subj_expression obj_hCG obj_influences obj_chemosensitivity obj_ovarian cancer obj_cells obj_apoptosis obj_inhibitory
9590136	Our findings suggest that LH/hCG influences the chemosensitivity of ovarian cancer cells through an apoptosis-inhibitory signal possibly via up-regulation of IGF-1 expression.	PT-causality	subj_inhibitory subj_signal subj_regulation subj_IGF-1 subj_expression obj_hCG obj_influences obj_chemosensitivity obj_ovarian cancer obj_cells obj_apoptosis obj_inhibitory
9654650	Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity.	CGE-decreased	subj_utility subj_compounds subj_inhibition subj_breast cancer cell estrone sulfatase subj_activity obj_utility obj_compounds obj_inhibition obj_breast cancer obj_cell obj_estrone obj_sulfatase
9654650	Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity.	IGE-	subj_utility subj_compounds subj_inhibition subj_breast cancer cell estrone sulfatase subj_activity obj_utility obj_compounds obj_inhibition obj_breast cancer obj_cell obj_estrone obj_sulfatase
9654650	Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity.	CCS-unidentifiable	subj_utility subj_compounds subj_inhibition subj_breast cancer cell estrone sulfatase subj_activity obj_utility obj_compounds obj_inhibition obj_breast cancer obj_cell obj_estrone obj_sulfatase
9654650	Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity.	PT-	subj_utility subj_compounds subj_inhibition subj_breast cancer cell estrone sulfatase subj_activity obj_utility obj_compounds obj_inhibition obj_breast cancer obj_cell obj_estrone obj_sulfatase
9790546	BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	CGE-decreased	subj_relying subj_suppression subj_systemic subj_androgen hormone subj_levels obj_: obj_For obj_patients obj_metastatic prostate cancer obj_treatment obj_palliative obj_relying
9790546	BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	IGE-	subj_relying subj_suppression subj_systemic subj_androgen hormone subj_levels obj_: obj_For obj_patients obj_metastatic prostate cancer obj_treatment obj_palliative obj_relying
9790546	BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	CCS-unidentifiable	subj_relying subj_suppression subj_systemic subj_androgen hormone subj_levels obj_: obj_For obj_patients obj_metastatic prostate cancer obj_treatment obj_palliative obj_relying
9790546	BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	PT-	subj_relying subj_suppression subj_systemic subj_androgen hormone subj_levels obj_: obj_For obj_patients obj_metastatic prostate cancer obj_treatment obj_palliative obj_relying
9816210	One of the best examples of a correlation between high levels of a protease in a primary tumor and poor prognosis is urokinase plasminogen activation in breast cancer.	CGE-increased	subj_tumor subj_poor subj_prognosis subj_urokinase plasminogen subj_activation subj_breast subj_cancer obj_urokinase obj_plasminogen obj_activation obj_breast cancer
9816210	One of the best examples of a correlation between high levels of a protease in a primary tumor and poor prognosis is urokinase plasminogen activation in breast cancer.	IGE-unchanged	subj_tumor subj_poor subj_prognosis subj_urokinase plasminogen subj_activation subj_breast subj_cancer obj_urokinase obj_plasminogen obj_activation obj_breast cancer
9816210	One of the best examples of a correlation between high levels of a protease in a primary tumor and poor prognosis is urokinase plasminogen activation in breast cancer.	CCS-normalTOcancer	subj_tumor subj_poor subj_prognosis subj_urokinase plasminogen subj_activation subj_breast subj_cancer obj_urokinase obj_plasminogen obj_activation obj_breast cancer
9816210	One of the best examples of a correlation between high levels of a protease in a primary tumor and poor prognosis is urokinase plasminogen activation in breast cancer.	PT-observation	subj_tumor subj_poor subj_prognosis subj_urokinase plasminogen subj_activation subj_breast subj_cancer obj_urokinase obj_plasminogen obj_activation obj_breast cancer
9849446	After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer.	CGE-increased	subj_65 subj_months subj_increase subj_TGF-beta 1 subj_1 subj_independent subj_predictor obj_survival obj_secondary obj_primary obj_breast cancer
9849446	After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer.	IGE-	subj_65 subj_months subj_increase subj_TGF-beta 1 subj_1 subj_independent subj_predictor obj_survival obj_secondary obj_primary obj_breast cancer
9849446	After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer.	CCS-unidentifiable	subj_65 subj_months subj_increase subj_TGF-beta 1 subj_1 subj_independent subj_predictor obj_survival obj_secondary obj_primary obj_breast cancer
9849446	After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer.	PT-	subj_65 subj_months subj_increase subj_TGF-beta 1 subj_1 subj_independent subj_predictor obj_survival obj_secondary obj_primary obj_breast cancer
9857236	In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.	CGE-increased	subj_interpretation subj_pathological subj_elevation subj_bFGF subj_pre subj_menopausal subj_breast obj_bFGF obj_pre obj_menopausal obj_breast cancer obj_patients
9857236	In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.	IGE-	subj_interpretation subj_pathological subj_elevation subj_bFGF subj_pre subj_menopausal subj_breast obj_bFGF obj_pre obj_menopausal obj_breast cancer obj_patients
9857236	In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.	CCS-unidentifiable	subj_interpretation subj_pathological subj_elevation subj_bFGF subj_pre subj_menopausal subj_breast obj_bFGF obj_pre obj_menopausal obj_breast cancer obj_patients
9857236	In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.	PT-	subj_interpretation subj_pathological subj_elevation subj_bFGF subj_pre subj_menopausal subj_breast obj_bFGF obj_pre obj_menopausal obj_breast cancer obj_patients
